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The work described in this thesis involves a series of studies on the
hormonal and intracellular regulation of the expression of the prolactin
<PRL) and growth hormone (GH> genes. The studies are based on both rat
pituitary tissue and human pituitary adenoma tissue, and the regulation of
both rat and human genes is discussed.
In initial studies cDNA/mRNA hybridization assays were used to assess the
regulation of messenger RNA production, first in primary cell cultures of
rat pituitary tissue, and then in a series of GH or PRL-secreting human
pituitary adenomas. The effects of dopamine and dopaminergic drugs,
somatostatin, hypothalamic releasing hormones and intracellular signalling
systems were variable among different human tumours, but in general hPRL
and hGH mRNA levels in tumour cells were less responsive to inhibition than
rPRL or rGH mRNA levels in normal rat pituitary tissue.
Secondly, the potential mechanisms for PRL gene regulation by intra¬
cellular signals were studied using the clonal rat pituitary GH3 cell line.
Transfection analysis was used to assess the role of the promoter region of
the rat PRL gene in calmodulin-dependent regulation of transcription: a
defined region of proximal 5'-flanking DNA conferred marked calcium/
calmodulin responsiveness onto a bacterial reporter gene. The role of
nuclear protein binding to this region of the gene was studied using gel
mobility shift assays, and this technique wa6 used to study both the
possible mechanisms for the calcium/calmodulin regulation of nuclear
protein binding to DNA in PRL gene expression. The results showed that
nuclear protein binding to DNA is affected by calmodulin antagonists, and
suggest that the mechanisms for intracellular regulation of the PRL gene
overlap with those of its tissue-specific expression.
Finally, preliminary attempts were made to apply the transfection and gel
shift techniques to human pituitary tumour tissue, and showed that such
techniques may Indeed be applicable even to small quantities of pituitary
tumour tissue, and may throw some light on possible pathogenetic mechanisms
for pituitary adenoma formation.
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PROLACTIN AND GROWTH HORMONE GENE REGULATION
1.1 INTRODUCTION
Pituitary adenomas presenting with hypersecretion of prolactin (PRL) or
growth hormone (GH) are important problems in clinical endocrinology.
Despite much research the pathogenesis of human pituitary adenomas has
until recently remained almost completely unknown. The past ten years have
seen an enormous advance in our knowledge of the structure and expression
of the PRL and GH genes, and also of some of the important proteins which
are involved in their transcriptional regulation. The fruits of this new
understanding are Just beginning to be applied more directly to the 6tudy
of human disease. Major advances have recently been made in knowledge of
basic cellular control mechanisms in normal and neoplastic pituitary
tissue, and these may well influence future therapeutic strategies for
diseases of the pituitary.
This chapter will present a brief description of the PRL-GH gene family,
with a review of our present understanding of tissue-specificity and
hormonal regulation in the control of gene transcription. This general
introduction will form the background to an attempt in this thesis to apply
several recently developed molecular biological techniques to human
pituitary tumour tissue. The use of hybridization analysis will first be
illustrated in studies of PRL mRNA regulation in normal rat pituitary
tissue (Chapter 2), and then applied to studies of PRL- and GH-secreting
human pituitary adenomas which suggest abnormal hormonal regulation of hPRL
and hGH mRNA accumulation (Chapters 3 and 4). Then studies of gene
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promoter function and DNA-protein interactions will be described with
applications of the techniques of transient transfection analysis and gel
retardation analysis to a study of calcium/calmodulin regulation of rat PRL
gene promoter function (Chapters 5 and 6>. Preliminary applications of
these techniques to pituitary tumour tissue will be described with
tentative evidence for possible abnormal DNA-protein interactions (Chapter
7) before a concluding assessment of our present understanding of the
molecular pathogenesis of pituitary adenomas (Chapter 8).
1.2 THE PROLACTIN AND GROWTH HORMONE GENE FAMILY
1. 2. 1 Gene structure and relationships
The genes coding for PRL and GH are related and form part of a family
which also comprises chorionic somatomammotrophin (CS, or placental
lactogen, PL; reviewed in Miller & Eberhardt, 1983). In the rat there is a
single GH gene (Barta et al, 1981), a single rPRL gene (Cooke & Baxter,
1982) and several rCS/PL genes (Duckworth et al, 1986). In man, while the
single hPRL gene (Cooke et al, 1981; Truong et al, 1984) is located on
chromosome 6 (Owerbach et al, 1981), there is a cluster of related hGH and
hCS/hPL genes (Martial et al, 1979; Seeburg, 1982) grouped together on
chromosome 17 (Owerbach et al, 1980; George et al, 1981; Kidd & Saunders,
1982; Hirt et al, 1987), as shown in Figure 1.1. The single hGH-N gene is
expressed primarily in the pituitary and alternative spllclngs of the
nuclear pre-mRNA generate multiple mature cytoplasmic mRNAs, among which
one encodes the 20kd variant protein (which constitutes 5-10% of pituitary
GH), and another would code for a novel 17.5kd protein (Lecomte et al,
1987). The variant GH gene, hGH-V, was first shown to be functional (that














hPRL | 11 [ Chromosome 6
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Figure 1. 1 Arrangement of human GH/CS gene cluster and the
structure of human GH-N, GH-V and PRL genes, with
exons shown as black boxes and respective scales
shown in kilobases (kb).
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direct its expression in monkey kidney cells in vitro (Pavlakis et al,
1981); however the endogenous human hGH-V mRNA was only recently found in
placental tissue and in very small amounts in a pituitary adenoma
(Frankenne et al, 1987). The structure of hGH-V mRNA has recently been
determined from a human placental cDNA library, and two different mRNAs
appear to be generated by alternative splicing of the gene, giving rise to
two distinct proteins (Cooke et al, 1988). The hCS-L gene is thought to be
a non-functional pseudogene, but hCS-A and hCS-B are expressed in
syncytiotrophoblast tissue (McWilliams & Boime, 1980).
Among the human genes there is considerable coding sequence homology, up
to 92% between hGH and hCS (Cooke et al, 1980; Cooke et al, 1981), and 42%
between the hPRL and hGH genes (Martial et al, 1979; Seeburg, 1982; Truong
et al, 1984). Indeed between species there is significant homology of
coding sequences, 73% between human and rat PRL and 75% between human and
rat GH (Cooke et al, 1981). It has been calculated from data on the
conservation of coding sequences and splicing sites that the PRL and GH
genes derived from a single primordial gene and began to diverge about 400
million years ago, the period when fish and quadrlpeds started their
evolutionary divergence (Cooke et al, 1981; Cooke & Baxter, 1982).
Interestingly, the proximal regulatory 5*-flanking DNA sequences are also
highly conserved between the rat, bovine and human PRL genes (Cooke et al
1982; Camper et al, 1984; Truong et al, 1984), particularly in regions
thought to be important for tissue-specific gene expression.
Further members of the PRL gene family have recently been described in
other tissues. Distinct from the placental lactogen genes, "proliferin"
has been identified from a mouse cDNA library, and appears to be linked to
cellular proliferation (Linzer & Nathans, 1984; Linzer et al, 1985; Lee St
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Nathans, 1987); a placental "proliferin-related protein" gene and a third
prolactin-like protein and gene have also been described (Linzer & Nathans,
1985; Colosi et al, 1988; Duckworth et al, 1988). These genes map to
chromosome 13 in the mouse, along with PRL itself (Jackson-Grusby et al,
1988) and show some sequence homology with PRL, but their tissue
specificity differs.
PRL itself is synthesized at low levels in non-pituitary tissue, notably
in human decidual endometrial tissue during pregnancy, although its
regulation differs substantially from that in the pituitary gland. For
example decidual PRL secretion is unaffected by dopamine (Golander et al,
1979; Richards et al, 1982) or oestrogen (Daly et al, 1983; Rosenberg &
Bhatnagar, 1984), yet is stimulated by progesterone (Riddick & Daly, 1982;
Daly et al, 1983), and by insulin and insulin-like growth factor 1
(Thrailkill et al, 1988, 1989).
So far there is no information regarding possible hormonal regulation of
decidual PRL mRNA accumulation. PRL mRNA has been detected in human
decidual cells (Clements et al, 1983; Taii et al, 1984), and the human
decidual PRL cDNA sequence is almost identical to that of the pituitary
cDNA, confirming that there is only a single copy of the hPRL gene per
haploid genome (Takahashi et al, 1984). However the decidual mRNA has a
slightly different size from pituitary mRNA which is not accounted for by
the length of the poly-adenylated tail (Gellersen et al, 1989); this might
suggest either alternative splicing of nuclear pre-mRNA or a different
transcription initiation site, possibly due to different transcription
factors in decidual cells.
Finally, prolactin mRNA and protein production occurs at low levels in
human IM-9 lymphocytic cells, but whether this may imply some latent
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biological function remains to be seen as normal human lymphocytes have no
detectable prolactin mRNA (Dimattia et al, 1988).
1.2.2 Opjogepy
Despite the close structural similarities between their genes, PRL and GH
exhibit quite distinct developmental patterns and tissue-specific
expression. PRL and GH are produced in separate cell types within the
pituitary gland, lactotrophs and somatotrophs, and immunocytochemical
studies suggest that they are expressed in the pituitary only late in fetal
development (Gash et al, 1982). However, rat PRL and GH may be co-
expressed in the same cell, and such somatomammotrophs may predominate in
the late fetal pituitary, according to an immunocytochemical study
(Hoeffler et al, 1985). In the rat, a comparison of immunocytochemical
studies with in situ hybridization data has recently shown that PRL mRNA
accumulates well before PRL can be detected by immunostaining; as PRL is
secreted in fetal rats, this indicates that it is synthesized but not
stored in the fetal pituitary, possibly reflecting lack of fetal
hypothalamic dopamine production (Hooghe-Peters et al, 1988).
Co-production of PRL and GH has been shown in adult rat pituitary tissue
both by immunocytochemical studies and also by reverse haemolytic plaque
assays (Frawley et al, 1985; Nikitovich-Winer et al, 1987). The potential
for co-expression of the PRL and GH genes in a single cell type has
suggested that tissue-specific expression of these genes may be at least
partly controlled by a single common factor (Nelson et al, 1988), and




The regulation of gene transcription is currently considered to be
exerted by the specific interaction of regulatory proteins <trans acting
factors) with given DNA sequences (cis elements). Different types of
cls/trans coupling are thought to allow both tissue-specific expression and
also hormonal induction or inhibition of gene transcription. The cis
regulatory sequences are frequently located within promoter regions, or may
be part of a separate "enhancer" element that can regulate transcription at
a distance, either within or outside of the structural gene, upstream or
downstream from the transcription initiation site (Figure 1.2). Changes in
the three-dimensional structure of DNA may allow the DNA-bound trans
factors to interact with the transcription initiation complex (as shown
schematically in Figure 1.3, and for reviews see Dynan & Tjian, 1985;
Ptashne, 1986; Maniatis et al, 1987 and Ptashne, 1988). Several trans
factors have been identified (some of which correspond to cellular proto-
oncogenes), including steroid and thyroid hormone receptors (see Evans,
1988, for review) and activator proteins such as API and AP2 which are
thought to mediate the effects of intracellular messenger systems (Lee et
al, 1987; Imagawa et al, 1987). The structure of many of these factors is
now becoming understood, and indicates that they may interact, for example
by dimerization, to activate gene transcription (see Mitchell & Tjian,
1989, for review).
The regulation of PRL and GH gene transcription involves two aspects:
tissue-specific expression and hormonal regulation. Although these will be
considered separately, the final level of transcriptional activity presum¬
ably reflects Integration of both systems, and indeed it seems likely that
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Figure 1.2 Arrangement of putative regulatory regions (open
boxes) in relation to the transcription initiation
site, exons (Ej black boxes) and introns <I) in a
model gene. The generation and splicing of
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TRANSCRIPTION INITIATION COMPLEX
Figure 1. 3 Possible interaction of cis and trans elements.
Upper: cis elements in the gene are Indicated as
white areas to which trans-acting factors (black
blobs) are bound. The transcription initiation
site is shown by the right-angled arrow.
Lower: possible interaction of bound trans factors
with RNA polymerase II by looping of DNA; protein-
protein interactions are suggested by links
between the trans factors within a transcription
initiation complex.
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understanding these mechanisms should involve (i> the identification of els
elements in a given gene; Cii> precise definition of els/trans interactions
- that is, demonstration of protein-DNA binding and identification of trans
acting factors involved; and (iv) purification and cloning of trans acting
factors, and assessment of their regulation. Such an approach ha6 been
used with great success in the case of the PRL and GH genes, for example
with the definition of steroid and thyroid hormone receptor structure and
DNA binding characteristics, and also the identification of the pituitary
tissue specific factor Pit-l/GHF-1, and these will be considered in detail
next.
1.4 TISSUE-SPECIFIC EXPRESSION
The PRL and GH genes are present in all cells, but are expressed only in
pituitary or placental tissue; indeed the respective levels of mRNA for
hGH-N and hCS may differ by as much as 10,000-fold despite considerable
sequence homology, raising the intriguing question of the possible
mechanisms which confer this tissue-specificity of gene expression. In the
case of both PRL and GH it is noteworthy that segments of the 5'-flanking
sequence are markedly conserved between species, suggesting their
functional importance. The PRL and GH genes have ^normally been considered
separately, and they will be discussed separately here before summarising a
picture of our current understanding. However, the mechanisms responsible
for conferring tissue specificity for PRL and GH gene expression may in
fact be at least partly shared, and a common pituitary trans-acting factor,
Pit-l/GHF-1, has recently been identified which appears to bind to the
upstream elements not only of the PRL and GH genes, but also the TSH-p
subunit gene (Nelson et al, 1988). This factor has subsequently been
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cloned and identified by two independent groups (Bodner et al, 1988;
Ingraham et al, 1988). The hypothesis of a common tissue-specific
targeting mechanism which operates in vivo has received further support
from the recent finding that upstream elements of the GH gene can direct
expression of the gene in transgenic mice to lactotrophs and thyrotrophs as
well as to somatotrophs (Lira et al, 1988).
1.4.1 PROLACTIN
1.4. 1. 1 Cis elements
The technique of transfection analysis has been used to study the role of
the 5'-flanking DNA sequences of the rPRL gene. This technique involves
the construction of fusion genes which contain putative regulatory elements
linked to reporter genes such as bacterial chloramphenicol acetyl
transferase (CAT); the expression of CAT activity is therefore a function
of promoter activity and can be readily measured in mammalian cell
extracts. By transfecting rat pituitary GH3 cells with a series of PRL-CAT
fusion genes containing up to 3kb of PRL 5'-flanking DNA, Nelson et al
(1986) identified two regulatory sequences whose deletion led to a drop in
CAT gene transcription. A distal element located between -1831 and -1530
base pairs (bp) upstream of the transcription initiation site (or "cap
site") accounted for 98-99% of basal tissue specific expression, and a
proximal element (-422 to -36bp) accounted for 1-2% of activity. Both cis
elements acted as enhancers, that is they conferred cell-type specific
expression to a "neutral" viral promoter sequence independently of their
position or orientation.
Although the studies of Nelson et al (1986) suggested that the distal
enhancer region was relatively more important, the proximal enhancer
element alone is sufficient to direct tissue-specific expression in its own
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right. The functional importance of the proximal region of the PRL 5'-
flanking DNA has been indicated by in vitro transcription experiments,
using nuclear protein extracts to reconstitute transcription from a gene
promoter element in a cell-free system. In vitro transcription experiments
with GH3 cell extracts suggested that the proximal regulatory elements were
sufficient for tissue-specific expression of the rPRL gene: accurate
initiation of transcription could be found using 420bp of 5'-flanking rPRL
DNA, and whereas nuclear proteins from various cell types could direct
transcription from viral gene promoters, only pituitary extracts could do
so using the PRL promoter template DNA (Cao et al, 1987; Cao et al, 1988;
Gutierrez-Hartman et al, 1987). Similarly, transient transfection studies
have demonstrated that the proximal 250bp of the bovine PRL 5'-flanking
sequence are adequate to confer tissue specific reporter gene expression
(Camper et al, 1985). In summary, therefore, both the proximal and the
distal enhancer elements are involved in tissue specific expression of the
rPRL gene, though optimal enhancer activity probably requires synergism
between the two.
1.4.1.2 Cis/trans interactions
The first study of protein-DNA interactions in the rPRL gene suggested
that pituitary-derived nuclear proteins were able to bind to two long
stretches of 5'-flanking DNA extending as far as -4800bp upstream of the
cap site (White et al, 1985). Subsequent studies have employed nuclease
protection assays (protein binding protects DNA from nuclease digestion) to
locate much more precisely the nucleotide sequences which bind trans-acting
tissue-specific proteins.
Proximal protein binding sites Different studies and different techniques
have yielded slightly differing results, but up to four protein binding
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sites have been identified within the first 210bp 5' to the cap site, as
shown in Figure 1.4 (Elsholtz et al, 1986; Schuster et al, 1988; Cao et al,
1987; Gutierrez-Hartman et al, 1987; Cao et al, 1988; Nelson et al, 1988;
Lufkin et al, 1989). At least three of these proximal sites are pituitary
specific as the protein binding is seen only with pituitary cell proteins
and not with proteins from other tissues.
Of the four sites, the most proximal, between positions -30 and -78 has
also been found to behave as an enhancer element which confers the
transcriptional response to epidermal growth factor (EGF> and phorbol ester
(Elsholtz et al, 1986). Using gel retardation assays it has been found
that the electrophoretic mobility of this DNA element is reduced by protein
binding, specifically with extracts from pituitary cells, but not from
other cell types (Elsholtz et al, 1986; Schuster et al, 1988), again
providing independent evidence for tissue-specific nuclear protein
interactions with this region. In addition, an 18bp imperfect palindrome
within this region appears to contain a TATA element which can initiate
non-pituitary transcription from a site at -27bp from the usual initiation
site. This may be prevented in pituitary cells by the presence of Pit-
1/GHF-l binding nearby, thus offering a further potential mechanism for
cell-type specific gene expression (Barron et al, 1989).
The second protein binding site (-115/-130) may not be tissue-specific
(Gutierrez-Hartmann et al, 1987) in that it may be found with non-pituitary
protein extracts. However the fourth of these four proximal sites
corresponds closely to a sequence identified by Lufkin & Bancroft (1987)
which is able to direct gene transcription in hybrid pituitary-fibroblast
fusion cells, but not in fibroblast cells alone. These data together
provide direct evidence for the presence in pituitary cells of a diffusible
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protein factor that can Increase transcriptional rate, and whose effect is
mediated by binding to 3 or 4 sites within the proximal enhancer region.
Distal binding sites Using DNase I footprinting, Nelson et al (1988) found
that in addition to the four proximal protein binding sites described
above, there were four distal sites between positions -1579 and -1718 in
the rPRL gene (Figure 1.4). None of the total of eight sites were found
with non-pituitary protein preparations in these studies, but interestingly
the sites mutually competed for protein binding, suggesting that all eight
bound a single protein factor; in addition protein binding was effectively
reduced by competition with the tissue-specific enhancer sequences in the
rat GH gene. One of these distal protein binding sites was Independently
demonstrated by Kim et al (1988), immediately adjacent to the oestrogen
response element. The data of Nelson et al (1988) suggested the existence
of a single pituitary-specific factor, named "Pit-l", which binds to
enhancer regions of both PRL and GH genes. In fact it is now clear that
Pit-l is the same as the GH-specific factor GHF-I described by Lefevre et
al, (1987); this gene has now been cloned independently by the two groups
(Bodner et al, 1988; Ingraham et al, 1988), and is discussed in more detail
below.
1.4.1.3 Human prolactin gene
The tissue-specific regulation of the human prolactin gene has only been
much more recently studied, but the organization of at least the proximal
element of the 5' flanking region appears similar. Transfection studies
have shown that 740bp of hPRL promoter DNA can direct tissue-specific
expression of the CAT reporter gene in pituitary cells, but not in HeLa
cells. DNase I footprinting studies have indicated pituitary-specific
trans factor binding to three sites, corresponding to the highly homologous
- 15 -
DISTAL ENHANCER REGION PROXIMAL ENHANCER REGION
4D 3D 2D ID ERE












4P 3P 2P 1P m
















Figure 1. 4 Diagram of proposed binding sites in the rat PRL
gene for the pituitary-specific factor (Pit-l/GHF-
1>, shown as cross-hatched boxes 1P-4P and 1D-4D.
The oestrogen response element (ERE) is shown as a
stippled box, and putative response elements are
Indicated below.
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sites 1,3 and 4 in the rat gene, except that "site 4" is slightly further
upstream (Lemaigre et al, 1989). However it is worth noting that these
studies employed nuclear proteins derived from rat pituitary cells, and not
human tissue, and thus the evidence for a human Pit-l/GHF-1 protein is so
far indirect. This question will be addressed in the gel retardation
studies described in Chapter 7.
1.4.2 GROWTH HORMONE
1.4.2.1 Cls elements
Transfection studies using rat GH promoter-CAT fusion genes have shown
that as little as 235bp of rat GH 5*-flanking sequence are able to confer
cell-type specificity onto a reporter gene (Nelson et al, 1986). The
degree of expression fell dramatically with deletion of more than 181bp 5'
to the cap site, implying the presence of a tissue-specific enhancer
element between -181 and -235bp; however neither elements extending from
-235 to -146, nor from -181 to the cap site, were fully effective,
suggesting that the putative enhancer element was relatively extensive.
Independent transfection studies using much longer stretches of rat GH
promoter and 5'-flanking sequences (1800bp) confirmed that CAT expression
was restricted to pituitary cells, but this restriction of specificity was
lost when 5' sequences were deleted down to the -309 or -183 positions
(Larsen et al, 1986a). This suggested the presence of upstream repressor
elements which normally prevented gene activation in non-pituitary cell
types. Although these data conflict with those of Nelson et al (1986), in
suggesting that tissue-specificity is not conferred solely by 235bp of 5'-
flanking sequences, further data from Larsen et al (1986b) showed that
sequences between -183 and -202 were able to confer thyroid hormone
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responsiveness, but only in pituitary-derived cell lines. Thus there is
evidence for overlap between these two aspects of gene regulation: a
thyroid hormone response element (discussed in more detail below) may
respond in a tissue-specific manner; or conversely, hormone responses may
be mediated by interaction with tissue-specific trans factor binding, and a
larger enhancer region consisting of a thyroid hormone response element may
be functionally linked with tissue-specific elements (Ye et al, 1988).
1.4. 2. 2 Cls/trans interactions
Gel retardation analysis has been used to demonstrate tissue-specific
protein interactions with rat GH 5'-flanking sequences by Ye & Samuels
(1987). Nuclear protein extracts from pituitary GO or GH4C1 cells
selectively retarded the electrophoretic migration of -104/+7 and -236/-146
restriction fragments, whereas nuclear proteins from rat hepatoma or
fibroblastic cells failed to do so.
More precise localization of protein-binding sites within rat GH 5'-
flanking DNA has been undertaken with DNase I footprinting studies. As for
the studies on the rPRL gene, the exact details vary slightly between
different reports, but two consensus footprints may be deduced between
positions -98 and -62 ("GCl"), and -140 and -106 ("GC2"), as summarised in
Figure 1. 5 (Ye et al, 1988; West et al, 1987; Catanzaro et al, 1987; Glass
et al, 1987; de Groot et al, 1988). Other footprints have been shown
further upstream (Glass et al, 1987; de Groot et al, 1988); a site at
-220/-241, termed "GC3" has recently been shown to be pituitary-specific,
but binds a diferent protein factor from the GCl and GC2 sites (Gu6rin &
Moore, 1988). The spatial relationship between the two proximal elements
is important, and Ye et al (1988) showed that proteins must bind on the
same side of the DNA helix to preserve full efficacy of this region,
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Figure 1.5 Diagram of proposed protein binding sites in the rat
and human GH genes, as described by different authors.
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suggesting that contact between two protein-DNA complexes is necessary.
1. 4. 2. 3 Human GH gene
TranBfection studies of the human GH gene showed that 500bp of 5'-
flanking DNA allowed expression of a reporter gene in rat GO or GH3 cells,
but not in the non-pituitary Rat-1, HeLa or placental JEG-4 cell lines
(Lefevre et al, 1987), suggesting the presence of a cell-type specific
enhancer element within this region. Likewise Cattini et al (1986a), using
deletion analysis, found that an element between -230 and -180 was
necessary for pituitary-specific expression.
Using DNase I footprinting, Lefevre et al (1987) found three hGH sites
binding proteins from rat GC cell extracts at -66/-93, -106/-140 and -254/-
290; of these three sites, part of site 2 and all of the distal site 3 were
also protected by HeLa cell extracts. Thus two pituitary-specific protein
binding sites were identified (sites 1 and 2a; Figure 1.5), and they
mutually competed for binding of a single protein factor which was named
"GHF-l". Mutations within either site abolished GHF-1 binding. In fact
both GHF-1 sites contain regions very highly homologous to the GC1 and GC2
sites described for the rGH gene promoter (West et al, 1987; Catanzaro et
al, 1987) and have similar locations. GHF-1 is not the only protein
involved however, and Imagawa et al (1987) have demonstrated footprints
from binding of purified "Activator Protein-2" (AP-2) to two further sites
in the hGH gene 5'-flanking region: AP-2 is a trans acting factor which is
involved in intracellular messenger signalling, and is not a tissue-
specific factor, and indeed the more distal 6ite in fact coincides with the
non-tissue-specific site 3 found by Lefevre et al (1987), as shown in
Figure 1.5.
The functional importance of these protein-binding regions in maintaining
-20-
hGH gene transcription has been demonstrated by in vitro transcription
experiments. Bodner & Karin (1987) found that 289bp of hGH 5'-flanking DNA
was able to efficiently support transcription with pituitary GC cell
nuclear protein extracts. HeLa cell extracts alone were much less
efficient in supporting transcription from the hGH promoter template, but
complementation with pituitary extracts increased transcriptional activity.
Mutations in each of the two GHF-1 binding sites caused a severe reduction
in transcriptional activity of the template.
1.4.3 SUMMARY: FUNCTION AND NATURE OF PIT-l/GHF-1
For both the PRL and GH genes, in both man and rat, there is evidence for
the existence of DNA sequences which are responsible for tissue-specificity
of gene expression. Binding of nuclear proteins to these regions has been
demonstrated, and appears to be responsible for establishing basal levels
of gene transcription. Two sites within the rat and human GH promoter DNA
are homologous and appear to bind the same protein trans acting factor
(GHF-1, or GC1/GC2); eight sites upstream of the rPRL gene, and at least
three sites for the hPRL gene also appear to bind a single trans factor,
(Pit-1) and sequences of the GH gene compete for protein binding. Thus a
single protein in both rat and human (Pit-l/GHF-1> may be responsible for
directing expression of both genes and may also bind to the promoter of the
TSH-{5 gene (Nelson et al, 1988).
The cDNA encoding Pit-l/GHF-1 has recently been cloned (Bodner et al,
1988; Ingraham et al, 1988) and the sequence identity confirmed. The
factor is now known to be a 33kD protein, which contains an amino-terminal
60-amino-acid region which is related to the "homeodomain" which
characterizes a class of genes important in embryonic development in
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Drosophlla. It has therefore been described as a member of the "POU"
family of homeodomain transcription factors (Herr et al, 1988; Mitchell 4
Tjian, 1989). At the carboxy-terminal a 76-amino-acid region is homologous
to the mammalian transcription factor Oct-2, which regulates lymphoid-
epeclfic expression of Immunoglobulin genes. Another member of the POU
family, Oct-1, has a similar DNA recognition sequence, but has a ubiquitous
tissue distribution. Minor changes in DNA recognition sequence are
sufficient to change the tissue specificity of these transcription factors
between pituitary and lymphoid cell types (Elsholtz et al, 1990). Detailed
studies on the functional domains of Pit-l/GHF-1 (Theill et al, 1989) have
6hown that the homeodomain is sufficient for DNA-binding to the hGH gene
promoter, and its activity is stimulated by the POU-specific domain.
Transcriptional activity appears to be dependent on a separate domain, rich
in hydroxylated amino-acids and named the STA domain (serine, threonine-
rich activation domain). This feature is shared by Oct-2 and another
member of the POU-domain family, unc-86.
There is disagreement on the crucial point as to whether Pit-l/GHF-1
protein can bind to both the PRL and GH promoters (Mangalam et al, 1989) or
Just the GH promoter (Castrillo et al, 1989; Theill et al, 1989; Karin et
al, 1990). However, Pit-l/GHF-1 mRNA i6 expressed in lactotrophs and
thyrotrophs as well as somatotrophs (Crenshaw et al, 1989). Affinity
purified Pit-l/GHF-1 is able to direct transcription in vitro from both the
PRL and GH promoters, and permanent transfectlon studies have shown that
even low-level expression (a6 well as the very high level expression
obtained with transient transfection) of the Pit-l/GHF-1 gene in
heterologous HeLa cells will activate transcription of constructs
containing either PRL or GH promoters (Mangalam et al, 1989; and see also
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Ingraham et al, 1988). The most direct demonstration that cis-active
elements binding Pit-l/GHF-1 are indeed important in vivo in directing
tissue-specific expression has recently come from experiments using
transgenic mice. Lira et al (1988) 6howed that upstream sequences of the
rat GH gene were able to direct expression of a linked human GH structural
gene predominantly in pituitary somatotrophic cells, but also in
lactotrophs and thyrotrophs, while not in gonadotrophs or corticotrophs.
The fact that Pit-l/GHF-1 is found in three pituitary cell types suggests
that some restrictive mechanism must exist to specify PRL or GH gene
expression in their respective cell phenotypes. Transgenic mouse
experiments have shown that the PRL upstream enhancers directed pituitary-
specific reporter gene expression: either the proximal or the distal
enhancer elements directed low-level expression, but when both elements
were combined they interacted synergistically to direct high-level
expression which was confined exclusively to lactotrophs. When the distal
enhancer element was isolated from its flanking DNA, it directed reporter
gene expression to thyrotrophs as well as lactotrophs (Crenshaw et al,
1989). A speculative model was therefore proposed in which the proximal
and distal enhancer elements themselves could activate PRL gene expression
in lactotrophs but restict it in somatotrophs, while DNA elements flanking
the distal enhancer region restricted PRL expression in thyrotrophic cells.
However there may be other mechanisms in operation as well, determining the
level of Pit-l/GHF-1 expression and activity: GH gene expression is
extinguished when pituitary cells are fused with heterologous somatic L-
cells, and this process is accompanied by loss of GHF-1 mRNA accumulation
and protein production (McCormick et al, 1988). This suggests that a
repressor factor restricts the tissue-specific expression of Pit-l/GHF-1
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itself, and it is likely that more interacting factors will be discovered.
In summary, a current working hypothesis suggests that a single trans¬
acting factor directs cell-type-specific expression of three genes <PRL, GH .
and TSH-p) to three cell types within the pituitary, and that additional
undefined DNA-protein interactions restrict the ultimate expression pattern
to just one of these hormone genes in each case. The pattern of gene
expression within a single cell type presumably reflects the integration of
a variety of other signals such as thyroid hormone, glucocorticoids, sex
steroids and peptide hormones. The proximity of Pit-l/GHF-1 sites to
hormonally responsive regions in both genes is noteworthy, and it may be
that some hormonal signals exert their effect by modifying the binding of
tissue specific factors, or by covalent modification of trans factors that
are already bound to DNA sequences, increasing or decreasing their ability
to interact with the RNA polymerase II transcription initiation complex.
Immediately before submitting this thesis, two further important studies
have been published on the nature of Pit-l/GHF-1, which both favour its
role as a GH-specific transcription factor. Doll£ et al (1990) have found
that Pit-l/GHF-1 mRNA expression in the fetal mouse pituitary is confined
to somatotrophs, apart from a transient period of lower level expression in
lactotrophs, which then disappears. The expression in somatotrophs
preceded that of GH itself by three days. Secondly, McCormick et al (1990)
have analysed the Pit-l/GHF-1 promoter and found that it contains two CREB
binding sites, but also a binding site for Pit-l/GHF-1 itself, and a site
for a "somatotroph determining factor". Thus Pit-l/GHF-1 expression was
cAMP-responsive and perhaps mediated cAMP regulation of GH production; once
produced, it can maintain its own production, committing the cell's
somatotrophic differentiation.
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1.5 HORMONAL AND INTRACELLULAR REGULATION
Whereas the tissue-specific expression of the PRL and GH genes involve a
common mechanism, at least in part, their hormonal regulation differs
markedly. A large number of hormonal signals may act upon given cell
types, and in principle these might act either independently or by
modulating ti6sue-specific control mechanisms. Thus, hormonally induced
trans-acting factor activation may either have a direct effect on
"dedicated" hormone-responsive DNA sequences, or an indirect effect by
modulating tissue-specific protein (for example Pit-l/GHF-1) interactions
with DNA. The latter possibility has recently been proposed to explain the
action of the glucocorticoid receptor on the PRL gene (Adler et al, 1988).
Oestrogen and thyroid hormones exert their effects by binding to specific
nuclear receptors which have been shown to be DNA-binding proteins, and
much of our present understanding of receptor-DNA interactions derives from
exciting recent work on nuclear receptor structure (reviewed by Evans,
1988). But peptide hormones and dopamine, which bind to membrane
receptors, must act through Intermediate intracellular signalling systems
via "second messengers" (Berridge, 1985; Brown et al, 1985), and the ways
in which these act to regulate gene transcription is much less clear. For
these substances, the relevant pathways linking second messenger formation
to trans-activating proteins have yet to be characterized: do the various
intracellular signals linked to given membrane receptors initiate a cascade
which converges onto a final common pathway in the nucleus, or is the
variety of second messenger signals an Important channelling mechanism




1.5.1.1 Nuclear hormone receptors
PRL gene transcription is affected by a wide variety of hormones (Table
1. 1); for some of these, hormone responsive elements have been clearly
identified in the 5*-flanking region of the PRL gene.
Oestrogen 17-p-oestradiol causes increased accumulation of PRL mRNA in rat
pituitary cells in vitro (Stone et al, 1977) and in vivo (Tong et al,
1989), and this effect is due to a rapid stimulation of the rate of gene
transcription (Maurer, 1982a; Shull & Gorski, 1984; Waterman et al, 1988).
There is little or no effect with progesterone or androgens, although
androgens may reduce the oestrogen-induced stimulation in vivo (Tong et al,
1989). The stimulatory effect of oestrogen is exerted by direct binding of
oestrogen receptor (ER) to the rPRL gene (Green & Chambon, 1986; Evans,
1988), and an oestrogen response element (ERE) in rat PRL 5'-flanking DNA
has been located more than 1500bp distant from the transcription initiation
site (Maurer, 1985; Maurer & Notides, 1987; Waterman et al, 1988;
Somasekhar & Gorski, 1988). This ERE is close to a region of ONase I
hypersensitivity, which may be Important in the mechanism of
transcriptional activation (Durrin et al, 1984; Durrin & Gorski, 1984); but
the ERE is also Immediately adjacent to one of the four distal Pit-l/GHF-1
binding sites (Kim et al, 1988; Nelson et al, 1988) suggesting possible
interactions between oestrogen receptor and the Pit-l/GHF-1 protein.
G1ucocorticolds Dexamethasone inhibits PRL gene transcription by an action
exerted within the proximal 5"-flanking region of the rat and bovine gene
promoters (Camper et al, 1985; Adler et al, 1988; Sakai et al, 1988;
Somasekhar & Gorski, 1988). The bPRL gene promoter contains multiple



















Cyclic AMP + +
Calcium + +
Phorbol ester +
Table 1. 1 Summary of known effects of hormones and intracellular
messenger substances on gene transcription or mRNA
accumulation. + indicates stimulation, and - indicates
inhibition.
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appear to differ from positive GRE consensus sequences (Sakai et al, 1988).
However interestingly it was found that an inhibitory effect of oestrogen
on the proximal region of the rPRL promoter could be expressed in specially
manipulated circumstances (by inducing over-expression of the ER); it was
then shown that the inhibitory effect of the glucocorticoid receptor (GR)
and the overexpressed ER was not exerted by their DNA-binding domain (Adler
et al, 1988). Thus, the stimulatory and inhibitory effects of these
receptors were exerted by different parts of the molecule, and the negative
effects did not involve direct protein-DNA interaction but mo6t probably
indirect effects on other DNA-binding proteins.
Various protein-protein interactions have recently been proposed for
glucocorticoid receptor action on other genes, where the spatial
arrangement of glucocorticoid response elements is critical and are
frequently clustered with other trans factor binding sites (Schtlle et al,
1988). Indeed in the pituitary glycoprotein a-subunit gene, Akerblom et al
(1988) found overlap between the cAMP responsive region of the gene
promoter and the GR binding element, and suggested that negative regulation
could result from interference of a hormone-receptor-DNA complex with other
positive trans-activating proteins.
Thyroid hormone and Vitamin D Two other nuclear receptors, binding T» and
vitamin D respectively, are closely related (Evans, 1988), and seem likely
to exert effects on the PRL gene, but in contrast to the rapid advances in
knowledge of GH gene regulation by Ts, less is known about their mechanism
of action on the PRL gene. It has been shown that T» inhibits PRL mRNA
accumulation in rat pituitary cells (Maurer, 1982b; Stanley & Samuels,
1984), and that the weak thyroid hormone agonist drug phenytoin has similar
effects (Davis et al, 1986). Transient transfection of GH cells with
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plasmid expression vectors containing the c-erb-A a and 0 genes (encoding
T3 receptors) have shown T3-inducible inhibition of expression of a co-
transfected PRL promoter-reporter gene construct, providing the first
evidence that c-erb-A proto-oncogenes can directly affect the PRL (and also
GH) gene expression (Forman et al, 1988).
However the overall picture is complex. Transient transfection assays in
GH3 cells using deletants of the rPRL promoter have disclosed both
positively and negatively acting T3-response elements in the distal
(-1530/-1565bp) and proximal (-292/-38bp) enhancer regions respectively
(Day & Maurer, 1989a). Furthermore, different GH cell lines display
different responses of transfected rPRL-CAT constructs to T3, with
stimulation in GH^Cl cells, but inhibition in GH, cells (Stanley, 1989).
Thus the rPRL gene possesses countervailing response elements, and also
that different cells presumably possess different trans-acting factors, the
balance of which determine the ultimate cellular response to T3.
Vitamin D has been shown to stimulate cytoplasmic accumulation of rPRL
mRNA (Wark & Tashjian, 1983) and this stimulation is antagonized by
glucocorticoid (Wark & Gurtler, 1986); however little more is so far known
about the interaction of Vitamin D receptor with this target gene. It
seems reasonable to speculate that nuclear receptors for T3 and vitamin D
may interact with DNA or other trans factors in a manner similar to the ER
and GR, and indeed it has been found that T3-receptor may bind to oestrogen
response elements in a transcriptionally inactive form, to decrease the
overall level of gene transcription (Glass et al, 1988).
1.5.1.2 Peptide and dopamine regulation
Thyrotrophin-releasing hormone (TRH) stimulates rPRL gene transcription
within minutes, and increases cytoplasmic mRNA accumulation (Laverriere et
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al, 1983; Murdoch et al, 1983; White & Bancroft, 1983). In addition TRH
increases the half-life of cytoplasmic mRNA from 17 to 27 hours (Laverriere
et al, 1983). Similar stimulation is seen with epidermal growth factor
<EGF; White A Bancroft, 1983; Murdoch et al, 1985b). Supowit et al (1984)
showed by transfection studies that 3000bp of 5'-flanking DNA conferred EGF
responsiveness onto a reporter gene, and for the bovine PRL gene the
proximal 250bp were sufficient to allow stimulation by TRH and EGF (Camper
et al, 1985), implying that the proximal enhancer region contains the
necessary sequences for recognition of the intracellular signals generated
by these two peptide hormones. Vasoactive intestinal peptide (VIP) also
elevates PRL mRNA levels in pituitary cells (Carrillo et al, 1985).
Dopamine rapidly inhibits PRL gene transcription, as does the dopaminergic
drug bromocriptine (Maurer, 1980, 1981, 1982c; and see Chapter 2),
consistent with the well known dopaminergic suppression of prolactin
secretion. Basic fibroblast growth factor markedly stimulates rPRL mRNA
accumulation but has no effect on GH mRNA (Black et al, 1989), and finally,
Y-amino-butyric acid (GABA) inhibits and insulin stimualtes PRL mRNA
accumulation (Loeffler et al, 1985; Prager et al, 1988).
These various hormones are thought to act through different intracellular
mechanisms: TRH stimulates the hydrolysis of membrane phospholipids
resulting in protein kinase C activation and calcium mobilization, and
leading to phosphorylation of cytoplasmic and nuclear proteins (Drust &
Martin, 1982; Murdoch et al, 1982; Gershengorn, 1986;); EGF activates a
transmembrane protein kinase (Stoschek A King, 1986); VIP activates
adenylate cyclase (Gourdji et al, 1979), which results in phosphorylation
of a different group of proteins than with TRH action (Drust et al, 1982;
Murdoch et al, 1983). Thus the rPRL gene is likely to be controlled by a
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number of interacting intracellular messenger systems (Bancroft et al,
1985; Murdoch et al, 1985a).
1.5.1.3 Intracellular messenger pathways
Cyclic AMP Cyclic AMP has been shown to increase PRL gene transcription
(Maurer, 1981), and forskolin (which activates adenylate cyclase) increases
cytoplasmic mRNA accumulation (Murdoch et al, 1982b; Dave et al, 1987).
Cyclic AMP responsive elements (CREs) have been defined for various genes
including the pituitary glycoprotein oc-subunit (Delegeane et al, 1987), VIP
(Tsukada et al, 1987) and somatostatin (Montminy & Bilezikjian, 1987). The
best understood system involves the trans-acting factor CREB (CRE binding
protein) a 43kD protein which binds to an octameric CRE (Montminy &
Bilezikjian, 1987; Hoeffler & Habener, 1990). The DNA binding and
transcriptional efficacy of thi6 protein may be regulated by its phospho¬
rylation by cAMP-dependent protein kinase (Yamamoto et al, 1988). While
cAMP has clear effects on rPRL gene expression, these probably do not
involve CREB, as there are no classical CREs in the relevant enhancer
regions. However a second well documented system of cAMP regulation is
mediated by the trans-acting factor AP-2, which has two binding 6ites in
the hGH promoter (Imagawa et al, 1987) and a potential site in the rPRL
promoter. The cAMP induction was seen with promoter sequences as short as
127bp, which had little basal promoter activity (Keech & Guterrez-
Hartmann, 1989). Interestingly, however, another study showed that basal
as well as cAMP induced PRL gene expression involves both isozymes of the
catalytic subunit of protein kinase A (Maurer, 1989), and co-expression of
the protein kinase inhibitor gene in transfected cells reduces PRL promoter
induction by EGF, phorbol ester and oestradiol (Day et al (1989). Thus
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there is evidence that cAMP may interact with the mechanisms for tissue-
specific basal gene expression.
Calcium The intracellular signals known to mediate TRH action on PRL
secretion are intracellular calcium and protein kinase C. Intracellular
calcium appears to be crucial for PRL gene expression: GH3 cells grown in
low-calcium medium respond to addition of calcium by a dramatic rise in
both PRL synthesis and mRNA accumulation (White et al, 1981), which occurs
within 10 hours. On the other hand, removal of extracellular calcium by
EGTA rapidly reduces PRL mRNA levels to undetectable levels, whereas GH
mRNA levels show a smaller, slower fall (Gick & Bancroft, 1985). Calcium
influx into cells induced by the dihydropyridine calcium channel agonist
Bay K 8644 can stimulate PRL gene transcription rate (Hinkle et al, 1988;
Laverriere et al, 1988), again suggesting an effect of intracellular
calcium concentrations per se. However, studies utilising calcium
ionophores have been difficult to interpret, with conflicting results:
Murdoch et al (1985b) found no effect of either ionomycin or A23187 alone
on PRL gene transcription rate although they did synergise with the effect
of the phorbol ester TPA; in contrast Laverriere et al (1988) found that
both these agents increased transcription. A recent detailed study of
these agents has suggested that these ionophores may have non-specific
effects on gene transcription due to disruption of normal calcium gradients
between different intracellular compartments (White et al, 1989), rather
than the more specific responses seen using the dihydropyridine agents that
affect voltage sensitive channels only.
A requirement for calcium has further been demonstrated by studies using
calcium channel blocking agents such as verapamil, nifedipine or diltiazem,
and calcium antagonists such as cobalt (Murdoch et al, 1985b; Davis et al,
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1988a; Hlnkle et al, 1988). Studies with calmodulin-antagonist drugs have
suggested that PRL mRNA accumulation is calmodulin-dependent (Murdoch et
al, 1985b; White, 1985; Bancroft et al, 1985). The possible molecular
mechanisms for calcium/calmodulin action in the induction of PRL gene
transcription are discussed in detail in Chapter 5. However one particular
mechanism may involve the calcium/calmodulin-dependent nuclear protein, DNA
topoisomerase, which has DNA-unknotting and relaxing activity in vitro
(White & Preston, 1988). DNA topoisomerase interacted with three sites
within 3000 bases of PRL 5'-flanking DNA , and one of these sites was
within the first lOObp (White & Preston, 1988). Further recent evidence
from transfection studies have suggested that a "calcium regulatory
element" may lie within the first 174 bases of the 5' flanking DNA (Jackson
& Bancroft, 1988).
Protein kinase C PRL gene transcription is stimulated by activation of
protein kinase C with tumour-promoting phorbol esters such as 12-0-
tetradecanoyl phorbol 13 acetate (TPA; Murdoch et al, 1985b). Studies of
rPRL gene 5'-flanking DNA have demonstrated an upstream TPA response
element (Supowit et al, 1984). This in fact coincides exactly with the
EGF-response element, and lies between -78 and -35 bases upstream from the
transcription start site (Elsholtz et al, 1986). Thi6 region of DNA is
clearly of major interest as it forms part of a putative calcium-regulatory
element and a site of DNA topoisomerase action (Jackson A Bancroft, 1988;
White A Preston, 1988), but also represents the first proximal binding site
for Pit-l/GHF-1 (Nelson et al, 1988).
Great progress has recently been made regarding protein kinase C effects
on the transcription of other genes, notably the glycoprotein a subunit,
which are mediated by the trans-acting factor AP-1, encoded by the Jun
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proto-oncogene <Lee et al, 1987; Curran 4 Franza, 1988; Hoeffler et al,
1989). However It remains unclear whether AP-1 is Implicated In phorbol
ester stimulation of PRL gene expression, or whether other mechanisms are
Involved.
In summary, responses to various intracellular messenger systems seem to
involve proximal 5'-flanking DNA sequences in the rPRL gene, and the
relevant response elements may coincide with binding sites for Pit-l/GHF-1.
However such response elements may be multiple, and Day & Maurer <1989b)
have recently shown that the distal enhancer region (-1713/-1495) conferred
regulation by TRH, EGF and cAMP (though interestingly, not phorbol ester)
onto a reporter gene. These responses were equal to those seen with the
proximal enhancer, and a synergistic interaction was found between these
agents and oestradiol, suggesting co-operation between DNA-bound trans¬
acting factors.
1. 5. 2 GROWTH HORMONE
The number of probable hormonal regulators of the GH gene is rather
smaller than for PRL (Table 1. 1). The best studied of these regulators is
thyroid hormone (reviewed by Samuels et al, 1988), which is well known to
be a major regulator of GH secretion in vivo, at least in the rat; the
peptide hormones, growth hormone releasing factor (GRF), somatostatin and
IGF-I have so far received much less attention.
1.5.2.1 Thyroid hormone
Rat GH gene transcription is Induced by Ts by up to ten-fold in vivo and
in vitro in the pituitary GC cell line (Spindler et al, 1982; Nyborg et al,
1984; Yaffe & Samuels, 1984). This induction coincides with T» receptor
occupancy and alterations in chromatin structure (Nyborg et al, 1986). The
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c-erb-A proto-oncogene, which encodes a T3 nuclear receptor has now been
shown in co-transfection experiments to induce GH gene expression (Forman
et al, 1988).
The cis elements involved in this T3 regulation have been more precisely
located by transfection studies using various lengths of rat GH gene
promoter linked to reporter genes. In a series of experiments with cells
that had stably integrated the exogenous constructs into their genome, T3
induction could be observed with progressively smaller promoter fragments
from 1800bp (Casanova et al, 1985) down to 235bp of 5*-flanking DNA (Crew &
Spindler, 1986). Further analysis showed the simultaneous presence of a
positive and a negative thyroid response element (Wight et al, 1987); the
first of these behaved as an enhancer (at position -254/-241) but the
second did not, and overlapped with the TATA box (position -46/-21). Later
studies with staged deletions of 5' and 3* regions in rGH fragments (from
which the negative element had been deleted), mapped the borders of the
positive element to position -194/-169 (Wight et al, 1988) corresponding
closely to a T3 receptor footprint described by Koenig et al (1987), and
which contains part of a site that binds the c-erb-A proto-oncogene
translation product (Glass et al, 1987).
In transient expression studies of transfected cell6 (Larsen et al,
1986a; Flug et al, 1987), the data differed slightly from the results
described above, perhaps because the constructs are not Integrated in the
host cell genome and have a higher copy number of constructs per cell,
which might compete for binding of 6ome regulatory factors. Larsen et al
(1986a) found that sequences between positions -183 and -202 were able to
confer thyroid hormone responsiveness, but only in pituitary cell types,
indicating that a thyroid hormone response element itself may have tissue-
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specific characteristics. Ye et al <1988) proposed that two interacting
tissue-specific cis elements (at -137/107 and -95/-65> are functionally
linked with the Ts response element to act as an enhancer-like unit which
confers both cell-type-specific and Ta-regulated gene expression. Both
were necessary to confer regulated expression to heterologous promoters,
and it was suggested that the T3-receptor-DNA complex is able to enhance
the function of the cell-specific elements to increase the level of rat GH
gene expression. Finally, gel retardation and DNase I footprinting studies
have shown that purified Ta-receptor can bind to upstream regions of the GH
gene, and that there may in fact be multiple sites which can interact with
receptor within the region -530/+7 (Ye & Samuels, 1987; Apriletti et al,
1988; Lavin et al, 1988; DeGroot et al, 1988).
1. 5. 2. 2 Glucocorticoids
Transcription of the endogenous rat GH gene is induced by five to twenty-
fold in the GH cell line (Martial et al, 1977; Evans et al, 1982; Wegnez et
al, 1982). Initial attempts at studying the mechanism of glucocorticoid
action were undertaken using heterologous (non-pituitary) recipient cells
which had stably integrated the transfected rGH gene into their genome
(Doehmer et al, 1982; Kushner et al, 1982; Karin et al, 1984; Miller et al,
1984). A rGH promoter region as short as 248bp was able to confer
glucocorticoid induction to a reporter gene in heterologous cells (Heiser &
Eckhardt, 1985), but in transient transfection analyses using rGH 5'-
flanking DNA linked to a reporter gene in pituitary cells, Crew & Spindler
(1986) and Flug et al (1987) found only minimal glucocorticoid effects.
Birnbaum & Baxter (1986) found that a promoterless rGH gene was
glucocorticoid inducible, with mRNA of a nearly correct size, suggesting
that glucocorticoid response elements (GREs) were contained downstream, not
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upstream, from the transcription initiation 6ite. A GRE has been described
in the first intron of the human GH gene (Slater et al, 1985), and although
such a site has not yet been shown in the rat GH gene, its first intron
does not contain typical GRE sequences.
1. 5. 2. 3 Peptide hormone regulation and intracellular messenger systems
Hypothalamic GRF stimulates rat GH gene transcription in primary cell
cultures (Barinaga et al, 1983; Gick et al, 1984; Barinaga et al, 1985),
and also in transgenic mice overexpressing the human GRF precursor gene
(Hammer et al, 1985a). Somatostatin reduces rat GH mRNA accumulation (Wood
et al, 1987), although another study showed no immediate effects on
transcriptional rate (Barinaga et al, 1985). Insulin blocks T» stimulation
of rGH secretion (Melmed & Slanina, 1985) and may inhibit GH mRNA
accumulation (Melmed et al, 1985a; Yamashita & Melmed, 1986), but depending
on culture conditions, other workers have found that insulin may also exert
stimulatory effects (Isaacs et al, 1987a). Ectopic hypersecretion of GH by
transplanted tumours in the rat has been shown to inhibit GH mRNA
accumulation in vivo (Yamashita et al, 1986a), and this autoregulation
probably involves negative feedback from insulin-like growth factor 1
(IGF-lj Yamashita & Melmed, 1987).
Transcription of the rat GH gene may be modulated independently of GH
release: GRF stimulation of GH release is highly dependent upon extra¬
cellular calcium, whereas both basal and GRF-stimulated GH gene transcript¬
ion are much less 60 (Barinaga et al, 1985). Rat GH mRNA accumulation is
somewhat inhibited by removal of extracellular calcium but this effect is
much less marked than for PRL mRNA (Gick & Bancroft 1985; Bancroft et al,
1985). GRF is thought to exert its effect on somatotrophs through
- 37 -
stimulation of adenylate cyclase, and its effects on rat GH gene
transcription may be mimicked by exogenous cAMP (Clayton et al, 1986) and
adenylate cyclase activation, but not by activation of protein kinase C or
cell depolarization, which stimulate only secretion of GH (Barinaga et al,
1985; Morita et al, 1987).
1.5.2.4 Human GH gene
Analysis of stable transformants obtained by transfection of the human GH
gene with 500bp of promoter sequences into GH3 cells (Cattini et al, 1986b)
has shown that T3 inhibits hGH gene transcription while stimulating that of
the rat GH gene. However this T3 inhibition is not clearly linked to the
hGH promoter as it could not be shown in transient expression studies using
the CAT reporter gene (Cattini & Eberhardt, 1987; Brent et al, 1988). The
endogenous gene may not always behave in a similar fashion to a transfected
construct. Transcriptional control of the endogenous human GH gene has
been the subject of limited study, using tissue obtained from surgically
removed pituitary somatotroph adenomas. Isaacs et al (1987b) found
stimulation of hGH gene mRNA accumulation by dexamethasone, but no effect
of T3, in contrast to the inhibitory effects of T3 seen in 7 of 11 rat GC
cell lines stably transfected with a human GH gene construct. These
differences between transfected and endogenous genes, and the variability
of the transfection data, suggest that the cellular environment is
critically important in determining the ultimate response to a hormonal
stimulus.
Although a T3 response element has not yet been precisely identified in
the human gene, T3 receptor from lymphoblastic IM-9 cell nuclear extracts
is able to bind specifically between positions -129 and -290 in the 5'-
flanking region of the gene (Barlow et al, 1986), a position similar to
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that of the positive Ta response element in the rat gene. Glucocorticoids
stimulate expression of the transfected human GH gene (Robins et al, 1982;
Cattini et al, 1986b; Brent et al, 1988) similar to their effect on the rat
gene, and glucocorticoid response element has been demonstrated within the
first intron of the gene, that is, downstream of the transcription
initiation site (Eliard et al, 1985; Moore et al, 1985; Slater et al,
1985). A weaker glucocorticoid receptor binding site found within the
promoter region (Eliard et al, 1985) could be responsible for the hGH-CAT
response to the hormone (Cattini 4 Eberhardt, 1987).
Little work has been reported on the effects of peptide hormones on the
human GH gene, but Yamashita et al (1986b) showed suppression of hGH mRNA
levels by IGF-1 using cultured cells from a human pituitary adenoma; IGF-1
also prevented GRF-induced stimulation of GH mRNA levels. The
intracellular messenger systems which may regulate GH gene transcription in
the human pituitary are not yet known, but Brent et al (1988) showed that
the transfected hGH promoter was cAMP-responsive. The hGH promoter
contains no CREB binding sites, but its two AP-2 sites are not required for
cAMP induction of reporter gene expression, in transient transfection
assays (Dana 4 Karin, 1989), and thus the cAMP induction may involve Pit-
1/GHF-l, or perhaps another novel cAMP response element. Thi6 aspect of
hGH gene regulation is explored in the studies described in Chapter 4 of
this thesis.
1.5.3 SUMMARY: INTRACELLULAR CONTROL OF TRANSCRIPTION
For both the PRL and GH genes, a wide variety of hormones and intra¬
cellular signalling systems appear to have significant transcriptional
effects. Whereas basal tissue-specific expression of the PRL or GH genes
- 39 -
requires the interaction of Pit-l/GHF-1 with defined sites in their
promoters, modulation of a given level of expression may involve additive
effects of adjacent or distant hormone response elements, or modification
of Pit-l/GHF-1 or other factors already bound to their cis elements.
For the DNA-binding nuclear hormone receptors, the molecular basis of
their effects is increasingly well understood, with evidence for both
direct protein-DNA effects, and also for indirect protein-protein-DNA
interaction. The picture is much less clear for the effects of intra¬
cellular second messenger systems. However a number of interesting models
have recently been proposed for cAMP action on other genes, which may be
relevant (reviewed by Roesler et al, 1988). In a cell-free system the
transcription of the urokinase plasminogen activator gene is enhanced by
addition either of cAMP itself or of the purified kinase catalytic subunit
(Nakagawa et al, 1988). Thus a model may be proposed whereby cAMP (formed
as a result of membrane receptor activation) activates a kinase, resulting
in dissociation of its catalytic subunit: this is then translocated to the
nucleus and phosphorylates a positive nuclear trans-acting factor to
enhance gene transcription by RNA polymerase II. The trans-acting factor
CREB, whose transcriptional activity may be enhanced by cAMP-dependent
phosphorylation (Yamamoto et al, 1988), fits into thi6 model very neatly,
although there may be other potential mechanisms in addition. Very
recently, it has been found that CREB may activate transcription of Pit-
l/GHF-1, whose increased level of expression would then enhance GH gene
expression (McCormick et al, 1990), showing that even in this relatively
simple scheme, more than one transcription factor may be involved.
It is now recognised that many proto-oncogene products are directly
involved in intracellular signalling pathways and the regulation of gene
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transcription (Berridge, 1986), and some such proteins are now implicated
in the expression of the prolactin and GH genes, apart from the well known
example of the T» receptor, encoded by the proto-oncogene c-erb-A (Sap et
al, 1986; Weinberger et al, 1986). It has been shown that GRF, acting via
cAMP, can stimulate somatotroph cell division and also rapidly Increases
levels of c-fos mRNA (Billestrup et al, 1986; Billestrup et al, 1987). The
function of the fos protein in the pituitary is not yet known, but there is
now good evidence that it interacts, probably by dimerization, with the
proto-oncogene product, c-jun, which encodes "activator protein 1" (AP-1),
a recognised transcription factor which is responsive to activation of
protein kinase C (Lee et al, 1987; Chiu et al, 1988; Curran & Franza, 1988;
Hoeffler et al, 1989; Karin, 1989; Mitchell & TJian, 1989). Another such
factor, AP-2, appears to be linked both to protein kinase C and to cAMP
(Imagawa et al, 1987), and it will be interesting to learn whether the
potential AP-2 binding sites in the prolactin and GH gene promoters are
involved in intracellular control, and Indeed whether they may interact
with Pit-l/GHF-1 binding sites.
1.6 CONCLUSIONS
In this background review, I have discussed the tissue-specific and
intracellular mechanisms for the regulation of the PRL and GH genes. The
cell-type-specification of expression probably involves more than one
pituitary-specific nuclear protein, and the role of Pit-l/GHF-1 has been
discussed. In terms of the mechanisms of hormonal control of PRL and GH
expression, the actions of steroid, thyroid hormone and peptide hormones on
gene transcription are rapidly being clarified. In particular, many of the
relevant DNA response elements are now Identified, and in some cases the
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trans-acting factors are known. Interestingly, the response elements
involved in hormonal control of these two genes are closely related to
Pit-l/GHF-1 binding sites, if not coincidental, thus the mechanisms of
intracellular regulation appear to impinge on those of tissue-specificity.
A general speculative model may perhaps be proposed whereby the basal level
of gene transcription is determined by constitutive tissue-specific factor
binding, and the hormonal stimulation or inhibition of transcription is
superimposed, mediated by interactions between Pit-l/GHF-1 and other
hormone-regulated or 2nd messenger-regulated nuclear proteins such as CREB,
AP-1 or others yet to be identified.
The potential importance of such mechanisms in the pathogenesis of
pituitary disease is unknown, but abnormalities of hormone gene
transcriptional control may be involved. An approach to this topic forms
the subject of much of this thesis.
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CHAPTER 2
DOPAMINERGIC REGULATION OF RAT PROLACTIN
oRNA ACCUMULATION
2.1 INTRODUCTION
Prolactin <PRL> secretion and gene transcription are inhibited by
dopamine and dopaminergic drugs such as bromocriptine, and the PRL-
inhibitory effect of bromocriptine has been of dramatic benefit
clinically in the treatment of PRL-secreting pituitary tumours. In
addition to reducing serum PRL levels, both bromocriptine and the newer
ergot derivative pergolide have been shown to reduce the size of large
prolactinomas (McGregor et al, 1979; Kendall-Taylor et al, 1982; Franks
& Jacobs, 1983). The reduction in size of these tumours may be dramatic
(Clayton et al, 1985), and although the mechanisms for such shrinkage
are not understood, a close relationship appears to exist between the
control of hormone production and that of tumour growth.
Very little is known about the dopaminergic regulation of endogenous
PRL gene transcription in human pituitary tissue, and this will form the
subject of the studies described in Chapter 3. However before
presenting this work, and in order to demonstrate the application of a
simple hybridization assay to such studies on normal pituitary tissue,
this Chapter will describe the effects of three different dopamine
agonist agents on cultured rat pituitary cells.
The clinical use of bromocriptine and pergolide has become well-
established, but the frequency of adverse effects has led to the recent
development of two new agents, CV 205-502 and CQP 201-403 (Sandoz
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Pharmaceuticals). CQP 201-403 is a propylergoline and CV 205-502 a
benzolg]quinoline (Nordmann & Petcher, 1985), and while both agents are
ergot derivatives, their structure differs substantially from
bromocriptine (Figure 2.1), and thus their effects and potency might be
expected to differ. Both drugs in fact appear to be more potent than
bromocriptine in lowering serum PRL in vivo in both normal subjects and
in hyperprolactinaemic women (Grevel et al, 1986; Rasmussen et al, 1987;
Hanssen et al, 1988; Rasmussen et al, 1988).
Both CV 205-502 and CQP 201-403 inhibit PRL release by normal rat
pituitary tissue and also human prolactinoma tissue in vitro, as studied
by the perifusion technique (Venetikou et al, 1987). These studies
showed that in comparison to the transient inhibitory effect of
dopamine, both agents caused profound and prolonged inhibition of PRL
secretion, while there was little or no effect on growth hormone <GH)
release. Thus it is clear that these newer dopamine agonists reduce
prolactin release, but there is so far no information as to possible
effects on hormone synthesis, which may be important if the drugs are to
be of value in the long term treatment of hyperprolactlnaemia or in
attempts to reduce the size of large prolactinomas.
The effects of both agents on PRL mRNA accumulation were compared
with those of bromocriptine in rat pituitary tissue, using the
cytoplasmic dot hybridization method developed by White & Bancroft
(1982). This technique has been extensively used for the study of
pituitary hormone gene expression in vitro (Carrillo et al, 1985;
Clayton et al, 1986; Davis et al, 1986; Preston & White, 1988), and it
is simple and relatively rapid, allowing comparison of mRNA levels in
multiple tissue samples.
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For these experiments the use of the clonal GH cell lines was not
possible as these cells lack functional dopamine receptors. Normal rat
pituitary tissue was therefore required, and for these studies primary
monolayer cell cultures were prepared from normal rat pituitary glands
as described in Appendix Al.1. Briefly, up to 10 male rat pituitary
glands were chopped into small fragments before enzymatic dispersion
using collagenase and hyaluronidase. The cell suspension was washed
free of enzyme solution, the cells counted, and plated onto 24-well cell
culture plates at a density of approximately 5 x 10* cells/well.
The cells were allowed to attach to the culture dishes for several
days, and were then transferred to serum-free medium before treatment
for 24-hour periods with either CV 205-502, CQP 201-403 or bromocriptine
(Sigma Chemical Company, Poole, Dorset, UK). All three drugs were
initially dissolved in ethanol, before dilution in culture medium. At
the end of treatment periods, medium was removed for radioimmunoassay of
released hormone (Appendix A4.1), and cells were scraped from culture
wells for preparation of cytoplasmic samples.
Messenger RNA concentrations were estimated using the technique of
cytoplasmic dot hybridization. The procedure is described in detail in
Appendix A3. 1. Briefly, cytoplasmic samples were prepared from the
cultured cells, and applied in duplicate onto a hybridization transfer
membrane. Membranes were prehybridlzed before hybridization for 24h
with radlolabelled cDNA probes for rPRL (Gubbins et al, 1979) or rGH
(Harpold et al, 1978), then washed to remove unbound probe, and
subjected to autoradiography for 3-5 days at -70*C. Statistical
comparisons were made with one-way analysis of variance.
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2.3 RESULTS
2.3.1 Dose-dependent inhibition of PRL release and mRNA levels
Both CV 205-502 and CQP 201-403 caused similar dose-dependent
inhibition of PRL release in initial experiments to 8.9% and 13.6% of
control release respectively at lOOnM concentrations <P < 0.001 compared
to control; Figure 2.2). A similar dose-dependent inhibition was seen
with bromocriptine, although the maximal suppression was slightly less
<24.7% of control secretion at lOOnM bromocriptine). GH release in
these experiments was somewhat variable but no consistent dose-dependent
effect was seen (P > 0.05; Figure 2.3).
Both agents inhibited PRL mRNA accumulation. The dose-dependency of
mRNA accumulation with each drug was somewhat variable, but
statistically significant inhibition of PRL mRNA levels (to 69% and 52%
of control in single experiments) was seen with doses of CV 205-502 and
CQP 201-403 as low as InM (P < 0.05 compared to control; Figure 2.4).
However the maximal inhibition was in all experiments less than that
seen for PRL release, similar to that seen with bromocriptine, and the
greatest degree of suppression seen in individual experiments was to 42%
of control with lOOnM CQP 201-403.
2.3.2 Pooled data for lOOnM doses of CV 205-502 and CQP 201-403
Because of individual variability between dose-response experiments,
a comparison was made of maximally effective PRL-inhibitory doses of
CV 205-502, CQP 201-403 and bromocriptine using data pooled from three
separate experiments; this confirmed the striking inhibition achieved by
all three agents on PRL release (P < 0.005 compared to control in each











Figure 2.2 Effect of increasing doses of CV 205-502 (open
bars) and CQP 201-403 (hatched bars) on PRL
release from cultured rat pituitary cells. Data
are means t SEM, n = 7 replicate culture wells,
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Figure 2. 3 Effect of increasing doses of CV 205-502 and
CQP 201-403 on GH release from cultured rat
pituitary cells. Data are means ± SEM, n - 7
replicate culture wells, pooled from the two
separate experiments shown in Figure 2. 2;
* P < 0.001 compared to control.
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Figure 2.4 Efects of increasing doses of CV 205-502, CQP 201-
403 and bromocriptine on relative PRL mRNA
concentrations. mRNA data are expressed in
arbitrary units of optical density (0. D.),
relative to control values of 1.0. Data are
means ± SEM, n = 3-4 replicate culture wells from
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Figure 2.5 Effects of lOOnM doses of CV 205-502, CQP 201-403
and bromocriptine on PRL release, PRL mRNA
concentrations, GH release and GH mRNA
concentrations. Messenger RNA data are expressed
in arbitrary units of optical density (0. D. ),
relative to control values of 1.0. Data shown are
combined results of 3 (PRL data) or 2 (GH data)
separate experiments, n = 8-18 replicate culture
wells for each group; * 2P < 0.005 compared to
control.
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PRL mRNA accumulation was clearly reduced by all three dopamine agonist
agents, but this inhibition was less marked than that of PRL secretion,
only to 50%, 67% and 51% of control values by CV 205-502, CQP 201-403
and bromocriptine respectively (P < 0.005 compared to control in each
case; Figure 2.5). In contrast, no inhibitory effects were seen on
either GH release or GH mRNA accumulation <P > 0.5; Figure 2.5).
2.4 DISCUSSION
In this Chapter, the technique of cytoplasmic dot hybridization
analysis has been applied to study dopaminergic inhibition of PRL mRNA
accumulation in primary cultures of rat pituitary cells. The data
confirm previous data for the inhibitory effect of bromocriptine on rPRL
mRNA and show that both of the novel dopamine agonist drugs had similar
inhibitory effects on PRL but not GH production.
In contrast to the profound inhibitory effects of both agents on PRL
release, the inhibition of PRL mRNA accumulation was less marked, but
comparable to that achieved by a similar high (lOOnM) dose of bromo¬
criptine. The reason for this lesser effect on mRNA levels may be the
relatively long half-life of PRL mRNA <~ 17 hours; Laverriere et al,
1983; Rosenfeld et al, 1987), which means that rapid changes in the rate
of gene transcription have slow effects on the cytoplasmic accumulation
of mRNA species. In previous studies of the effect of bromocriptine,
50% inhibition of PRL mRNA accumulation was seen between 24 and 48
hours, (similar to the present findings with CV 205-502 and CQP 201-
403), though maximal suppression of mRNA levels took up to 96 hours
(Maurer, 1980). These two newer dopamine agonist drugs are more potent




yet the data shown here do not provide clear evidence for greater
potency at the level of mRNA accumulation, and further studies of longer
term effects of lower doses of these drugs would be necessary to detect
differences between the potency.
Neither CV 205-502 nor CQP 201-403 had any significant effect on
either GH release or GH mRNA levels in this study. One previous study
of these drugs in vitro showed a small inhibition of GH release with CQP
201-403 and no effect with CV 205-502 (Venetikou et al, 1987), although
both drugs at least partly blocked the stimulation of GH release by GRF.
The present data confirm previous findings that GH mRNA levels were
unaffected by bromocriptine (Wood et al, 1987), as was found with both
the new dopamine agonist drugs.
In conclusion, these results document suppressive effects on
lactotrophs of three structurally different dopamine agonist agents,
both at the level of acute hormone release but also a pre-translational
site of action, to reduce PRL mRNA accumulation and hence PRL synthesis.
Thus the technique of cytoplasmic dot hybridization can be applied to
normal rat pituitary tissue to demonstrate dopaminergic suppression of
PRL mRNA levels. Chapter 3 will describe the application of the same
techniques in an in vitro study of an aggressive prolactinoma, in an




CLINICAL AND CELL CULTURE STUDIES
3. 1 INTRODUCTION
Prolactin-secreting pituitary tumours commonly present in women as small
intrasellar microadenomas, but especially in men, the tumours may be much
larger, and present as macroadenomas more than 1cm in diameter (Nabarro,
1982; Grossman & Besser, 1985). Dopamine agonist drugs have an important
role in the management of these tumours, and may be highly successful in
reducing their size as well as their endocrine effects (Vance 4 Thorner,
1987). "Giant" prolactinomas, of several centimetres diameter and with
major extrasellar tumour extension, are rare and may provide special
problems of management. One reported case showed marked shrinkage within
six days of bromocriptine therapy, and almost complete regression of the
tumour mass after 6 months of treatment (Clayton et al, 1985). Two further
cases of giant invasive prolactinomas (more than 4cm diameter) treated with
bromocriptine have been reported (Murphy et al, 1987): one tumour was only
partially responsive to bromocriptine, both in terms of serum PRL levels
and tumour size, although the other tumour had responded satisfactorily by
about eight years after radiotherapy.
There have been a limited number of in vitro studies on human PRL-
secreting tumours, usually using perlfuslon systems, (for example,
Venetikou et al, 1987; Bevan et al, 1989). These studies have provided
useful information on the hormonal responsiveness of these tumours in terms
of PRL secretion in vitro, which may differ from that found in normal rat
or human pituitary tissue (Jones et al, 1989). The properties of the type
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2 dopamine receptor appear to be essentially normal in non-functioning
tumours (Bevan et al, 1989), but in prolactinomas responses to dopamine or
bromocriptine in vitro appear to differ among different tumours (Bevan et
al, 1989).
There is so far no information about prolactin gene expression in human
prolactinomas. One reason for this is the limited amount of tissue
available for in vitro study: in many centres the referral rates for
pituitary surgery in these patients are relatively low compared to other
tumour types, patients being treated with dopamine agonists alone or in
conjunction with radiotherapy. One study has recently reported that the
v-fos protooncogene was amplified in a single prolactinoma <U et al; 1988),
but there have so far been no reports of regulated expression of the hPRL
gene Itself.
In the last chapter, rPRL mRNA levels were shown to be readily
suppressible by three different dopamine agonist drugs, suggesting that the
technique of cytoplasmic dot hybridization would be appropriate to attempt
to study the endogenous hPRL gene in prolactinoma tissue. In this chapter
one case of an unusually aggressive and locally invasive prolactinoma will
be described, with the results of cell culture studies that were performed
on the tumour to assess regulation of PRL secretion and mRNA levels by
bromocriptine.
3.2 CASE REPORT
The patient (M. H. > first presented in 1982 at the age of 40y with a 6
week history of frontal headache, diplopia and right sided ptosis. He had
been previously fit and healthy, and took no medication. On examination,
he had partial right 3rd, 4th and 6th cranial nerve palsies, and there was
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partial loss of the nasal field of vision in the left eye. Skull X-ray
showed an expanded pituitary fossa, and CT scan revealed a tumour extending
laterally and into the right sphenoid sinus, but with little suprasellar
extension. Endocrine testing pre-operatively revealed a serum PRL of
91,600 mU/L (normal levels <500mU/L), and partial hypopituitarism. At a
frontal craniotomy all of the intrasellar tumour was removed, but some of
the laterally extending tissue was not accessible. Histological
examination of the pituitary tissue revealed "excessive nuclear variation"
with a large number of mitoses.
Post-operatively, serum PRL levels fell only slightly but he became
panhypopituitary. He was treated with hydrocortisone, thyroxine and
testosterone replacement therapy, and commenced on bromocriptine 7. 5 mg
daily, before receiving 4500cGy external irradiation of the pituitary
region (three fields, 30 fractions over six weeks). Serum PRL levels fell
to a nadir of 11,000 mU/L after two months on bromocriptine 7. 5 mg daily,
but over the next nine months through 1983 it gradually rose to over 39,000
mU/L, despite increasing doses of the drug to 15 mg daily (Figure 3. 1).
Bromocriptine was discontinued during 1984 in view of its lack of
sustained effect on serum PRL levels, but he remained clinically well over
the next two years. However, in April 1986, he developed right sided 9th,
10th and 12th cranial nerve palsies, in addition to his pre-existing 3rd,
4th and 6th nerve palsies. Serum PRL was 120,000 mU/L (Figure 3.2). CT
scan appearances were little changed compared to 1982, but the tumour was
assumed to have extended inferiorly to cause lower cranial nerve damage. A
further trial of bromocriptine was commenced, using doses up to 30 mg
daily. Although this indeed reduced PRL levels to 20,000 mU/L (Figure
















Figure 3. 1 Patient MH: serum PRL levels 1982-1984 (days O-
600), showing the first hypophysectomy (Hypox) and
radiotherapy (DXT), and the initial treatment with
bromocriptine (dose indicated by hatched bar).
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Figure 3.2 Patient MH: serum PRL levels 1986-88 (days 1200-
2000), showing the second hypophysectomy (Hypox),
and radiotherapy (DXT) to the skull base, and
further treatment with different dopamine agonist
drugs (doses indicated by hatched bars). Note
logarithmic vertical scale.
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a transethmoidal hypophysectomy in an attempt to reduce the tumour bulk. A
large mass of tumour extended laterally to the right, superiorly and
inferiorly, and was largely removed. Histological examination showed a
cellular chromophobe neoplasm with solid sheets of pleomorphic cells with
hyperchromatic nuclei and a variable amount of cytoplasm. Numerous
binucleate cells and mitotic figures were found. Tumour tissue was
obtained at this operation for the in vitro studies of PRL release and mRNA
accumulation.
Serum PRL levels remained very high, despite a trial of pergolide
treatment. However the patient then developed a right parapharyngeal
abscess. This was treated successfully with antibiotics, but a residual
hard lymph node was found at the angle of the right mandible. Excision
biopsy revealed a lymph node adjacent to a mass of tumour tissue within the
internal jugular vein. Histological examination revealed only reactive
changes in the lymph node, but confirmed infiltration of the vein wall with
pleomorphic cells which showed positive immunostaining for PRL; furthermore
a fragment of this tissue secreted immunoreactive PRL when cultured in
vitro (data not shown), confirming extension of the pituitary tumour.
The patient was treated with further radiotherapy to the neck and skull
base <3000cGy, 10 fractions over 14 days), in an effort to halt further
extracranial extension of the pituitary tumour, and serum PRL levels in
fact fell markedly over the next three months from 140,000 to 18,000 mU/L,
in the absence of any further bromocriptine therapy. A subsequent trial of
the dopamine agonist drug CV 205-502 (described in Chapter 2) was started
in an attempt to reduce tumour bulk in the inferior petrosal sinus. Acute
administration of this agent caused transient suppression of serum PRL

















Figure 3.3 Patient MH: response of serum PRL to single doses
of bromocriptine <2. 5mg; open triangles) or CV205-
502 (25pg; open squares). Serum PRL levels during
a control day are shown by a solid line. Serum
PRL is shown here on a linear scale for clarity.
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However this suppression was not sustained with chronic treatment with
CV 205-502 (75 pg daily) over the subsequent three months, and serum PRL
remained between 12,600 and 22,100 mU/L. The patient reverted to
bromocriptine treatment, but PRL levels continued to rise gradually to over
4-6,000 mU/L in 1988. The patient complained of facial pain at this time,
and clinical examination suggested involvement of the right fifth cranial
nerve by tumour. A third hypophysectomy operation was performed in a
further attempt to reduce the tumour bulk. Tumour tissue was obtained at
the second hypophysectomy operation (1986) for the studies described in
this Chapter, and from the third operation (1988) for the transfection
6tudy described in Chapter 7.
3.3 CELL CULTURE STUDIES
3.3.1 Methods
Pituitary tumour tissue was enzymatically dispersed using collagenase and
hyaluronidase, using the same techniques employed for rat pituitary tissue
(see Chapter 2 and Appendix Al. 1). The yield of pituitary cells was
approximately 9. 0 x 10s cells, with a viability of 85% as assessed by
trypan blue dye exclusion. Dispersed prolactinoma cells were plated onto
plastic cell culture dishes at a density of approximately 2 x 10* viable
cells in 2ml per well in final culture medium (Dulbecco's modified Eagle's
medium containing 10% horse serum, 2.5% fetal calf serum and 2mM
glutamine). Cells were allowed to attach to the plastic dishes and were
grown in monolayer culture for five days before experiments commenced; they
were then washed by repeated medium exchanges, and treated with
bromocriptine or dopamine in serum-free medium for 24 hours.
Bromocriptine (Sigma Chemical Co, Poole, Dorset) was dissolved initially
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in ethanol before dilution in culture fluid; dopamine (Sigma) was dissolved
in culture fluid with ascorbic acid, in order to reduce degradation of the
dopamine. Thyrotrophin-releasing hormone (TRH; Roche Pharmaceuticals,
Welwyn, Herts) was dissolved directly in culture fluid.
Medium was then removed for radioimmunoassay of released hormone, using
MRC 83/562 as hPRL standard, and MRC 66/217 as hGH standard. These
radioimmunoassays were kindly performed by Miss Judy Webb and Dr DA Heath,
Department of Medicine, Queen Elizabeth Hospital (PRL), and Dr SS Lynch,
Department of Clinical Endocrinology, Birmingham & Midland Hospital for
Women (GH). Blank samples consisting of culture fluid alone showed no
cross-reaction in either assay, and assay coefficients of variation were
less than 10%.
Cytoplasmic extracts were prepared for dot hybridization analysis, which
was carried out as described for the studies in Chapter 2 (Appendix 3. 1),
using a 32P-labelled cDNA probe specific for hPRL (Truong et al, 1984),
which was generously provided by Dr JA Martial, University de Li£ge,
Belgium. The DNA probe was radiolabelled by nick translation, as described
in Appendix 2. 1.
3. 3. 2 Results
Over the first four days in culture, the cells produced large quantities
of PRL, and very small amounts of GH (Figure 3.4); however GH secretion was
not detectable in subsequent 24h incubations, implying that any
contamination with normal pituitary tissue was negligible. Treatment for
24h with both lOnM and lOOnM bromocriptine reduced PRL release from the
cultured cells to approximately 50% of control values; lOpM dopamine had a
similar effect. On the other hand, hPRL mRNA levels were only minimally
















Cultured human prolactinoma cells: accumulation of
PRL and GH in culture fluid over days 1-4. Data

















Figure 3. 5 Cultured prolactinoma cells: PRL secretion (open
bars) and mRNA accumulation (stippled bars).
Cells were treated for 24h as shown, and mRNA data
are expressed in arbitrary units of optical
density. Data are means ± SEM, n=4 per group;
*P<0.05, **P<0. 002 compared to control.
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effect (Figure 3.5). These results contrast markedly with the data
presented in Chapter 2 (and see also Wood et al, 1987) using normal rat
pituitary tissue, where dopaminergic inhibition of rPRL mRNA levels to
about 50% of control was readily observed.
A single high dose of TRH (lOOnmol/L) stimulated PRL release, but had
only marginal and non-significant effects on hPRL mRNA levels (not shown),
again in contrast to its well documented effects in rat pituitary tissue.
3.4 DISCUSSION
The case presented in this Chapter had an exceptionally aggressive and
locally invasive PRL-secreting pituitary tumour, which had spread along the
skull base with local extension through the inferior petrosal sinus to
emerge from the skull within the internal jugular vein. The tumour was
partially responsive to dopamine agonist therapy, because acute challenges
with bromocriptine and CV 205-502 transiently suppressed serum PRL levels.
However the suppression of serum PRL was not sustained despite moderately
high doses of three different dopamine agonist drugs. Resistance of a
small proportion of prolactinomas to dopamine agonist therapy is well-
recognised (Thorner et al, 1980; Breidahl et al, 1983; Bannister &
Sheridan, 1987), but the reasons for this resistance are not understood.
Although this is just a single and exceptional case, the opportunities to
study such tumours in vitro are rare and may provide valuable information
about the potentially abnormal intracellular regulation of hormone
production.
The cellular basis of for this dopamine resistance is not yet understood.
In a series of human pituitary tumours, membrane-associated dopamine (D-2)
receptors appear to be present and to have normal binding characteristics
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(Bevan et al, 1986). In two dopamine-resistant lactotroph tumours in the
rat, loss of membrane receptor-associated G-proteins has been described
(Collu et al, 1988), which would explain a loss of dopamine action despite
intact dopamine-receptor binding. The present tumour did respond to
dopamine agonists in vivo, and also in vitro in terms of hormone secretion,
so lack of dopaminergic receptors or absence of receptor-associated
proteins cannot explain the longer-term dopamine "resistance". However
there was no significant effect of high doses of either bromocriptine or
dopamine on hPRL mRNA accumulation. This contrasts with the findings in
normal rat pituitary tissue presented in Chapter 2, where bromocriptine and
two other dopamine agonists caused readily detectable suppression of rPRL
mRNA levels (albeit to a lesser extent than hormone secretion). The
techniques used for these experiments were identical, so it seems unlikely
that this reflects a technical limitation of the hybridization assay.
In the present tumour, therefore, it appears that hPRL mRNA accumulation
(and hence, presumably, hPRL synthesis) is relatively independent of
regulation by TRH and dopamine, in contrast to short-term secretion of the
hormone. If abnormalities at the level of membrane receptors and G-
proteins are excluded by the PRL secretion data, then these findings
suggest a possible abnormality between second messenger generation and gene
transcription. Examples of such a mechanism might include abnormal
regulation or production of a protein kinase or its substrate, or a nuclear
DNA-binding protein. Amplified expression of certain proto-oncogenes in
pituitary tumours could have these effects. Evidence that such a
supposition may be correct has come from U et al (1988) who analysed
genomic DNA from a single prolactinoma and a normal pituitary gland, and
found amplification of v-fos in the tumour. The fos proto-oncogene is
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known to be involved in the action of AP-1 (Curran & Franza, 1988), and is
responsive to cyclic AMP (Billestrup et al, 1987), and therefore amplified
v-fos expression could conceivably result in sustained non-suppressible
stimulation of PRL gene transcription, without necessarily interfering in
the hormonal regulation of acute hormone release.
In order to be more confident of such speculative conclusions it will be
necessary to study more pituitary tumours to see if the present findings
are typical or exceptional. While prolactinomas are now only rarely
available for in vitro study in many centres, GH-secreting tumours are more
readily obtainable from pituitary surgery, and data for hGH mRNA regulation
in a series of such tumours will be presented in Chapter 4.
- 67 -
CHAPTER 4
GROWTH HORMONE mRNA REGULATION IN
HUMAN SOMATOTROPH TUMOURS
4.1 INTRODUCTION
Knowledge of the hormonal control of GH gene expression has so far been
largely based on studies of rat pituitary cells, and the availability of
clonal rat pituitary cell lines has allowed detailed examination of the
mechanisms involved as outlined in Chapter 1. Detailed study of the
endogenous human GH (hGH) gene has been limited by the difficulty in
obtaining sufficient tissue, but may be important in relation to the
possible pathogenesis of GH-secreting pituitary tumours. Cytoplasmic
levels of hGH mRNA in pituitary tumour cells may be suppressed in vitro by
insulin-like growth factor 1 (IGF-1; Yamashita et al, 1986) and increased
by dexamethasone but not by thyroid hormone in contrast to rat GH (rGH)
mRNA (Isaacs et al, 1988). However there is so far no information as to
the possible effects of the other important regulators of somatotroph
function on endogenous hGH gene expression in human pituitary tissue.
In the preceding Chapter, a single aggressive prolactinoma was studied
using the technique of cytoplasmic dot hybridization, and tentative
conclusions were drawn from the apparent resistance of mRNA levels to
hormonal manipulation in vitro. GH-eecreting tumours are frequently
treated primarily by pituitary surgery, and therefore this tissue is more
readily available for in vitro study. In view of this, it was decided to
apply the techniques used in the earlier study to a series of GH-secreting
tumours obtained from hypophysectomy operations carried out at the Queen
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Elizabeth Hospital, Birmingham. In this Chapter data is presented on the
hormonal and intracellular control of hGH release and mRNA accumulation in
cultured cells from six human somatotrophic tumours. The cells were
exposed to various substances including a GH-releasing factor fragment (GRF
1-29 amide), somatostatin and bromocriptine; in addition forskolin and
phorbol ester were tested in order to determine the possible involvement of *
adenylate cyclase and protein kinase C in hGH synthesis and secretion.
4. 2 MATERIALS AND METHODS
4. 2. 1 Cell culture
Pituitary adenoma tissue was obtained for cell culture from routine
transsphenoidal or transfrontal hypophysectomy operations on six patients
with acromegaly. Only one of the tumours (tumour 1, patient EJ) was
markedly aggressive and resistant to therapy, with very high GH levels and
major extrasellar extension. He had had two previous hypophysectomy
operations, with radiotherapy twelve years earlier; he had failed to
respond to bromocriptine, and had only a partial response to somatostatin
(GH levels falling from 6700 to 1900 mU/L. The tissue was obtained from
this man's third hypophysectomy. The other tumours were more typical, and
the pituitary surgery was the primary mode of therapy; patient details are
outlined in Table 4. 1.
At operation, pituitary tumour tissue was immediately placed in ice-cold
culture fluid, which consisted of Dulbecco's modified Eagle's medium (Glbco
BRL, Paisley, Scotland), supplemented with 10% horse serum and 2.5% fetal
calf serum (Gibco BRL) with antibiotics. The tissue was chopped into small
- 69 -
Tumour Patient's Basal serum GH Unstimulated GH




1 M, 34y 4100 75 ± 10
2 M, 42y 32 67 ± 10
3 M, 42y 160 249 ± 39
4 M, 39y 130 398 ± 30
5 F, 42y 130 64 ± 4. 7
6 F, 36y 14 55 ± 2. 5
Table 4. 1 Summary of patient details, showing random pre¬
operative serum GH levels, with mean unstimulated
GH release in vitro over a 24h incubation period
(these data are means t SEM, n=3-8 replicates in
each case).
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fragments and enzymatically dispersed using collagenase and hyaluronidase
as for the studies in Chapters 2 and 3 (described in Appendix Al.1).
Each pituitary tumour yielded between 2.0 and 7. 8 x 10s cells, with a
viability determined by trypan blue exclusion of 84-95%. Dispersed adenoma
cells were plated onto plastic culture dishes at a density of 1-2 x 10s
cells per well in 2ml of culture fluid, incubated at 37*C in a humidified
atmosphere of 5% C02: 95% air, and allowed to grow in monolayer culture for
at least five days before experiments were carried out. The cells were
then washed by repeated (serum-free) medium exchanges and treated for 24h
with test substances in serum-free culture fluid. After treatment periods
culture fluid was removed for radioimmunoassay of released hGH, and cell
cytoplasmic extracts were prepared for mRNA determinations.
4. 2. 2 Materials and radioimmunoassays
GRF 1-29 amide (of equal potency to authentic human GRF; Bachem, Saffron
Walden, Essex, UK) and somatostatin 1-14 (Sigma Chemical Company, Poole,
Dorset, UK) were dissolved directly into culture fluid. Forskolin
(Calbiochem, Cambridge, UK) and bromocriptine (Sigma) were dissolved
initially in ethanol, and the phorbol esters 12-0-tetradecanoyl phorbol-13-
acetate (TPA; Sigma) and phorbol 12, 13-didecanoate (PDDj Sigma) were
dissolved in dlmethylsulphoxide, before dilution in culture fluid
immediately before experiments.
Human GH released into culture fluid was measured by radioimmunoassay
using MRC 66/217 hGH standard; these assays were kindly carried out by
Dr SS Lynch, Birmingham & Midland Hospital for Women. Blank samples
consisting of culture fluid alone did not cross-react in this assay. Mid-
range intra- and inter-assay coefficients of variation were less than 10%.
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4. 2. 3 roRNA measurements
Messenger RNA accumulation was measured by cytoplasmic dot hybridization
as in Chapters 2 and 3 (described in Appendix A3. 1). Cells were scraped
from culture dishes and cytoplasmic extracts were prepared. Cytoplasmic
samples were applied in duplicate to a hybridization transfer membrane,
before pre-hybridization, hybridization and autoradiography. A cDNA probe
specific for hGH (Martial et al, 1979) was radiolabelled with cr^P-dCTP
using the random primer (oligo-labelling) technique (see Appendix A2. 2) to
a specific activity of approximately 0. 5 x 10* dpm/pg DNA.
The degree of hybridization was assessed by scanning densitometry of
developed autoradiographs; for each experiment mRNA results were expressed
in arbitrary units of optical density relative to control samples which
were assigned the value of 1.0 units (100%).
For the Northern blot analysis total RNA was extracted from cells grown
in monolayer culture from tumour 1 (Chirgwin et al, 1979; and see Appendix
A3.2.1), and then separated by agarose gel electrophoresis before blotting
onto nitrocellulose and hybridization (see Appendix A3. 2. 2).
4.3 RESULTS
Similar densities of viable cells were plated onto culture wells in each
experiment, and the amount of hGH released by unstimulated tumour cells in
culture was relatively similar except for tumours 3 and 4, where basal hGH
release was over foui—fold higher (Table 4. 1).
Cultured cells obtained from tumour 1 were used to prepare RNA for
Northern blot analysis (Figure 4.1). This confirmed that a single species
of hGH mRNA was present, and that its size was approximately 1000 bases,
the expected size for this mRNA (Robins et al, 1982) and in accordance with
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one previous report of such studies on human pituitary tissue (Yamashita et
al, 1986).
The effects of lOnM GRF 1-29 amide were studied in four tumours <1,2,3 &
6; Figure 4.2); hGH release was stimulated in three of the four tumours,
though the degree of stimulation varied from 129% to 199% of control
values. Moderate stimulation of hGH mRNA levels was likewise seen only in
these three tumours, with values of 130% to 167% of the control levels in
each case.
Somatostatin (lpM) was studied in all six tumour cultures (Figure 4.3).
GH release was inhibited in four cases, though the degree of inhibition in
the responsive tumours varied from 35% to 79% of control values. In
contrast, hGH mRNA accumulation was not consistently affected: slight and
non-significant reductions were seen in two of the six cases, the maximum
suppression being only to 70% of control values, and other values ranging
between 80 and 176% of control (NS>.
Bromocriptine (lOOnM) was studied in four tumour cultures (1,2,3 & 4;
Figure 4.4). GH release was reduced in all four cases to between 50 and
75% of control values (though significantly so in only two) whereas hGH
mRNA was significantly suppressed in only one of the four tumours to 70% of
control, and was unaffected in the others.
All six tumour cultures were treated with lOpM forskolin (to activate
adenylate cyclase, and thus raise intracellular concentrations of cyclic
AMP), and the phorbol ester TPA (lOOnM; activating protein kinase C), and
the results are shown in Table 4.2 (and see also Figure 4.1). Forskolin
doubled hGH release and moderately increased mRNA levels in tumours 1 and
2, but had no effect in the others. However it is noteworthy that tumours







Northern blot hybridization analysis of RNA
(lOpg/lane) extracted from cultured cells from
tumour 1. The cells were treated for 24h with
control medium (CON), lOpM forskolin (FSK) or
lOOnM TPA before extraction of RNA. The RNA was
electrophoresed on a 1% agarose gel, and blotted
onto a nitrocellulose membrane for hybridization
with the 32P-labelled hGH cDNA probe followed by
autoradiography. Standard DNA size markers (in
kilobases) migrated as indicated at the right of
the autoradiograph. (See also Table 2 for












Figure 4.2 s Effects of GRF on tumours 1,2,3 & 6. Cultured
pituitary tumour cells were incubated with control
medium or lOnM GRF 1-29. amide for 24h. Hormone
release data(hatched bars)are expressed in terms
of percentage of unstimulated hGH secretion (see
Table 4.1); mRNA data (solid bars) are expressed
in arbitrary units of optical density, also as
percentage of control values in unstimulated
groups of cells. Data are means ± S. E. M. , n = 5-8
replicate culture wells per group, *P<0. 02
compared to control samples for each tumour.
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Figure 4.3 Effects of somatostatin on tumours 1-6. Cultured
pituitary tumour cells were incubated with control
medium or lpM somatostatin for 24h. Hormone
release data(hatched bars>and mRNA data (solid
bars) are expressed as in Figure 4.2, and are
means ± S. E. M. , n = 4-8 replicate culture wells
per group, *P<0. 02, **P<0.005 compared to control










Figure 4. 4 Effects of bromocriptine on tumours 1-4. Cultured
cells were incubated with control medium or lOOnM
bromocriptine for 24h. Hormone release data
(hatched bars)and mRNA data (solid bars) are
expressed as in Figure 4. 2, and are means ±
S. E. M. , n = 4-7 replicate culture wells per group,




1 2 3 4 5 6
Forskolin (10pM)
hGH release 197437* 193424* 148418 77+37 82±5 108±11
<X control)
hGH mRNA 178+9* 132+30 80410 93444 120420 86411
(% control)
TPA <lOOnM)
hGH release 426470** 263439** 193425* 5548* 12046 13042*
(.% control)
hGH mRNA 109420 155425 90410 80430 160430 112416
(% control)
Table 4. 2 GH release and mRNA levels in tumours 1-6 in
response to treatment for 24h with forskolin or
phorbol ester (TPA). Hormone release data are
expressed in terms of percentage of unstimulated
hGH secretion (see Table 4. 1); mRNA data are
expressed in arbitrary units of optical density,
also in terms of percentage of control values in
unstimulated groups of cells (100%). Data are
means 4 S. E. M. , n = 3-6 replicate culture wells
per group, *P<0. 02, **P<0. 001 compared to control
samples for each tumour; all other data are not
significantly different from control.
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3 showed a smaller response and tumour 6 failed to respond at all to either
agent. The tumour-promoting phorbol ester TPA stimulated hGH release in
four of the six cases, while the non-tumour-promoting phorbol ester PDD had
no significant effect in one experiment (tumour 3): hGH release with lOOnM
PDD was 121 ± 6% of control (n=4 replicates, P > 0.05), compared to
193 ± 25% of control with lOOnM TPA (n=4, P < 0.02). In contrast, hGH mRNA
levels showed no consistent changes, with non-significant stimulation by
TPA seen only in tumours 2 and 6 (Table 4.2).
*.* DISCUSSION
In this Chapter the technique of cytoplasmic dot hybridization analysis
used in the studies of the single prolactinoma (Chapter 3) has now been
applied to study regulation of endogenous hGH mRNA in a series of six
GH-secreting tumours. One of the tumours was sufficiently large to yield
adequate tissue for RNA extraction for Northern blot analysis. This was an
important control experiment, as it demonstrated that the cDNA probe used
in the dot hybridization experiments was recognizing a single RNA species
of appropriate size in the cultured tumour cells.
The present results show first, that responses of both hGH release and
mRNA accumulation are very variable between different tumours but differ
from those of normal rat pituitary tissue in vitro. As in the case of the
prolactinoma studied in Chapter 3, the data show that mRNA levels do not
necessarily parallel changes in hormone secretion, and suppression of
secretion by somatostatin does not imply suppression of mRNA acumulatlon.
Growth hormone release and mRNA levels were stimulated in three out of
four tumours by GRF 1-29 amide. Previous reports have indicated
stimulation of hGH release by equipotent doses of GRF 1-40 and GRF 1-44 in
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five out of six tumour cultures, although the increases varied between 30
and 500% above control (Adams et al, 1984). GRF is known to stimulate rGH
mRNA levels (Barinaga et al, 1983; Gick et al, 1984; Barinaga et al, 1985)
and one previous report describes stimulation of hGH mRNA accumulation by
GRF, though only to approximately 35% above control values (Yamashita et
al, 1986). Relatively small effects of GRF 1-29 amide were also seen in
the present studies, though this could be partly explained by the absence
in the culture fluid of supplementary glucocorticoid, which is known to
augment somatotroph responsiveness to GRF (Simard et al, 1985; Clayton et
al, 1986) or to the relatively short (24h) incubation period. One of the
four tumours was completely unresponsive in terms of both hGH mRNA levels
and secretion.
Somatostatin and bromocriptine in high doses had clear inhibitory effects
on hGH release, confirming the data of Lamberts et al (1987), although the
effects of bromocriptine differ from those found with rGH secretion, which
wa6 unaffected by dopamine agonists in normal rat pituitary tissue (see
Chapter 2). Although hGH mRNA levels were suppressed by bromocriptine in
one tumour, no consistent pattern was found for mRNA accumulation in the
other three, and somatostatin likewise had no consistent effect on mRNA
either. The effects of somatostatin on rGH mRNA accumulation in rat
pituitary cells are controversial: using identical experimental techniques
and design, one study showed that somatostatin treatment for 24h reduced
rGH mRNA levels to 35% of control, comparable to the suppression of rGH
release (Wood et al, 1987). However another study found no effect of
somatostatin on rGH mRNA levels in the GHa cell line (Gick & Bancroft,
1987). Barinaga et al (1985) found no effect of somatostatin on rGH
transcriptional rate using a run-on assay, however subsequent studies from
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the same group have demonstrated a delayed Inhibition of steady state mRNA
levels In normal rat pituitary cells (W. Vale, personal communication).
One previous report, using a quantitative in situ hybridization technique
to study three human somatotroph tumours, has described the failure of
somatostatin to suppress hGH mRNA levels (Levy A Lightman, 1988). The lack
of effect of somatostatin in the present series of six tumours cannot be
explained by lack of membrane receptors in view of the inhibition of hGH
release in four of the six, and the data might therefore suggest abnormal
post-receptor signal transduction.
Cyclic AMP is known to be involved in GRF action, and high intracellular
levels of cAMP stimulate rGH release and endogenous rGH gene transcription
in normal rat pituitary tissue (Barinaga et al, 1985), and also the
transcription of a reporter gene from the hGH promoter region in
transfected rat pituitary cells (Brent et al, 1988). Forskolin caused
significant stimulation of hGH release and mRNA accumulation in only two
tumours. These two tumours also showed the most marked responses to
GRF 1-29 amide, implying that the coupling between cAMP generation and hGH
gene transcription and hormone release was intact in these cases; on the
other hand, the lack of response to either GRF or forskolin in the other
tumours might suggest uncoupling at some level between receptor and
cellular response. Vallar et al (1987) found a sub-group of about 30% of
somatotroph tumours characterized by higher hGH secretion rates and high
intracellular cAMP levels; in these tumours adenylate cyclase activity was
not stimulated by GRF, and this was related to the presence of a mutated Ga
protein (Landis et al, 1989; and see the discussion in Chapter 8.2.3). In
the absence of data for cAMP accumulation it is not possible to say whether
the present results indicate two differing types of tumours with
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distinctive levels of basal adenylate cyclase activity, although there was
no correlation between GRF-responsiveness and the absolute level of basal
hGH secretion.
In previous studies of rat pituitary tissue, activation of protein
kinase C by phorbol esters was found to stimulate rGH release without
increasing rGH gene transcription, in contrast to activation of adenylate
cyclase which increased both processes (Barinaga et al, 1985; Morita et al,
1987). In the present study, TPA was able to stimulate hGH release up to
four-fold basal levels, demonstrating that protein kinase C can mediate hGH
release. However TPA had no consistent effects on hGH mRNA levels
suggesting that as in the rat, protein kinase C has no effect on hGH gene
regulation.
In conclusion, the present data show that the previously recognized
heterogeneity in the patterns of hGH release by pituitary tumour cells in
vitro also applies to hGH mRNA accumulation. However, more importantly,
the data imply that there may be divergences between the regulation of hGH
secretion and of mRNA production, as in the case of somatostatin, which
could result in the rate of gene transcription being relatively autonomous
and independent of receptor-mediated inhibitory control. This recalls the
pattern seen with the single prolactinoma described in Chapter 3.
Uncoupling between cAMP production and hGH production may be a further
factor in a group of somatotroph tumours. Several different mechanisms may
underlie the development of adenomatous change in the pituitary gland,
including hypomethylation of the hGH gene itself (U et al, 1988), amplified
proto-oncogene expression <U et al, 1988) and abnormal signal transduction
CVallar et al, 1987; Landis et al, 1989). The apparent relative autonomy
of hGH gene transcription seen in the present study may be related to these
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findings and could be involved in tumour pathogenesis. The mechanism for
this may be related to amplified proto-oncogene expression, but any further
analysis of such factors requires in vitro models to study the mechanisms
of gene transcription in detail, both in normal and tumourous pituitary
cells. The next two chapters will describe the application of transfection
analysis and gel retardation analysis to study intracellular regulation of
PRL gene expression in rat pituitary cells; Chapter 7 will then return to
the topic of pituitary tumours with a presentation of possible applications
of these techniques to human adenoma tissue.
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CHAPTER 5
CALMODULIN-DEPENDENCE OP PROLACTIN GENE EXPRESSION:
HYBRIDIZATION AND TRANSFECTION STUDIES
5.1 INTRODUCTION
The hybridization studies described in the earlier chapters provide
descriptive information regarding mRNA accumulation, which may be important
in understanding how the regulation of hormonal synthesis may differ from
that of acute release. The next stage, however, is to address the possible
mechanisms for hormonal or intracellular regulation of gene transcription.
One well documented example of PRL gene regulation which may be amenable to
more detailed study is the role of calcium and calmodulin. In this Chapter
the effect of calmodulin antagonists on PRL mRNA accumulation will be
described, and then the technique of transient transfection analysis will
be used to investigate the role of 5'-flanking sequences from the rPRL
gene.
PRL gene expression has a critical requirement for calcium: previous
studies have shown that PRL mRNA accumulation (much more than GH mRNA) is
highly dependent upon calcium, and both intracellular calcium stores and
influx of extracellular calcium are involved (White et al, 1981; Gick &
Bancroft, 1985; Hinkle et al, 1988; Davis et al, 1988; Laverriere et al,
1988). Recently, Jackson & Bancroft (1988) have used the technique of
transient transfection analysis to show that the proximal 172bp of 5'-
flanking DNA from the rPRL gene are able to confer calcium-responsiveness
onto a reporter gene, and therefore any calcium-responsive DNA element may
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be contained within this part of the proximal enhancer region of the gene.
The effects of calcium on the rPRL gene may be mediated either by
protein kinase C or by calmodulin (CaM). Earlier work based on the use of.
phenothiazlne CaM antagonists has suggested that CaM is involved also in
regulating PRL mRNA accumulation and gene transcriptional rate (Murdoch et
al, 1985aj White, 1985), but these drugs are recognised to have effects on
other intracellular signalling systems including protein kinase C itself.
In this Chapter the question of the role of CaM in PRL gene regulation
will be addressed using results from two different experimental approaches.
First, hybridization studies were used to study the effects of CaM
antagonists on mRNA levels as a measure of the control of the endogenous
rPRL gene; secondly transient transfection assays were applied to assess
the control of transfected rPRL gene promoter sequences by assay of the
expression of the chloramphenicol acetyl transferase (CAT) reporter gene.
Two specific CaM antagonist agents were employed in the present studies:
the highly specific naphthalene sulphonamide CaM antagonist W7 (N-(6-
aminohexyl)-l-naphthalene sulphonamide; ICBO approximately 30pmol/L) which
has only very slight effects on protein kinase C, and a more potent and
more specific iodo-derivative of W7, 5-iodo-l-C8 (abbreviated "W8" here,
ICso approximately 3pmol/L) which has no detectable effect on protein
kinase C (MacNeil et al, 1988).
5.2 MATERIALS AND METHODS
5. 2. 1 GH-_ cell culture and radioimmunoassays
GH3 cells obtained from the European Collection of Animal and Cell
Cultures (ECACC), were grown in continuous monolayer culture as described
in Appendix A1.2. Cells were maintained in Ham's F-10 medium supplemented
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with 5% fetal calf serum CGibco, Paisley, Strathclyde, UK) and 10% horse
serum (Glbco). Cells were subcultured from single donor cultures two days
before experiments, and then washed with serum-free medium before treatment
with test substances in serum-free F-10 medium. Prolactin secretion Into
culture fluid was measured by radioimmunoassay (as described in Appendix
A4. 1) using reagents supplied by the National Hormone and Pituitary
Program, NIADDK, Bethesda, MD, USA; results are expressed in terms of the
standard rPRL-RP3.
5. 2.2 Hybridization studies: mRNA measurements
Relative cytoplasmic concentrations of PRL and GH mRNA were measured by
cytoplasmic dot hybridization analysis as described in Appendix A3. 2.
Briefly, plasmid probes containing cDNA inserts specific for rPRL (Gubbins
et al, 1979) or rGH (Harpold et al, 1978) were labelled with 32P-dCTP by
nick translation (see Appendix A2.1) to a specific activity of
1-2 x 10®dpm/pg DNA. Cytoplasmic samples were applied in duplicate to
hybridization transfer membranes, usually at 1:10 - 1:50 dilution,
membranes were prehybridized and then hybridized with the labelled cDNA
probes. After hybridization and autoradiography, mRNA data were
quantitated by scanning densitometry and data expressed in arbitrary units
of optical density (0. D. ) of the developed autoradiographs.
5. 2. 3 Transient transfectlon studies
GHS cells were transfected with synthetic DNA constructs consisting of
395bp or 958bp of the rat PRL promoter (Lufkin & Bancroft, 1987), or as a
control the Rous sarcoma virus (RSV) promoter, linked to the bacterial
chloramphenicol acetyl transferase (CAT) gene. Two days before
transfection, GH3 cells were subcultured onto 100mm Petri dishes at 4 x 10®
cells per dish. On the day of transfection cells were washed with serum-
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free medium, before the addition to each dish of lOpg plasmid DNA in 5ml
medium containing 50mM Tris (pH 7.5) and lOOpg/ml DEAE dextran. After 30-
60 minutes this medium was removed, and the cells washed before addition of
fresh medium or test substances for 48h (or for the last 16-24 hours of
this period for experiments involving cobalt chloride or calmodulin
antagonists).
At the end of the incubation period, medium was removed from the culture
dishes, and the cells were washed in ice-cold phosphate buffered saline
(PBS). Cells were then harvested by trypsinization (2-3ml of 0.5% trypsin
per plate), washed, and lysed with 0.5% Triton X-100 in 0. 25mM Tris (pH
7.6). Cell lysates were centrifuged at 15000^ for 4 min, and supernatants
from the cell lysate were assayed for protein content using the Lowry
technique (see Appendix 5.1), and stored for assay of CAT activity.
5.2.4 Assay for CAT activity
CAT activity was assayed as described by Gorman et al (1982) in a lOOjxl
reaction volume containing lOOpg cell lysate protein, 12mM acetyl Coenzyme
A, and 0. 2pCi ,'*C-labelled chloramphenicol. Reactions were incubated for
16h at 37*C, and samples were then extracted with an equal volume of ethyl
acetate. Acetylation products were separated by thin layer chromatography;
samples were spotted onto the TLC plate, which was placed in a sealed tank
containing 200ml chloroform: methanol (19:1), and the solvent front allowed
to migrate two thirds of the distance of the plate. The plates were air-
dried and autoradiographed for 3-4 days. The developed autoradiographs
were aligned with the TLC plates to locate the non-acetylated chloramph¬
enicol and its acetylated products; the corresponding spots were cut out
from the TLC plates and their radioactivity quantitated by liquid scintill-
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otion counting. Results are expressed as percent acetylation of total
chloramphenicol/lOOpg protein.
5. 2. 5 Materials
W7 (Sigma, Poole, Dorset, UK) and 5-iodo-l-C8 [termed "W8" here (MacNeil
et al, 1988)1 were initially dissolved in dimethylsulphoxide and freshly
diluted in F-10 culture fluid before experiments. Verapamil was purchased
from Abbott Laboratories Ltd, Queensborough, Kent, and Bay-K-8644 was a
gift from Bayer Pharmaceuticals Ltd. Radiolabelled chloramphenicol was




The CaM antagonist W7 caused dose-dependent reduction in PRL secretion,
and PRL mRNA levels fell to 26% of control after 24h incubation with lOOpM
W7 (Figure 5. 1). Thyrotrophin-releasing hormone (TRH, lOOnmol/L)
stimulated both PRL secretion and mRNA levels about two-fold, while W7
(lOOpmol/L) reduced both PRL secretion and mRNA levels and prevented any
stimulation by lOOnM TRH (Figure 5.2). OH mRNA levels in these
experiments showed slight reductions (to 77-92% of control) in the presence
of lOOpM W7, but these were much less marked than for PRL mRNA (Figure
5.3). High doses of W7 (lOOpM and above) caused rounding of GH3 cells and
reduced adherence to the culture dishes, but did not affect cell viability
as determined by trypan blue exclusion.
5. 3. 2 Transfection experiments
GH3 cells showed no endogenous CAT activity, while cells transfected
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with the RSV-CAT construct had high levels of activity, with up to 90%
acetylation of chloramphenicol per lOOpg protein. Transfection efficiency
differed between different experiments, but in general transfection with
the PRL-CAT constructs resulted in acetylation of approximately 15% of that
seen with the RSV-CAT construct.
In initial experiments to validate calcium responses of the transfected
constructs, GH3 cells were transfected with rPRL<-395)-CAT: treatment with
both 50pM verapamil and 0. 3mM cobalt chloride dramatically reduced CAT
activity to approximately 5% of control levels; on the other hand,
treatment with the calcium channel agonist BAY-K-8644 (200nM) modestly
increased CAT activity to 148% of control, as has been reported previously
(Jackson & Bancroft, 1988; Figure 5.4).
The two CaM antagonists W7 and W8 both markedly reduced CAT activity in
GHa cells transfected with rPRL<-395)-CAT (Figure 5.5). W8 at 3pM reduced
CAT activity to 73% of control levels (mean of two similar experiments),
and to 14 ± 6% of control at IOjiM concentration (mean t S. E. M. from four
separate experiments). W7 reduced CAT activity to 6% and 5% of control at
10 and 50pM concentrations respectively (mean of two similar experiments).
The degree of inhibition of CAT activity by W8 was similar using both PRL-
CAT constructs: using the rPRL(-395)-CAT construct activity was reduced by
lOpM W8 to 14% of control levels, and with the rPRL(-958)-CAT construct to
22% of control (means of four and two independent experiments respectively;
see Table 5. 1 for full data). The effects of CaM antagonists were
partially promoter specific: the CaM antagonist W8 (lOpM concentration)
reduced CAT expression from the RSV promoter to 25% of control, but the
inhibition was much greater in the same experiment with the two PRL
promoters used (10% of control with rPRL(-958)-CAT, and 7% of control with
0 lufl 100UM
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Effects of calmodulin antagonist W7 on GH3 cells.
Effects of treatment with 1 or lOOpM W7 for 24h on PRL
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Effects of co-incubation with lOOpM W7 and lOOnM TRH
for 24h on PRL mRNA accumulation (n=12 replicates per
group pooled from 3 similar experiments, P < 0.01
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lo-ure 5 3 % Effects of W7 and TRH on GH mRNA in the same
experiments; n=6 from the experiment shown in panel A,
. _ — i i .i _— _. X m 4 n nenol R .and n=12 from the experiments shown in panel B,








Figure 5.4 Transient transfection of GH3 cells with RSV-CAT or
rPRL<-395)-CAT constructs. Effects of cobalt chloride
(0. 3mM>, verapamil <50pM> or Bay K 8644 (200nM) on CAT
expression. The Figure shows results of TLC separation
of ,'*C-labelled chloramphenicol from acetylated
products as a measure of CAT activity in the GH3 cell
extracts.
- 93 -
o o o o o o
RSV 0 3pM 10p.M 1Op.M 50|J.M
-CAT I-W7 I-W7 W7 W7
PRL(-395)-CAT
Figure 5.5 Effects of two calmodulin antagonists (W7 and W8) on
acetylation of ' "^-chloramphenicol by cytoplasmic
extracts of GH3 cells transfected with rPRL-<-395)-CAT.
The first lane shows cells transfected with RSV-CAT
plasmid. A single experiment is shown (see text and
Table 5. 1), and cells were treated with CaM antagonists





Figure 5.6 Effects of lOpM W8 on acetylation of '■•C-chloramph-
enicol by cytoplasmic extracts of GH3 cells transfected
either with the RSV-CAT construct, with rPRL-(-958)-
CAT, or rPRL-<-395)-CAT, and treated with W8 for 24h



















































Table 5. Transient transfection assays: experimental data for six experiaents
using calmodulin antagonists, with the X acetylation of "C-labelled
chloramphenicol generated with each construct as determined by thin
layer chromatography and liquid scintillation counting,
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rPRL<-395)-CAT), implying that the PRL gene promoter is specifically CaM-
sensitive and that the proximal 395bp of 5*-flanking DNA accounts for all
the CaM responsiveness seen with the longer promoter sequence (Figure 5.6).
5.4 DISCUSSION
In this Chapter, hybridization analysis has been employed to demonstrate
the marked calmodulin sensitivity of PRL mRNA accumulation (compared to GH
mRNA) in GHa cells, and the mechanisms of these effects have been studied
using transient transfection assays. The data indicate that highly
specific CaM antagonists have major effects which involve 5'-flanking DNA
sequences from the proximal enhancer region, within 395 bp of the
transcription initiation site.
The precise role of calcium in basal and stimulated PRL gene
transcription has been a subject of some controversy. Calcium is an
important co-factor for protein kinase C, which is an established
stimulator of PRL gene transcription (Murdoch et al, 1985; Elsholtz et al,
1986), but it also activates the calcium-binding protein calmodulin.
Recent evidence has shown that down-regulation of protein kinase C by
chronic exposure of GH3 cells to phorbol esters does not affect the
increase in PRL mRNA levels induced by calcium (Bandyopadhyay & Bancroft,
1989), suggesting that this kinase is not essential for this effect.
Previous studies suggesting that calmodulin (CaM) is important in PRL gene
transcription have depended on the use of CaM antagonists such as
trifluoperazine and calmidazolium (Gick St Bancroft, 1985; Murdoch et al,
1985; White, 1985) whose specificity is relatively poor as they also
inhibit a number of other intracellular enzymes including protein kinase C
itself (MacNeil et al, 1988). The hybridization data presented here,
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obtained using the naphthalene sulphonamide drug W7, a more highly specific
CaM antagonist which has only minimal effects on protein kinase C, confirm
that PRL mRNA accumulation is indeed CaM-dependent, in contrast to growth
hormone mRNA which was only slightly affected by treatment with W7.
The transfection data showed that the rat PRL gene promoter was
efficient at directing expression of the CAT reporter gene in GH3 cells,
although less powerful than the RSV promoter. Chloramphenicol acetylation
was readily detected and quantitated, although transfection efficiency
varied considerably between experiments. The initial studies confirmed
that the two PRL-CAT constructs used were appropriately responsive to
calcium channel antagonist and agonist effects, as reported previously by
the originator of the constructs (Jackson & Bancroft, 1988), and the more
detailed later studies demonstrated that both 395 bp and 958 bp lengths of
promoter DNA conferred comparable inhibition on reporter gene expression.
Thus the effects of calcium and CaM appear to be mediated by effects on
5'-flanking DNA in the proximal enhancer region of the rat PRL gene.
Response elements have recently been defined for several hormones and
intracellular regulators within these enhancer regions (see Chapter 1).
For example, the transcriptional response to both EGF and protein kinase C
activation by phorbol ester is conferred by DNA sequences between positions
-35 and -78 base pairs upstream from the cap site (Elsholtz et al, 1986).
A precise response element for calcium itself has not yet been identified,
but the information required for a full transcriptional response to calcium
is contained within the first 174bp of DNA upstream from the cap site
(Jackson & Bancroft, 1988), and our results with Bay-K-8644 and verapamil
using the PRL(-395)-CAT construct confirm these findings.
Pharmacological manipulations of the calcium/CaM signalling system are
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likely to have wide-spread effects on cellular metabolism, and indeed our
data showed that the transcription of CAT from a viral promoter sequence
was also substantially reduced by W8. Likewise, three control promoter-CAT
constructs tested by Jackson & Bancroft (1988) in fact showed some degree
of calcium-induction. However these effects were much different in
magnitude compared to the effects on the PRL gene, and in the present study
W8 caused more inhibition of CAT expression using the two PRL constructs
tested than with RSV-CAT. The proximal enhancer region of the PRLgene
therefore appears to contain specific CaM response elementCs) which are
important in basal and TRH-stimulated gene transcriptional control.
However it is important to note that potential response elements may in
fact be multiple, and TRH, EGF and cyclic AMP effects have recently been
shown to be conferred onto a reporter gene by distal as well as by proximal
enhancer regions of the PRL gene (Day 4 Maurer, 1989b).
The 174bp calcium-responsive stretch of the PRL 5'-flanking DNA contains
three of the four proximal binding sites for the pituitary-specific
protein factor "Pit-l", (also termed "PUF-1H or "LSF-1")(Gutierrez-Hartmann
et al, 1987; Cao et al, 1988; Nelson et al, 1988; Lufkin et al, 1989). The
first such site coincides with a response region for EGF and phorbol ester
(Elsholtz et al, 1986) and also with a possible recognition sequence for
the CaM-dependent enzyme DNA topoisomerase (White & Preston, 1988),
inviting the speculation that these intracellular signals may exert their
effect by modifying the binding of tissue-specific proteins to DNA or to
other DNA-binding factors, or alternatively by modifying already-bound
trans-acting factors to affect their interaction with the transcription
initation complex. So far there are few data available that address this
question. One technique which has been developed to study DNA-protein
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interactions is that of the gel retardation assay, and in the next Chapter,
this technique will be described and applied to the question of the effects
of the CaM signalling system on the PRL gene.
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CHAPTER 6
STUDIES OF DNA-PROTEIN INTERACTIONS WITH THE PROLACTIN
GENE PROMOTER REGION: GEL RETARDATION ASSAYS
6. 1 INTRODUCTION
In the last Chapter, the transient transfection assay was used to
confirm that a defined region of PRL gene promoter DNA was capable of
conferring responsiveness to calcium and calmodulin onto a reporter gene.
Further definition of the precise response element would require more
detailed studies using deletant constructs containing progressively shorter
PRL 5'-flanking DNA sequences, but previous workers have reported
difficulty in obtaining adequate levels of basal reporter gene expression
in this particular system with shorter deletants (Jackson & Bancroft,
1988). Alternative techniques were therefore sought to assess the
functional role of putative response elements, and in this Chapter the
potential role of DNA-binding nuclear proteins in calcium/calmodulin
control will be addressed using the gel retardation assay; the possible
applications of this technique to the study of pituitary tumours will be
considered in the next Chapter.
Control of gene transcription is now recognised to involve specific
interactions between a number of nuclear proteins and short recognition
sequences in the enhancer regions of target genes. Some examples of these
interactions are now well characterized, for example the binding of nuclear
receptors for thyroid and steroid hormones to their respective response
elements to increase the rate of gene transcription. The nature of thyroid
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and steroid hormone receptors has been the subject of intense research
activity especially since the recognition that they share structural
features and certain functional characteristics (reviewed in detail by
Evans, 1988). For the rPRL gene, an oestrogen response element (ERE) has
been defined in the distal enhancer region, approximately 1500 bp upstream
from the transcriptional 6tart site, and immediately adjacent to the first
distal site for Pit-1 binding (Maurer & Notides, 1987; Waterman et al,
1988; Kim et al, 1988).
Nuclear proteins are now known to mediate the effects of certain
intracellular signalling pathways on gene transcription, and a number of
these proteins have recently been studied. Short cyclic AMP response
elements (CREs) have been described for several different endocrine genes
(for example Tsukada et al, 1987; Montminy & Bilezikjian, 1987; Akerblom et
al, 1988), and for one of these cases a CRE-binding protein, CREB, has been
purified and cloned (Montminy & Bilezikjian, 1987). A 7 bp phorbol ester
(TPA) response element (TRE) has been described which differs from one
consensus CRE by only a single base-pair deletion. This TRE binds a
protein known as Activator Protein 1 (AP-1), which is encoded by the
cellular proto-oncogene c-Jun (Lee et al, 1987; Curran & Franza, 1988).
Intracellular signalling systems are known to interact at a variety of
levels, but additional potential interactions at the level of target genes
now seem likely. Binding of nuclear proteins to such response elements may
involve protein-protein interactions such as dimerization: AP-1 is known to
interact with the proto-oncogene c-fos, and the proteins share sequences
("leucine zippers") which would permit dimerization (Karin, 1989). Other
protein-protein interactions have been postulated, including AP-1/CREB,
AP-l/AP-1, and CREB/CREB, in the regulation of genes such as the pituitary
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glycoprotein a-subunit (Hoeffler et al, 1989), although direct evidence for
this is not yet available (Mitchell & Tjian, 1989).
No such nuclear proteins have yet been identified which respond
specifically to the calcium/calmodulin signalling system, and indeed no
specific calcium response element has yet been identified for the rPRL
gene. However the evidence discussed in the last Chapter suggests that any
putative calcium/calmodulin response element may reside within the proximal
enhancer region of the gene, which contains three Pit-1 binding sites. It
was therefore conceivable that these sites might themselves act as response
elements for the calcium/calmodulin system, as well as for phorbol ester
and EGF, as has previously been shown for the first Pit-1 site (Elsholtz et
al, 1986).
This speculation led to the application of a simple assay to study the
binding of nuclear proteins to the rPRL proximal enhancer region. The gel
retardation assay has been widely established since its first descriptions
(Fried & Crothers, 1981; Fried & Crothers, 1984) as a simple and sensitive
technique for detection of protein binding to DNA sequences. The technique
relies on the fact that complexes of DNA with bound protein migrate through
polyacrylamide gels more 6lowly than unbound DNA fragments. An important
advantage of the assay is its greater sensitivity and speed than other
techniques such as DNase I footprinting. In addition, the assay provides
some information on the number and type of proteins bound, as each distinct
complex has a characteristic mobility and specificity, which allows
putative interactions between proteins to be studied. The DNA sequence of
interest is radiolabelled and incubated with protein extract before










Figure 6. 1 Diagram to illustrate the principle of the gel
retardation assay.
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speclficity of the interaction may be tested by competition studies using
an excess of homologous or unrelated DNA (see Figure 6. 1).
In this Chapter I shall describe the assay, and then present results of
preliminary studies of the effects of the calcium/calmodulin signalling
system on DNA-protein interactions in GH3 cells. In the next Chapter, I
shall outline some very early attempts to apply this technique to the study
of human pituitary tumours.
6.2 METHODS
6. 2. 1 Nuclear protein preparation from GH-, cells
Nuclear proteins were prepared from GH3 cells, essentially following the
method of Ohlsson & Edlund (1986). GH3 cells were grown to near confluence
in 100mm plastic culture dishes, in F-10 culture medium containing 10%
horse serum and 5% fetal calf serum. 1-5 x 10° cells were first washed in
Hanks Buffered salt solution, before being harvested by trypsinization
(0.25% trypsin) from the dishes (usually up to 30 dishes of semi-confluent
cells). Cells were washed in phosphate-buffered saline, centrifuged at
2300rpm for 10 minutes, and 1 volume of cells resuspended in 4 volumes of
buffer containing lOmM Hepes, 15mM KC1, 2mM MgCl2, 0. ImM EDTA, ImM
dithiothreitol (DTT) and ImM phenylmethylsulphonylfluoride (PMSF). Cells
were pelleted by centrifugation at 6000 rpm (Beckman SW 50 rotor) and
resuspended in 1 ml of buffer. The cells were broken by ten strokes in a
hand-held glass-glass homogeniser and the nuclei were pelleted by
centrifugation at lOOOOrpm for lOmin at 4*C (Beckman SW 50 rotor). Nuclei
were then resuspended in approximately 3ml buffer, and 4M ammonium sulphate
solution was gradually added (with constant vortexing) to a final concen¬
tration of 0. 3M, followed by continued agitation, on ice, for 30 minutes.
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The nuclear suspension was next centrifuged at 27,500 rpm for 60
minutes, and the supernatant precipitated by gradual addition of 0. 2g
ammonium sulphate per ml of supernatant, with constant vortexing and
shaking at 4* C. The 0. 2g/ml nuclear protein fraction was resuspended in
buffer containing 50mM Hepes, 50mM KC1, 0. ImM EDTA, ImM DTT, ImM PMSF and
10% <v/v> glycerol, and finally dialysed against 100 volumes of this buffer
(with three changes of buffer at 4*C over 4 hours). The dialysed extracts
were stored at -70*C or in liquid nitrogen for use in the gel retardation
assay.
For the studies of the effects of calmodulin antagonists, nuclear
protein extracts were prepared from GHS cells which were either grown in
serum free culture medium for 24 hrs, or treated for 24 hrs with 50pM W7 in
serum-free medium, or for 4 hrs with IOjjlM W8 before protein extraction.
6. 2. 2 Gel retardation analysis
Restriction fragments from the 5'-flanking region of the rPRL gene were
generated by digestion of the PRL(-395)-CAT construct with Hae III and
Ava II (-172/+33 fragment). In addition a synthetic 24bp oligonucleotide
sequence was studied (positions -162/-138, denoted MrPRL-P3"), containing
the third proximal binding site of the pituitary-specific protein Pit-1.
The sequence of this oligonucleotide is:
5'-GATCCCTTCCTGAATATGAATAAGAAATAAAAG-31
3' -GGAAGGACTTATACTTATTCTTTATTTTCCTAG-5 •
Restriction fragments were end-labelled with a"2P-dCTP using the Klenow
fragment of DNA polymerase, and rPRL-P3 was labelled with y32P~ATP using
thr forward reaction catalysed by T4-polynucleotide kinase (see Appendix
A2. 3).
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For the gel retardation assay approximately lng of labelled rPRL-P3 was
Incubated with lOpg nuclear protein extracts In the presence of 3pg poly-
(dl.dC) as a synthetic non-specific competitor DNA, with or without
unlabelled excess oligonucleotide or restriction fragments in specific
competition studies as indicated. Binding reactions were allowed to
proceed for 15-30 minutes at room temperature in a total volume of 20pl in
a buffer containing 150mM KC1, 25mM Hepes, 0. ImM EDTA, ImM DTT ImM and 10%
glycerol. DNA-protein complexes were then separated by electrophoresis on
a 7% polyacrylamide gel in 25mM Tris-188mM glycine buffer before
autoradiography for 1-8 hours.
6.3 RESULTS
6.3.1 Effect of GH~ nuclear protein on PRL -172/+33 fragment
In initial experiments, restriction fragments from the proximal enhancer
region of the rat PRL gene were prepared and end-labelled with 32P-dCTP.
Incubation of labelled fragment (-172/+33) with GHS cell nuclear extracts
resulted in formation of DNA-protein complexes which migrated more slowly
than free DNA on gel electrophoresis (Figure 6.2). This complex formation
was reduced by competition with an excess of rPRL-P3 oligonucleotide or of
unlabelled PRL -172/+33 fragment itself, but not by an excess of unrelated
oligonucleotide from the human insulin insulin gene promoter (kindly
provided by Dr D. S. W. Boam, Birmingham).
However these experiments were somewhat unsatisfactory in that poor
resolution of DNA-protein complexes was achieved. The region -172/+33
within the proximal enhancer region, which is reported to contain a calcium
responsive element (as described in Chapter 5), contains three binding
sites for the pituitary-specific protein, Pit-1 (Nelson et al, 1988). We
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therefore chose to perform more detailed gel retardation studies using this
oligonucleotide rPRL-P3 (-138/-162) as the labelled DNA sequence; this
represents the third such site within the proximal enhancer region, and has
high affinity for Pit-1 binding (Nelson et al, 1988).
6.3.2 Effect of GH~ nuclear protein on PRL-P3 oligonucleotide
Incubation of radiolabelled rPRL-P3 oligonucleotide with GHS cell
nuclear protein extract resulted in multiple retarded DNA-protein complexes
on gel electrophoresis. This protein binding was markedly reduced by
competition with a molar excess of unlabelled rPRL-P3 or an excess of
restriction fragment -172/+33 from PRL 5'-flanking DNA (Figure 6.3). That
this competition was sequence specific was suggested by the lack of
competition from even a 300-fold excess of mutated oligonucleotide from the
human insulin promoter ("Ins 5'").
6.3.3 Effect of calmodulin antagonists on nuclear protein binding
The effects of the calmodulin antagonists W7 and W8 were next examined.
In initial experiments, GH3 cells were treated for 24 hours with 50pM W7
before protein extracts were prepared; however, because of concerns as to
the specificity or possible undetected toxicity of treatment with W7 over
long periods, separate nuclear protein extracts were prepared from GH3
cells treated for just 4 hours with lOpM W8. Both treatment protocols gave
similar results, with a dramatic overall reduction in the number of
retarded complexes seen, and the appearance of a new low-mobility retarded
band which was not visible with control GH3 extracts and whose formation
was competed by excess unlabelled rPRL-P3 (Figure 6.4).
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+ + PRL -172/+33 compet
+ Insulin 3' compet.
Figure 6. 2 Gel retardation patterns seen with 33P-labelled
restriction fragment PRL -172/+33 with GH3 nuclear
protein extract. The migration of labelled DNA without
any protein extract i6 shown in lane 1, and with lOpg
GH3 protein extract in lane 2. Fragment binding was
competed by 10- 20- and 100-fold excess of unlabelled
PRL -172/+33 fragment itself (lanes 3-5), but not by an
excess of unrelated oligonucleotide from the insulin
gene promoter (lane 6>.
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Ins PRL PRL-P3 None
5' -172/+33 ol'go
Figure 6. 3 Gel retardation patterns seen with 32-P-labelled PRL-P3
oligonucleotide incubated with nuclear protein extracts
from GH3 cells alone (lane 1), or competed with300~,30-
or 3 -fold molar excess of unlabelled PRL-P3 (lanes 2-
4> or with excesses of rPRL restriction fragment -
172/+33 (lanes 5-7), or with 300-fold excess of human
insulin oligonucleotide (Ins-5', lane 8).
-110-




Figure 6.4 Effect of treatment of GH3 cells with calmodulin
antagonists on protein-DNA complex formation. Cells
were treated with either 50pM W7 for 24 hours, or lOpM
W8 for 4 hours before nuclear protein extraction and
protein incubation with labelled oligonucleotide
PRL-P3. Migration of free DNA is shown in lanes 1, 3
and 5; incubation of PRL-P3 with control protein
(untreated GH3 cell extract, "Con") in lane 2.
Proteins derived from cells treated with W7 or W8 are
shown in lanes 4 and 6 respectively, and in lane 7, the
reaction contained a 50-fold excess of unlabelled PRL-
P3 as competitor DNA (indicated +).
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CONTROL GH3 W 8 TREATED GH3
Figure 6.5 Effect of treatment of GH3 cells with lOpM W8 for 4h
before nuclear protein extraction on gel retardation
patterns with labelled oligonucleotide PRL-P3. Lanes 1
and 14 show the migration of free labelled DNA without
added nuclear protein; protein concentrations from
control and W8-treated cell6 were 10, 5, 2.5, lpg,
0. 5pg and 0. lpg in lanes 2-7 and 8-13 respectively).
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The overall apparent reduction in DNA-proteln binding induced by W8
treatment was detectable at a variety of different doses of nuclear protein
in the DNA-protein binding incubation reaction, but the appearance of the
low-mobility complex was only detectable with at least 2. 5pg protein, in
contrast to the major complexes seen with protein extracts from untreated
GH3 cells which could be detected with as little as 0. 5pg protein in the
incubation reaction (Figure 6. 5>.
6. ♦ DISCUSSION
In this Chapter the technique of gel retardation analysis of DNA-binding
proteins has been described, and applied in an attempt to answer the
questions raised in Chapter 5 regarding the mechanism of calmodulin action.
Gel retardation analysis is a simple and highly sensitive technique for
detecting binding of proteins to target sequences of DNA. The biophysical
nature of this in vitro protein-DNA interaction is not yet fully
understood. For example it appears that proteins do not dissociate from
DNA once entrapped in the gel (the "cage effect"), and a small number of
DNA binding proteins may in fact give rise to a several different possible
complexes, with a relatively large number of different binding states
(Cann, 1989). Nonetheless, it is now becoming widely used as a tool for
identifying DNA sequence-specific and tissue-specific protein binding
activities in nuclear extracts.
The results described here show that GH3 cell nuclear extracts contain a
protein factor that can bind specifically to proximal 5*-flanking sequences
from the rPRL gene. Competition studies using homologous and unrelated DNA
sequences confirmed DNA-specific binding of the pituitary nuclear protein
extracts. (Further studies using extracts from different tissues are
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descrlbed in the next Chapter.) The most striking finding was that
exposure of GH3 cells to two calmodulin antagonist drugs dramatically
altered the pattern observed. The findings are important because they
offer direct evidence that the binding efficacy of nuclear proteins may be
directly affected by manipulation of an intracellular signalling pathway
which is known to mediate the effects of extracellular hormones. Thus an
extracellular signal may exert effects on gene transcription by modifying
the binding of transcription factors to hormone response elements.
One previous report described a similar experimental protocol, showing
that the pattern of binding of pituitary nuclear proteins to the
EGF/phorbol ester response element (site IP) was unaffected by a 1-hour
exposure of cells to phorbol ester (Elsholtz et al, 1986). For some
transcription factors, their transcriptional activity of DNA-binding
proteins may be mediated by allosteric modifications of proteins already
bound to DNA (Montminy & Bilezikjian, 1987; Roesler et al, 1988; Mitchell &
Tjian, 1989). However studies on CREB have shown that cAMP may enhance DNA
binding and transcriptional activity (Yamamoto et al, 1988). A recent
report has provided evidence that exposure of cells to insulin induces the
appearance of a new protein that binds to the hGH promoter in gel
retardation assays; this DNA binding factor was not seen in untreated cells
(Prager et al, 1990). Hence it may be that intracellular signals are able
to modulate DNA-binding activity of transcription factors as one mechanism
of controlling gene transcriptional rate.
The present results show that exposure of pituitary cells to specific
calmodulin antagonists dramatically alters the pattern of protein binding
to the high affinity site 3P, suggesting that protein binding to DNA may
itself be calmodulin-sensitive. The proteins involved are as yet
-114-
uncharacterlzed, but further studies should clarify whether calmodulin
itself may be involved in complex formation, and also the effects of the
calcium-CaM system on protein binding to the other sites known to bind the
pituitary-specific factor Pit-1.
The studies presented in this Chapter have applied a simple technique
for the detection of pituitary nuclear protein interactions with DNA
sequences of interest. The results presented here were performed to
address the questions raised in Chapter 5 about the possible mechanism of
action of calmodulin in regulating PRL gene expression. However the
technique has a variety of other potential applications. In particular,
the question was raised in Chapters 3 and 4 of possible abnormalities of
hormone gene regulation in pituitary tumours. If it is the case that, for
example, the PRL gene is constitutively activated in certain prolactinomas,
it may be that abnormal trans-acting factors are responsible. The
sensitivity of the gel retardation assay may allow detection of abnormal
protein-DNA binding patterns, and preliminary work in this direction will
be presented in Chapter 7.
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CHAPTER 7
APPLICATION OF TRANSIENT TRANSFECTION AND
GEL RETARDATION ASSAY TO HUMAN TISSUES: PITUITARY AND PLACENTA
7. 1 INTRODUCTION
The techniques of transfectlon analysis and gel retardation analysis may
be useful In studies of gene regulation In human pituitary tumours.
Transient transfection assays may be used to compare the regulation of
exogenous (i.e. transfected) promoter sequences by hormonal manipulations
of cultured cells, which may be either from rat pituitary cell lines or
primary cultures of the pituitary tumours themselves. Such a technique
might therefore be used to assess to what extent the tumour cells contain
the machinery to allow appropriate regulation of a defined promoter
sequence. Regulation of the endogenous human growth hormone gene in human
somatotroph adenoma cells (by insulin, thyroid hormone and dexamethasone)
has been 6hown to differ from regulation of the promoter region transfected
into rat pituitary GC cell lines (Isaacs et al, 1987), implying that some
aspect of the intracellular environment was involved in determining the
transcriptional response. However there have been no reports so far of
transfection of human pituitary tumour cells themselves, and this might
provide more relevant information if it is feasible.
In the last Chapter, the technique of gel retardation assay was
described in relation to the calcium/calmodulin dependence of PRL gene
expression in the GH3 rat pituitary cell line. As suggested at the end of
that Chapter, this technique also may be applicable to the study of human
pituitary tumours. If it is hypothesized that expression of pituitary
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hormone genes may in some tumours be const itutively activated and not
susceptible to normal hormonal suppression, then the gel retardation assay
may offer a simple system for assessing the presence or absence of certain
proteins capable of binding to hormone gene response elements such as Pit-1
or AP-1. It has the advantage of greater sensitivity than the DNase I
footprinting technique, and also requires much less nuclear protein
extract.
In this Chapter a preliminary and unsuccessful attempt to carry out
transient transfection of a human prolactinoma will be described. Then a
technique of nuclear protein extraction from small amounts of human tissues
will be described, leading to the successful application of the gel
retardation assay using these extracts in preliminary studies of nuclear
proteins binding to a hPRL gene promoter sequence. The initial studies
used nuclear proteins derived from bovine and post-mortem human pituitary
tissue from patients who died of non-endocrine causes, and compared these
extracts with that derived from a pituitary tumour. Further studies were
also performed to demonstrate the presence of specific DNA-binding proteins
in human placental tissue. The nuclear protein extractions and gel
retardations described here were all carried out during a four week period
as a visiting fellow in the laboratory of Dr Alexandra Belayew and Prof
Joseph Martial, University de Li6ge, Belgium.
7.2 METHODS
7. 2. 1 Transient transfection of human prolactinoma cells
Prolactinoma tissue was obtained from the patient M. H. , whose clinical
history was summarised in Chapter 3. The data for hPRL mRNA accumulation
derived from experiments carried out on tissue obtained at hypophysectomy
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in June 1986 (see Chapter 3.2), while the present experiments were done on
tissue from the patient's third hypophysectomy operation in 1988.
The tissue was enzymatically dispersed as described in Appendix Al. 1, to
yield approximately 6 x 10® viable cells. These were plated out into
multiwell culture dishes at 5 x 10s cells per well, in Dulbecco's modified
Eagle's medium containing 10% horse serum and 2.5% fetal calf serum with
antibiotics. After 7 days in culture the cells were only partially
adherent to the culture dishes, but it was decided to attempt a transient
transfection using the DEAE-dextran method. Two constructs were employed:
the first consisted of the proximal 740 bp from the hPRL gene 5'-flanking
sequence linked to the CAT reporter gene, and the second consisted of the
proximal 500 bp from the hGH gene promoter linked to the CAT gene (both
kindly provided by Dr Alexandra Belayew and Prof Joseph Martial,
Laboratoire de G6nie G6n6tique, University de Li^ge, Belgium). Because of
the small numbers of cells available, RSV-CAT was not used as an internal
assessment of transfection efficiency.
The transfection procedure was carried out as described in Chapter
5.2.3, with extreme care taken during the washing stages to avoid loss of
poorly adherent cells from the dishes. Approximately 1.5 x 10® cells were
used in each group, pooled from several culture wells. Two groups of cells
were transfected with the hPRL(-740)-CAT construct and were treated after
transfection with either control serum-free medium or with medium
containing lOOnM bromocriptine for 48 hours before cell harvesting for the
CAT assay. One group of cells were transfected with hGH(-500)-CAT and were
left untreated.
The cells were finally harvested and cytoplasmic extracts prepared for
the CAT assay, which was performed as described as in Chapter 5.2.4.
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7. 2. 2 Normal bovine pituitary tissue: nuclear protein extraction
Bovine pituitaries were obtained from the Li&ge abattoir, and were kept
on ice after removal for 30 minutes before commencing the nuclear protein
extraction procedure.
The procedure for extracting nuclear proteins from cultured cells was
not directly applicable to intact tissues, therefore a technique was
modified for use with small amounts of tissue from a published report
(Gorski et al, 1986) describing the preparation of transcriptionally active
protein extracts from various mouse tissues. The buffers used in this
technique are viscous to ensure separation of nuclei from other organelles
after homogenization, and have low salt concentrations (with EDTA included
in initial homogenization buffers to remove magnesium and calcium ions, to
preserve chromatin structure) spermine and spermidine are included to
replace ionic positive charges.
Tissue was chopped with a scalpel blade, and then homogenized using a
30ml teflon-glass motor-driven homogenizer in 15-30ral homogenization buffer
[ lOmM Hepes, pH 7. 6; 25mM KC1; 0. 15mM spermine; 0. 5mM spermidine; ImM EDTA;
2M sucrose and 10% glycerol!. The homogenate was layered over a 10ml
cushion of homogenization buffer, and the nuclei pelleted by centrifugation
at 24,000 r. p. m. for 30 minutes in an SW28 rotor at 0*C. The nuclei were
resuspended in fresh buffer and counted at this stage: from 3 bovine
pituitary glands (approximately 5 grams of tissue), 20 x 10* nuclei were
obtained. The resuspension buffer was identical to homogenization buffer
apart from containing additional glycerol (made up to 20%) and reduced
sucrose (200mM, to allow more complete removal of the viscous supernatant)
and the nuclear suspension was recentrifuged for 1-5 minutes at 11,000
r. p. m. in a JA20 rotor (16, OOOg).
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The nuclei were then resuspended in 300pl nuclear lysis buffer [lOmM
Hepes, pH 7. 6; lOOmM KC1; 3mM MgCl2; 0. ImM EDTA; lmM dithiothreitol <DTT)j
0. ImM phenylmethylsulphonyl fluoride (PMSF), and 10% glycerol - DTT and
PMSF were added immediately before use], and manually homogenized using a
glass-glass homogenizer. An aliquot of the homogenized material wa6 taken
and its absorbance read at A2eo* before the remaining material was
extracted using ammonium sulphate to precipitate chromatin. 4M ammonium
sulphate (pH 7.9) was slowly added until reaching 10% of the total volume,
and the viscous materal gently shaken on ice for 30 minutes before
centrifugation at 45,000 r. p. m for 2 hours in a T150 rotor. The
supernatant was finally dialysed overnight against 2 changes of 250ml
dialysis buffer C25mM Hepes <pH 7.6); 40mM KC1; 0. ImM EDTA; ImM DTT, and
10% glycerol].
The concentrations of nuclear proteins after dialysis was 3-4pg/pl, and
aliquots of the protein extract were stored in liquid nitrogen before use
in gel retardation assays.
7. 2. 3 Normal human pituitary, pituitary tumour and placenta: nuclear
protein extraction
Normal human pituitaries were obtained from post-mortems carried out
within three hours of death from patients who had died of non-endocrine
disease. After initial experiments, one of these was used for protein
extraction exactly as described in section 7.2.2. The patient was a man
aged 58 years, who had died of myocardial infarction. The pituitary gland
was stored in liquid nitrogen before protein extraction, and weighed 0. 6g.
2 x 10® nuclei were obtained, and the final protein concentration was
approximately 0. 25pg/pil.
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A single pituitary tumour was subjected to nuclear protein extraction in
parallel with the normal pituitary tissue. The tumour was a TSH-secreting
macroadenoma from a 49 year old woman (G. McN. ) who presented with
thyrotoxicosis, with high levels of serum TSH. The tissue was kindly made
available for study by Dr W. A. Burr (Consultant Physician) and Mr Towns
(Consultant Neurosurgeon), Pinderfields Hospital, Wakefield. The patient
had partly responded to somatostatin analogue therapy, but was then treated
by a trans-sphenoidal hypophysectomy. Some of the tumour tissue was grown
in monolayer cell culture, and this had shown that TSH secretion in vitro
was unaffected by treatment with T3, but reduced to 50% of control with IpM
somatostatin (data not shown). 3 x 10s nuclei were isolated, but the final
protein concentration was just detectable at approximately 0. lpg/pl.
Finally, a nuclear protein extract was prepared from a normal human
placenta. The material used weighed 23g, and gave a final protein
concentration of 0. 2pg/pl.
7. 2. 4 Gel retardation assays
These assays were carried out precisely as described in Chapter 6. The
oligonucleotide was the same as that used in those studies of rat pituitary
proteins, there termed rPRL-P3; the same sequence is located in a similar
position in the human prolactin proximal enhancer region, and is identical
to the second of the three pituitary-specific protein binding sites
(putative Pit-l/GHF-1 binding sites) described in the proximal enhancer
region of the human prolactin gene (Lemaigre et al, 1989). Hence in these
studies it is termed hPRL-P2, even though the sequence is identical. For
comparison with the tissue protein extracts, previously prepared nuclear
protein extracts from GH3B6 cells were used; these extracts were prepared
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uslng the technique described by Dignam et al (1983), and so differ
slightly from those described in Chapter 6.
Competition studies were performed using either an excess of unlabelled
hPRL-P2, or of an unrelated oligonucleotide (the consensus binding site for
the CCAAT enhancer protein, C/EBP).
7.3 RESULTS
7. 3. 1 Transient transfection of prolactinoma cells
Cytoplasmic preparations were made from the cultured cells from this
tumour for assay of CAT activity. Chloramphenicol was separated from its
acetylated products by thin layer chromatography as before, and the
autoradiogram is shown in Figure 7. 1. The levels of acetylation were very
low, and did not vary among the three treatments studied. Cytoplasmic
extracts from cells transfected with hPRL(-740>-CAT and treated with
control medium generated 3.8% acetylation/mg protein, and those treated
with lOOnM bromocriptine gave an identical result. Extracts from cells
transfected with hGH(-500)-CAT gave 3.3% acetylation/mg protein.
These are very low levels of chloramphenicol acetylation, and suggest
that the transfection efficiency or cell viability after transfection was
very poor. This may reflect the fact that cells were only poorly adherent,
or that the absolute numbers of cells were inadequate to give reliable
results. Thus unfortunately the data are not adequate to draw any
conclusions as to the ability of the prolactinoma cells to respond to
dopaminergic control of transcription of the transfected promoter construct
for comparison with the data for mRNA presented in Chapter 3. However,
despite the technical problems experienced, it seems likely that transient








hPRL (-740) hGH (-500)
Transient transfectlon of cultured human prolactinoma
cells. Cross-hatched bars: hPRL(-740)-CAT, control
medium (-DA) and lOOnM bromocriptine <+DA>; stippled
bar: hGH(-500)-CAT, control medium.
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possible, and that valuable data may be obtainable about control of gene
transcription in these tumours.
7. 3. 2 Gel retardation studies
In initial experiments, bovine pituitary extract was compared to nuclear
extracts previously prepared (Bernard Peers, Laboratoire Central de G6nie
G6n6tique, Lifege, Belgium) from rat pituitary GH3B6 cells by the procedure
described by Dignam et al (1983). A variety of concentrations of KC1 were
employed, as the salt concentration is thought to be critical for protein
binding to DNA (Ausubel et al, 1989). A number of retarded DNA-protein
complexes were seen with both extracts, but the extent of different complex
formation was affected by KC1 (Figure 7,2). An artefactual (non-
competable) low mobility band was often seen at the top of gels, in these
and subsequent experiments, sometimes even in the absence of protein, but
this complex was not generally seen with KC1 concentrations of 75mM or
higher, and its significance remains uncertain. At least three faster-
running (higher mobility) bands were seen with both extracts, two of them
apparently identical with the different extracts, and one which was of
higher mobility with bovine pituitary extract than with GH3B6 extract, and
all of these bands were reproducibly and easily detected with KC1 concen¬
trations between 75 and 150mM (Figure 7.2). Thus these experiments
indicated that a technique for extracting nuclear protein from fresh tissue
could be applied to small quantities of pituitary tissue, and gave results
comparable to the technique of Dignam et al (1983) for cultured cells.
In the next experiments, bovine pituitary extract was used for
comparison with nuclear protein extracts (0. 2-2.Opg) prepared from a normal
human pituitary gland obtained post-mortem, and with proteins prepared from
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Bovine pituitary Rat
Figure 7. 2 Gel retardation analysis, comparing nuclear proteins
extracted from bovine pituitary tissue or rat GH3B6
cells. Lane 1, DNA (hPRL-P2) alone; lanes 2-10, DNA
incubated with lOpg nuclear protein. In lane 3, a 50-
fold molar excess of unlabelled hPRL-P2 was included.
KC1 concentrations were varied as indicated.
-125-
before this parameter was varied, and the previously noted artefactual low-
mobility band was a problem with these gels. However, specific bands
representing true DNA-protein complexes were seen with all three extracts,
and the pattern seen with human pituitary strikingly resembled that found
with bovine pituitary extracts with at least three retarded bands of
identical electrophoretic mobility (Figure 7.3). The pattern seen with
placental extracts differed: at least one of the two "pituitary" bands
(band 1) was retained, but a further lower mobility band (band 4) was now
seen, and the faster band also differed in its mobility.
Further experiments were performed to see whether these bands were truly
DNA-specific, and also to test the tissue-specificity (Figure 7.4). Here,
rat liver extract was used and generated a single band at a position
comparable to one of the "pituitary" bands. However the other two bands
were not seen with this extract. The human placental extract yielded a
band of similar mobility, which likewise was competed by a 50-fold molar
excess of hPRL-P2, but not by a 50-fold excess of C/EBP oligonucleotide.
The higher and lower mobility bands were only seen with KC1 ) 75mM, whereas
these complexes were not seen with the liver extract.
Finally, an experiment was performed comparing the nuclear protein
extract prepared from normal human (post-mortem) pituitary with that
prepared from the TSH-secreting pituitary tumour (2pg aliquots in each
case; Figure 7.5). Unfortunately in these experiments, an apparently
artefactual low-mobility band was again seen (present even with DNA alone,
not shown). Nonetheless, competition studies with excess of hPRL-P2 or
C/EBP oligonucleotides showed the presence of at least three specific bands
with the normal pituitary extract (competed by hPRL-P2 but not by C/EBP),
together with a further high-mobility band which was competed by both
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pituitary pituitary placenta
Figure 7.3 Comparison of nuclear proteins from bovine and human
pituitary tissue, and human placenta. Lane 1, labelled
DNA (hPRL-P2) alone; lanes 2-10, DNA incubated with
varying amounts of nuclear protein as shown.
Incubation carried out using 50mM KC1.
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x + Competitor + PRL3
DNA x CEB/P
150 100 50 50 150 100 75 50 50 50 [KC1] mM
Rat liver Human placenta
Figure 7.4 Comparison of nuclear proteins from rat liver and human
placenta, with varying KC1 concentrations as shown.
Each lane contained lOpg nuclear protein, and
competitor DNA (hPRL-P2, lanes 3 and 9; C/EBP, lane 8)








Comparison of nuclear proteins from normal post-mortem
human pituitary with TSH-secreting pituitary adenoma.
Each lane contains labelled hPRL-P2 oligonucleotide
with 2pg nuclear protein, together with no competitor
DNA (lanes 1 and 4), or 50-fold molar excess of hPRL-P2
(lanes 2 and 5) or C/EBP (lanes 3 and 6).
-129-
oligos. The tumour extract generated bands of quite different electro-
phoretic mobility from the normal pituitary, but the most prominent complex
was apparently DNA-specific as it was competed out by excess hPRL-P2 and
not C/EBP DNA.
7. * DISCUSSION
In this Chapter I have presented the results of preliminary experiments
applying a transient transfection assay and the gel retardation assay to
human pituitary tissue. The attempt at transient transfection was
unsuccessful, probably mainly due to poor condition of the cells before
transfection as well as their low numbers. The reason for attempting to
use this approach was to address the question of why these tumour cells had
apparently lost their responsiveness to dopaminergic inhibition of
prolactin mRNA accumulation. One possibility would be that the 5'-flanking
DNA of the endogenous hPRL gene was altered in some way that prevented
dopaminergic regulation of transcription; a second possibility would be
that a nuclear protein trans-acting factor (such as Pit-l/GHF-1) was
abnormal and unable to convey an intracellular signal to regulate
transcription. Thus transfection of a normal exogenous hPRL promoter
sequence might enable one to distinguish between these possibilities.
Transient transfection analysis has been successfully applied to primary
cell culture systems (Burrin et al, 1989) and the use of the 0-galacto-
sidase reporter gene and the substrate X-gal (with generation of a blue
reaction product visible by light microscopy; Riabowol et al, 1988) may
facilitate future studies in this direction.
The gel retardation assays were designed to seek the presence of a
nuclear protein similar to Pit-l/GHF-1 in human tissues which express the
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PRL gene. DNase I footprinting studies have shown that a single protein
factor present in the GH3B6 rat pituitary lactotroph cell line is capable
of binding to DNA sequences in the 5'-flanking region of the hPRL, hGH and
placental lactogen genes (Lemaigre et al, 1989). The proximal 740bp of 5'-
flanking DNA from the hPRL gene contain three binding sites for this
protein which have some homology with similar sites in the rPRL proximal
enhancer region which bind Pit-l/GHF-1. However there has so far been no
direct evidence that human pituitary cells contain a factor similar to rat
Pit-l/GHF-1.
The present preliminary results are important because they are the first
demonstration of a DNA-binding protein in the human pituitary gland. Human
placental tissue appears to contain a similar factor, though there are some
differences in the protein-DNA complexes formed. The identity of the
protein(s) is not yet precisely established, but the results of competition
studies suggest the presence of a Pit-l/GHF-l-like protein in that
competition for protein binding was observed only with a Pit-l/GHF-1
binding site, and not with a DNA sequence which binds another non-tissue
specific transcription factor (C/EBP).
There is also evidence for a DNA-binding protein factor present in the
thyrotrophinoma tumour cell nuclei. The rat Pit-l/GHF-1 mRNA and protein
are expressed not only in lactotrophs and somatotrophs, but al6o in
thyrotrophic cells (Crenshaw et al, 1989; Mangalam et al, 1989). Likewise,
studies of transgenic mice have shown that the presence of Pit-l/GHF-1
binding sites in a promoter sequence are able to target expression of a
reporter gene to all three cell types, but not to corticotrophs or
gonadotrophs (Ingraham et al, 1988). Thus it is reasonable to use the TSH-
secreting pituitary tumour to seek the possible presence of a Pit-l/GHF-1
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related factor. The results do Imply the presence of a Pit-l/GHF-l-like
nuclear protein In human thyrotrophlc cells, as observed in the rat. .
However the gel retardation pattern differed substantially from that seen
with normal pituitary tissue. The tumour tissue may be presumed to contain
a relatively pure population of thyrotrophic cells, whereas the normal
pituitary would contain a mixed cell population, with a predominance of
lactotrophs and somatotrophs. Because of the small amounts of tumour
tissue normally available it has not been possible to date to obtain
sufficient prolactinoma or somatotrophinoma tissue for a similar comparison
of neoplastic versus normal lactotrophs. Nonetheless, from the present
preliminary data, it may be postulated either that the DNA-binding protein
differs in different pituitary cell types, or that neoplastic cells may
differ from normal pituitary lactotrophs. If the latter possibility is
verified, it may be relevant to previous data (Chapters 3 and 4) which
suggest abnormal hormonal regulation of gene expression in human pituitary
tumours. Thus, the observed lack of suppression of PRL or GH mRNA levels
in tumour cells by dopamine and somatostatin respectively may reflect
abnormal constitutive expression due to changes in DNA-binding nuclear
proteins such as Pit-l/GHF-1.
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CHAPTER 8
CONCLUSIONS: MOLECULAR APPROACHES TO THE
PATHOGENESIS OF PITUITARY TUMOURS
8.1 INTRODUCTION
In this thesis, the techniques of RNA-DNA hybridization, transient
transfection analysis and gel retardation analysis have been described in
relation to studies of the regulation of pituitary hormone gene expression.
They have been increasingly widely used in published studies of gene
expression in rat pituitary cells, and two particular examples are given in
Chapters 2 and 5, which concentrate on regulation of the rat prolactin gene
by dopamine and calmodulin. In the other Chapters I have attempted to
apply these techniques to ask questions about possible abnormalities of
pituitary hormone gene transcription in human pituitary adenoma tissue.
These studies are invariably circumscribed by the lack of large amounts of
tissue, and the results reported here have to be regarded as somewhat
preliminary. However, they indicate that it is possible to study newly
developing hypotheses about the regulation of gene transcription, even in
small amounts of human pituitary tissue.
8. 2 GENE REGULATION AND PITUITARY ADENOMA PATHOGENESIS
The basic cellular mechanisms that may result in the formation of
hormone-secreting pituitary adenomas are not yet understood (Melmed et al,
1986; Melmed, 1990), but a number of recent studies of PRL and GH gene
expression have suggested some potential pathological processes which may
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be relevant. In particular it is interesting to note that for both PRL and
GH, hormone secretion and tumour growth appear to be functionally linked,
suggesting that the mechanisms for gene regulation elaborated above may
have direct relevance for understanding tumour growth.
8.2.1 Studies of mRNA regulation in pituitary tumours
Investigation of PRL and GH gene regulation in human pituitary tumour
tissue is clearly of interest, but such studies have been very few.
Yamashita et al (1986b) showed that hGH mRNA levels were appropriately
inhibited by IGF-I and stimulated by GRF in human somatotroph adenomas, as
has been found in normal rat pituitary tissue (Barinaga et al, 1983;
Yamashita & Melmed, 1987). The present studies discussed in Chapter 4
confirmed this appropriate effect of GRF, but found that somatostatin was
ineffective in suppressing GH mRNA levels in contrast to similar studies of
normal rat tissue. Quantitative in situ hybridization analysis has also
suggested a lack of suppression of GH mRNA by somatostatin in somatotroph
adenomas (Levy & Lightman, 1987) In Chapter 3, the study of an aggressive
prolactinoma showed resistance of hPRL mRNA accumulation to dopaminergic
suppression, again suggesting that gene expression in pituitary adenomas
may be relatively autonomous.
Isaacs et al (1987b) compared the expression of the endogenous hGH gene
in cultured human pituitary tumour cells with the hGH gene transfected into
rat cell lines, and found differences in T3 regulation, while insulin and
glucocorticoid regulation was similar. Again this may imply a tumour-
specific abnormality in GH gene control, but a certain answer to this
question will necessitate comparison of normal human pituitary tissue with
adenoma tissue. This is difficult to achieve as it is hard to obtain
viable normal pituitary tissue post mortem. However the technique of
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quantitative in situ hybridization analysis (Pixley et al, 1987; Levy &
Lightman, 1988) may prove helpful In further studies of very small tissue
samples such as periadenomatous tissue obtained at pituitary adenomectomy.
8. 2. 2 Hormone gene structure and proto-oncogenes
Abnormalities at the level of the hGH gene itself have been proposed by
U et al (1988) who found evidence for hypomethylation of the hGH gene and
its 5'-flanking region in adenomas compared to normal pituitary tissue:
gene hypomethylation is generally associated with enhanced expression in
tissues where the genes are normally expressed (Razin & Riggs, 1980;
Compere & Palmiter, 1981; Hjelle et al, 1982; Durrin et al, 1984;
Laverriere et al, 1986).
U et al (1988) also found that the c-fos proto-oncogene (but not c-myc)
was amplified in genomic DNA from a single prolactinoma, which is of
interest in that c-fos has been implicated in a mitogenic action of GRF and
cyclic AMP in somatotrophs (Billestrup et al, 1987), and is closely linked
to the DNA-binding and transcriptional activity of the transcription factor
AP-1 (Chiu et al, 1988; Curran & Franza, 1988; Karin, 1989; Mitchell &
Tjian, 1989). The role of such transcription factors in pituitary tumour
development has yet to be addressed, but abnormalities in their DNA-binding
or in their phosphorylation by kinases may clearly have major effects on
the level of gene transcription, and may be further sites of gene
dysregulation involved in adenoma formation. The recent cloning and
sequencing of cDNAs coding for the pituitary-specific transcription factor
Pit-l/GHF-1 (Bodner et al, 1988; Ingraham et al, 1988) will undoubtedly
stimulate investigation into the potential interactions between trans¬
acting factors in pituitary tumours.
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8. 2. 3 Abnormalities In membrane proteins: application of PCR
Abnormalities in membrane transduction proteins linked to intracellular
signalling systems have been recently been found in pituitary tumours. A
selective deficiency of G0 proteins has been reported in two dopamine-
resistant PRL-secreting rat pituitary tumours (Collu et al, 1988). These
G-proteins are thought to be involved in dopamine action, and thus their
deficiency or dysfunction might lead to dopamine resistance even where
dopamine receptors are present. Vallar et al (1987) reported apparent
constitutive activation of adenylate cyclase activity in a sub-set of human
GH-secreting adenomas, and suggested that an abnormality in the Gsa sub-
unit might be responsible.
This group have recently confirmed this hypothesis using the technique
of polymerase chain reaction (PCR). Complementary DNAs for the Gsa mRNA
were amplified by PCR from mRNA extracted from eight GH-secreting tumours.
When the amplified cDNAs were subcloned and sequenced, it was found that
the Gsa sub-units contained point mutations in all four of the GH-producing
tumours which demonstrated constitutively active adenylate cyclase activity
but in none of the other four tumours - transfection-expression experiments
using Gsa sequences containing these point mutations showed that they had
the effect of increasing adenylate cyclase activity in the transfected host
cells (Landis et al, 1989). Increased cAMP production results in GH
secretion, increased GH gene transcription, and also increased somatotroph
proliferation (Billestrup et al, 1986), and hence a "cause" of tumour
formation has been found in this sub-set of somatotroph tumours.
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8. 3 CONCLUSION
The prolactin and GH genes are related and their structure and
regulation have been extensively studied In rat pituitary cell systems.
Mechanisms for their tissue-specific expression and hormonal regulation are
rapidly being elucidated, and a complex picture of inter-related nuclear
protein/proto-oncogene effects on the genes is developing. The recent
identification and cloning of such trans-acting factors as Pit-l/GHF-1 and
AP-1 are major advances in the field, and will undoubtedly clarify our
understanding.
It seems likely that the technique of PCR will prove ideal for analysis
of abnormal gene structure in small amounts of tissue in a variety of
endocrine conditions where experimental data have suggested specific
molecular abnormalities. In the light of the data presented in this thesis
regarding pituitary tumours, it seems worthwhile to use PCR to seek
mutational abnormalities in nuclear proteins that are involved in GH and
PRL gene transcription: potential candidate proteins might include the
oestrogen receptor and the T3 receptor, but perhaps also Pit-l/GHF-1
itself, especially in the light of recent evidence that this protein may
mediate between the cAMP-CREB system, and somatotroph proliferation.
The pathogenesis of pituitary tumours remains a challenge, and has
recently stimulated the application of molecular biological techniques and
knowledge to human pituitary tissue. Whether tumour development can be
attributed to specific defects at the level of hormone and/or proto-
oncogene regulation within the nucleus will be the next exciting question






Al.l PRIMARY CELL CULTURE TECHNIQUE
For all studies Involving in vitro treatments of normal rat pituitary cells
or human pituitary tumours, primary monolayer cell cultures were prepared from
freshly obtained tissue. The technique was essentially a modification of that
first described by Vale et al (1972), which has been widely used to study the
control of secretion of different pituitary hormones. The procedure involves
enzymatic and mechanical dispersion of pituitary tissue, followed by plating of
dispersed cells onto multiwell plastic culture dishes. The cells are normally
allowed to recover from enzymatic dispersion for at least three days before
experiments commence.
Materials
Dulbecco's modified Eagle's medium ®MEM) was obtained in powdered form
(Gibco) and diluted with distilled deionized water, adjusted to pH 7.2, and
sterilized by membrane filtration. This medium was used with various
supplements as follows:




Dispersion medium: IM + 0.2% (w/v) collagenase
0.1% hyaluronidase type III
2pg/ml DNase I
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Final medium: IM + 10% (v/v> horse serum (Wellcome)
#
2.5% fetal calf serum (Glbco)
2mM L-glutamine
Procedure
All glassware was siliconzed ("Repelcote", Hopkin & Williams) and sterilized
by autoclaving before use. For experiments using normal rat pituitary tissue
(Chapter 2) male Wistar rats were anaesthetized with diethyl ether and
decapitated. The brain was rapidly removed and the anterior pituitary separated
from neurohyophysial tissue and placed in ice-cold Initial Medium. For
experiments using human pituitary tumour tissue, fragments of tumour were
obtained at trans-sphenoidal or trans-frontal hypophysectomy operations on
patients with pituitary tumours, and immediately placed in ice-cold Initial
Medium.
The tissue was chopped with a blade and the resulting small fragments were
incubated with Dispersion Medium at 37 *C in a siliconized trypsinizing chamber.
Enzymatic dispersion was assisted by mechanical agitation of fragments with a
magnetic stirrer bar and repeated trituration with a 1mm siliconized glass
Pasteur pipette. The dispersion was usually completed within 30 min, and the
cell suspension filtered through a 120pm nylon mesh to remove large undigested
clumps of tissue. The filtered suspension was centrifuged at 600# for 10 min
to remove enzyme solution, the pellet resuspended and washed twice more in
fresh Initial Medium.
Finally, cells were resuspended in 2ml Final Medium, and a 15pl aliquot was
diluted with 0.2% trypan blue for cell counting and assessment of viability.
Average cell yield was approximately one million cells per rat pituitary gland,
with over 90% viability. This cell suspension was then diluted in Final Medium
to allow plating of cells onto 24-well culture plates at a density of 1-5 x 10s
-140-
cells In 2ml per well. The cells were allowed to attach to the plastic culture
dishes and incubated in monolayer culture at 37*C in a humidified atmosphere of
95% air/5% carbon dioxide.
A1.2 GHa CELL CULTURE TECHNIQUE
The studies investigating calmodulin-dependence of prolactin mRNA
accumulation, transient transfection analysis and gel retardation analysis were
all carried out using the clonal rat pituitary GH3 cell line. This cell line is
one of several derivatives of the original GH cell line (Tashjian et al, 1968;
Tashjian 1979) originally obtained from an oestrogen-induced rat pituitary
tumour (MtT/W5; Furth et al, 1973). While GH3, GH3B6 and GH^Cl cell lines
produce large quantities of prolactin as well as growth hormone, the GH, line
produces mainly growth hormone, while the GC line produces no detectable
prolactin. All of these lines have been well characterized in terms of the
mechanisms of hormone secretion, and are widely used for the majority of
detailed studies of the regulation of growth hormone or prolactin gene
transcription.
GH3 cells were obtained as a growing culture from the European Collection of
Animal and Cell Cultures (ECACC; PHLS Centre for Applied Microbiological
Research, Porton Down, Wiltshire). The cells were grown in continuous monolayer
culture in antibiotic-free Ham's F-10 medium (Gibco) supplemented with 10%
horse serum (Gibco, HS3, cat ref 034-6055M) and 5% fetal calf serum (Gibco, cat
ref 011-06290M). In these conditions the cells had a doubling time of
approximately 48h.
Cells were fed with fresh medium every 3 days and usually subcultured once
weekly. In general, the cells were subcultured up to a maximum of 20 times.
All manipulations of the cells were performed using disposable plastic pipettes,
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and all solutions were filter-sterilised immediately before use.
Subculturlng technique
Cells were grown to near confluence in 25cm2 or 75cm2 culture flasks
(Falcon), and subcultured before cells began to detach. Cells never achieved
complete confluence, and were usually only semi-adherent.
1. Serum-containing F-10 medium was removed, and replaced with Hanks buffered
salt solution (HBSS; Gibco) to wash the cells.
2. This was aspirated and in turn replaced with 0.25% trypsin (type IX, Sigma)
for 30 sec.
3. Most of this excess trypsin was aspirated, and the cells were incubated at
37 *C for 5 min, covered with only a thin film of the trypsin solution.
4. Serum-containing F-10 medium was added to each flask, and the dispersed
cells thoroughly resuspended; the cell suspension was then aspirated and
added to fresh culture flasks. In general, cells were split 1:3 to 1:5.
Freezing and thawing of cells
A stock of deep frozen GH3 cells was maintained in liquid nitrogen for
provision of fresh cultures approximately every six months, to avoid excessive
sub-culturing.
Cells were trypsinized from flasks as described above, but were resuspended
in small volumes of neat fetal calf serum containing 9% dimethylsulphoxide
®MS0) as a cryopreservative agent. Approximately 10T cells per ml were then
placed in cryotubes, and gradually cooled to -70*C before transfer to the liquid
nitrogen bank for long-term storage.
Frozen cells were rapidly thawed as required to 37 *C, and diluted into serum-
containing F-10 medium, washed free of DMSO, resuspended in fresh medium and
plated into 75cm2 flasks.
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APPENDDC 2
RAD IOLABELLING OF DNA SEQUENCES
A2.1 LABELLING OF cDNA PROBES BY NICK TRANSLATION
Plasmids containing complementary DNA inserts encoding rat prolactin (Gubbins
et al, 1979), rat growth hormone (Harpold et al, 1978), and human prolactin
(Truong et al, 1984) were generously provided by Dr RA Maurer (University of
Iowa, USA), Dr FC Bancroft (Cornell University, New York, USA), and Dr JA Martial
(University de Lifege, Belgium) respectively. These cDNA probes were radio-
labelled by the nick translation reaction (Kelly et al, 1970). In this reaction
DNase I introduces nicks into the double stranded DNA sequence, and these nicks
act as loci for DNA polymerase I to replace the original nucleotides with
replicas that may be radiolabeled with a32P.
The reagents were purchased in the form of a kit (Amersham International,
catalogue ref. N 5000), and the protocol outlined below is derived from the
manufacturer's instructions. The reaction was performed on ice behind a perspex
screen.
1. Reagents were added: lpg plasmid DNA containing insert
20pl dNTP buffer (lOOpM dATP, dGTP & dTTP)
lOpl enzyme solution (5u DNA polymerase I and
lOOpg DNase I)
12.5pl or^P-dCTP (=312pmol)
distilled deionized water to volume of lOOpl
2. The reaction mix was gently agitated, then incubated at 15 *C for 90 min.
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3. The reaction was terminated by adding the reaction mix to a 10cm spin
column of Sephadex G-10 suspended in a buffer containing 150mM NaCl, lOmM
EDTA, 0.1% SDS and 50mM Tris-HCl, pH 7.5. The column was mounted in a 10ml
centrifuge tube containing the conical base of an Eppendorf 1.5ml tube,
centrifuged at lOOOrpm for 5 min, and the labelled DNA collected in the
eluate.
4. Incorporation was calculated as follows:
a. a 2pl aliquot of total reaction mix was added to 200pl water (= total
counts)
b. 20pl of this solution was added to 50pl carrier DNA (salmon sperm)
solution; 1ml 10% trichloracetic acid CTCA) solution added; mixture
incubated on ice for 15 min, to allow labelled cDNA and carrier DNA to
precipitate. Precipitated DNA collected onto glass-fibre disc by vacuum
filtration; disc washed with fresh TCA, dried, and counted by liquid
scintillation counting.
c. 20pl of total counts solution added to glass-fibre disc for counting.
d. 20pl of solution eluted from Sephadex column added to glass-fibre disc
and counted.
e. 20pl of column eluate TCA-precipitated and counted.
% incorporation = dpm on filter x 100%
total activity in dpm
Specific activity = dpm on filter x 202 x 100 dpm/pg.
20 2
Mean specific activity was 1-4 x 10® dprn/pg DNA.
5. Before use in a hybridization reaction, the labelled probe was denatured
by heating to 100'C and snap cooling on ice.
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A2. 2 LABELLING OF hGH cDNA BY RANDOM PRIFER TECHNIQUE
A2.2.1 Excision of hGH cDNA Insert
The hGH cDNA Is an 800bp Insert within pBR322, and can be excised using
Hindlll restriction enzyme before radiolabelling.
Buffer: 5x Tris-Borate-EDTA (TBE) 54g Trizma base
27.5g boric acid
20ml 0. 5M EDTA, pH8. 0
make up to 1 litre with dH20
Loading buffer 50mM Tris
50mM EDTA
0.5% SDS
0. 1% bromophenol blue
12.5% sucrose
1. 4pl of DNA (lpg/pl) added to Z\il enzyme with 2pl buffer (as recommended
by manufacturer), and made up to 20pl on ice.
2. Reaction mix incubated 4-16h at 37*C
3. Gel prepared: low melting point agarose <1% in 25mM (lx) TBE buffer)
boiled to dissolve agarose, and ethidium bromide added to stain DNA
bands.
4. Gel poured and allowed to set.
5i Loading buffer (2pl) added to cDNA and A Hindlll DNA markers.
6. Electrophoresis tank filled with lx TBE. Samples loaded into wells and
run at 60v (neg to pos) for l-2h.
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7. After electrophoresis, bands visualised under UV light, and band with
insert cDNA cut out with a scalpel blade, weighed (in Eppendorf tube)
and water added (1.5pl/mg agarose). Agarose boiled for 7 min, cooled to ■
37*C, and aliquots prepared for storage until required for labelling.
A2.2.2 Radiolabelling of excised cDNA probe
This technique relies on the use of random DNA hexamers that are able to
bind to sequences within a denatured cDNA probe, and act as primers to
allow initation of transcription from the other strand by DNA polymerase
(Feinberg & Vogelstein, 1983). The reagents were used in kit form
(Amersham, RPN 1601) and the protocol outlined below is essentially as
recommended in the manufacturer's instructions.
1. cDNA probe <25ng) was heat denatured by heating to 100*C for 2-3 min,
and snap-cooled on ice.
2. Reagents were added to cDNA: Multiprime buffer solution llpl
Primer solution 5pl
cr33P-dCTP (50pCi) 5pl





dATP, dGTP, dTTP in buffer containing
Tris-HCl pH 7. 8, MgCl2 and
2-mercaptoethanol
random hexanucleotldes in BSA solution
DNA polymerase I, Klenow fragment
(lu/pl) in 50mM potassium phosphate
(pH 6. 5), lOmM 2-mercaptoethanol and 50%
glycerol
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3. The reaction mix was gently mixed by pipetting, avoiding vortexing, and
was then incubated at room temperature for 3-24h,
4. Incorporation was checked by comparing TCA-precipitable counts from the
reaction mix with total counts, similarly to the procedure described for
nick translation in A2. 1. Mean specific activity was approximately
1 x 10® dpm/pg DNA.
5. Before use in a hybridization reaction, the labelled probe was denatured
by heating to 100*C and snap cooling on ice.
A2. 3 LABELLING OF OLIGONUCLEOTIDES WITH T4 POLYNUCLEOTIDE KINASE
Double stranded oligonucleotides may be end-labelled for use in gel
retardation assays using T4 polynucleotide kinase. This enzyme was first
purified from Escherichia coli infected with the T4 bacteriophage. In the
"forward reaction" (more widely used than the less efficient exchange
reaction), the enzyme catalyses the transfer of the terminal (y) phosphate
from ATP to the 5' hydroxyl terminus of DNA or RNA. The 5' end of a DNA
sequence may be radiolabelled whether it is recessed, overhanging or blunt-
ended.
In a 30pl reaction, reagents were added as follows:
1. 50mM Tris-HCl, pH 7. 5
lOmM MgCl2
5mM DTT
l-50pmol dephosphorylated DNA, 5' ends
50pmol (150pCi) y®2P-ATP <>3000 Ci/mmol)
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50pg/ml bovine serum albumin
20 units T4 polynucleotide kinase
2. The reaction mix was incubated at 37*C for 60 min, and terminated by
addition of lpl 0. 5M EDTA. If desired, labelled DNA could be separated





A3. 1 CYTOPLASMIC DOT HYBRIDIZATION ASSAY (White & Bancroft, 1982)
A3.1.1 Preparation of cytoplasmic samples
1. Medium was removed from cell culture wells for hormone assay, and cells
were scraped from the plastic surface in ice-cold phosphate buffered
saline (PBS), and centrifuged at 600# for 10 min.
2. Cells were resuspended in 1ml PBS, and recentrifuged at 15000g- for 30s.
3. Cells were resuspended on ice in 45pl Tris (lOmM) with ImM EDTA, pH 7.0.
4. Two 5pl aliquots of 5% Nonidet P40 were added, with mixing on ice for 5
min in between. [This step is designed to cause lysis of predominantly
the cytoplasmic membrane, leaving the cell nuclei intact, which can be
verified microscopically.]
5. The lysed cells were recentrifuged at 15000^ for 3 min, to pellet the
nuclei.
6. The cytoplasmic supernatant (50pl) was added to sterile Eppendorf tubes
containing 20pl 37% formaldehyde and 30pl 20x standard saline citrate
(SSC) buffer [ 3M NaCl and 0. 3M trisodium citrate, pH 7.01.
7. The final sample was heated at 60*C for 15 min, before storing at -70*C.
A3.1.2 Hybridization assay
The cytoplasmic samples were serially diluted (1:10 to 1:100) in 15x
SSC, and lOOpl of each dilution was applied in duplicate with suction to a
nitrocellulose or nylon hybridization transfer membrane held in a 96-well
perspex manifold ("Hybridot" apparatus, BRL). The membrane was baked at
80 *C for 90 to fix RNA to the membrane.
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Prehvbridization
The membrane was prehybridized, to block DNA binding to non-specific
sites on the membrane, by incubation at 42 *C for 16-24h in a polythene bag
with approximately 10ml of a buffer containing:
50% (v/v) deionized formamide
0. 2% (w/v) polyvinyl pyrollidone
0. 2% (w/v) bovine serum albumin
0. 2% (w/v) ficol1
0. 05M Tris-HCl, pH 7. 5
0. 1% (w/v) sodium pyrophosphate
1% (w/v) sodium dodecyl sulphate (SDS)
10% (w/v) dextran sulphate
lOOpg/ml denatured salmon sperm DNA
5. 8% (w/v) NaCl
Hybridization
The 32P-labelled cDNA probe (approx 250ng) was denatured by heating at
100*0 for 10 min then snap cooling on ice, diluted in approximately 2ml of
prehybridization buffer and then added to the prehybridization buffer
surrounding the membrane. The membrane was gently agitated in the
hybridization buffer for 16h at 42*C, using a shaking water bath.
Washing
After hybridization, the membrane was removed from the buffer containing
labelled probe, and was washed as follows:
Twice in: 2x SSC, 5 min, room temperature;
Twice in: 2x SSC with 1% SDS, 45 min, 65 *C;
Twice in: 0. lx SSC, 30 min, room temperature
[SSC buffers were prepared by dilution of 20x SSC stock solution.]
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Autoradlographv
Membranes were air-dried and then exposed to X-ray film (Cronex-4,
NIF100) using intensifying screens at -70*C for up to 72h. Intensity of
hybridization was measured by scanning densitometry of the developed
autoradiographs using a laser densitometer (LKB 2202 Ultroscan) to generate
optical density estimates for each dot. The optical density signal was
non-linear at the extremes of the range, and exposure of autoradiographs
therefore had to be judged to give a signal which would yield results in
the linear part of the range for at least one of the cytoplasmic dilutions
used.
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A3. 2 NORTHERN BLOT ANALYSIS
A3. 2. 1 RNA preparation: guanldine lsothiocvanate/caeslum chloride method
Total RNA was extracted from cultured human somatotrophinoma cells using ,
the technique described by Chirgwin et al (1979) for tissues enriched in
ribonucleases. The total RNA (including nuclear and cytoplasmic RNA is
relatively pure, uncontaminated by proteins. The technique relies on the
fact that RNA sediments more rapidly through a caesium chloride cushion
than DNA or protein; guanidine isothiocyanate (GI) is used to lyse cells
and inactivate ribonucleases simultaneously. Caution is required to ensure
that there is no nuclease contamination from skin or solutions, and all
glassware should be treated either by baking (800*C for at least 4h) or by
exposure to diethylpyrocarbonate solution (DEPC).
Solutions
4M guanidine isothiocyanate: Guanidine isothiocyanate 50g
Na-N laurylsarcosine 0. 5g
1M Na citrate pH 7. 4 2. 5ml
Surgine antifoam A 0. 33ml
Distilled water to 100ml
Filter under reduced pressure, and then add
0. 7ml p-mercaptoethanol.
5. 7M CsCl in 0. 1M EDTA: Caesium chloride, 96g/100ml
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Method
1. Add GI solution to cells in culture wells, and make this lysate up to
3ml with further GI solution, resuspendlng thoroughly to ensure cell
disruption.
2. Add solid CsCl to the homogenate, 1.2g CsCl per 3ml GI solution and
gently shake to dissolve.
3. Layer cell lysate onto 1. 2ml cushion of 5.7M CsCl/EDTA in a 5ml
polyallomer ultracentrifuge tube. Top up tubes with extra GI/CsCl
solution if necessary, and balance tubes.
A. Centrifuge in SW50. 1 rotor at 35000 rpm for 17h.
5. Carefully remove GI/CsCl from tubes, without disturbing the RNA pellet.
6. Thoroughly resuspend the pellet in lOOpl distilled water, and transfer
the RNA solution to a sterile Eppendorf tube.
7. Phenol extract the RNA to remove any protein: add equal volume of
phenol, vortex for 20s, and spin for 5 min in a microcentrifuge
(13000rpm>. Transfer upper aqueous layer to fresh Eppendorf tube, and
remove residual phenol by adding 0. 5ml water saturated ether. Shake
gently, then spin for 5 min, remove upper layer of ether and dry off
remaining ether by heating RNA solution at 50*C for 5 min.
8. Ethanol precipitate RNA: add l/10th volume of 3M Na acetate, pH 5. 2 and
mix; then add 2. 5 volumes absolute ethanol and mix. Precipitate RNA by
leaving tubes at -70*C for 2h or -20*C for 16h.
9. Pellet RNA by spinning for 10 min at 4*C in a microcentrifuge; a small
white pellet should be visible. Remove supernatant, and add 250pl cold
70% ethanol. Keep at -20*C for 10 min, then re-centrifuge for 5 min.
Remove ethanol, and dry pellet in a vacuum evaporator. The RNA may be
resuspended in lOpl sterile water and stored at -70*C.
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10. RNA content and purity is estimated by diluting in water and reading
optical density at 260nm and 280nm. At 260nm, one OD unit = 40pg/ml.
The 0D260/0D280 ratio should approach 2.0 if the RNA is uncontaminated
by protein or phenol.
A3.2.2 Agarose gel electrophoresis and Northern blotting
RNA species may be separated by electrophoresis through an agarose gel;
the percentage of agarose may be varied according to the size of RNA
species sought. For analysis of hGH mRNA, a 1.0% agarose gel was used.
The blotting procedure transfers RNA onto a nitrocellulose membrane where
they are fixed by baking before hybridization is performed as described in
section A3. 1. 2.
Solutions
0.25M phosphate buffer, pH 6.5 17.75g Na2HP0A
19.5g NaH2P0*
add distilled water to 1 litre
6M glyoxal Obtained as 6M solution, but should be
deionised by passage through a mixed bed
resin (Bio-Rad AG501-X8) until the pH is
neutral; store at -20*C in small
aliquots in tightly sealed tubes.
Loading buffer 50% glycerol
0. 01M phosphate buffer
0. 4% bromophenol blue
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Method
1. For each RNA sample, mix: 6M glyoxal 2. 7|il
DMSO 8. Opl
0. 1M phosphate 1. 6pl
RNA up to 20pg 3.7pl make up with
water.
2. Incubate RNA at 50*C for 60 min In tightly capped tube. For standards,
use an RNA marker ladder, or a total cellular RNA sample for ethidium
bromide staining to locate position of 28S and 18S ribosomal RNA. These
should be glyoxalated with the RNA samples.
3. Meanwhile pour agarose gel:
For a 1% gel add 2.0g agarose to 200ml 0. 01M phosphate buffer. Boil to
dissolve agarose, then cool to approximately 50*C before pouring.
Position comb before pouring the gel, and leave the comb in place until
the gel is quite cold. Add 0. 01M phosphate buffer to the
electrophoresis tank to submerge gel.
4. Cool RNA samples and standards to room temperature, and add 4pl sterile
loading buffer. Load samples and standards into wells immediately.
5. Run gel at 3-4 volts/cm for 4-5h. Recirculate buffer to maintain pH at
a constant level using a peristaltic pump, once the marker dye has
penetrated the gel.
6. Cut off standard track and stain with lpg/ml ethidium bromide. Keep
rest of the gel for Northern transfer.
7. Cut wicks of Whatman 3mm paper, and wet in 25mM phosphate buffer before
putting in tank. Cut nitrocellulose membrane to the same size as the
gel, and place over the wicks avoiding air bubbles. Place 5-8 sheets of
Whatman paper on the gel and then place blotting pads with a heavy
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weight on top. Leave overnight to allow RNA transfer onto the
nitrocellulose.
8. After transfer wash membrane in 25mM phosphate buffer, air dry, and
finally bake at 80*C for 2h. Finally, prehybridize, hybridize and wash
the membrane as described in section A3. 1.2.
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APPENDIX 4
PROLACTIN AND GROWTH HORMONE RADIOIMMUNOASSAYS
A4. 1 PROLACTIN RADIOIMMUNOASSAY
Prolactin secretion by cultured rat pituitary cells was assessed by
double antibody radioimmunoasay, using reagents provided by the US National
Hormone and Pituitary Program, NIADDK, Bethesda, Maryland, USA.
A4.1.1 Buffers and materials
Buffers
0.5M phosphate buffer: 0. 5M NaH2P0*, 0. 5M Na2HP0* in dH20,
pH 7. 4
0. 01M PBS: 0. 01M NaH2PO*, 0. 01M Na2HPO*, 0. 15M NaCl
in dH20, pH 7. 4
Assay buffer: PBS
+ 0. IX (w/v) EDTA
+ 0. \X (v/v) normal rabbit serum
+ 2% (w/v) BSA
Reagents
rPRL standards were prepared from rPRL-RP3 (NIADDK, reference
preparation 3) which was diluted in PBS + IX BSA, and stock solution stored
in aliquots of lOpg/lOOpl for up to 6 months. Standards (0. 78-100ng/ml)
were prepared by dilution in culture medium (DMEM + 0. 3X BSA) at the time
of assay.
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rPRL antiserum (rabbit: NIADDK-anti-rPRL-S-9) was stored in assay
buffer, and diluted to a final concentration of 1/4000 for addition to
assay tubes (tube concentration 1/12000).
Prolactin for iodination (NIADDK rPRL-I-5) was stored in 0.01M NaHC03 in
aliquots of 2. 5pg/25pl in siliconized glass Durham tubes for up to 6
months. A 15 x 1cm Sephadex G75 column was prepared and primed with PBS +
IX BSA. Reagents were added as follows:
rPRL-I-5 (2. 5pg) 25pl
0. 05M phosphate buffer 25pl
Na,2*I (lmCi) lOpl
Chloramine T (2.5mg/ml) 10pl
These reagents were gently mixed for 40s, and the reaction terminated by
adding 25pl sodium metabisulphite (2mg/ml in 0. 05M phosphate buffer).
Reaction products were separated on the Sephadex column and fractions
counted to assess incorporation (mean approximately 60%) and specific
activity (mean approximately 250pCi/pg). Iodinated rPRL was diluted in
assay buffer to provide 10000-15000 cpm/lOOpl for use in assays.
Sheep ant-rabbit IgG second antibody (Z-930, BDS Biologicals, Birmingham
University) was diluted in PBS to 1/80 (tube dilution 1/320).
A4.1.2 Assay procedure
The assay was performed at room temperature as follows:
Day 1. rPRL standard or sample lOOpl
Antiserum lOOpl
'"I-rPRL lOOpl
Day 2. Second antibody lOOpl
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Day 3. Tubes centrifuged at 1720# at 4*C for 45min. Supernatant
discarded and precipitate counted for bound radioactivity.
Non-specific binding (%NSB/total counts) and zero standard binding
(%Bo/total counts) were calculated, and a standard curve was constructed,
using a programmable calculator with a program developed by Rodbard &
Lewald (1970). Assay sensitivity was approximately lng/ml, and intra- and
inter-assay coefficients of variation at 9ng/ml were 6% and 10%.
A4.2 GROWTH HORMONE RADIOIMMUNOASSAY
Rat growth hormone (GH) was assayed using a fractional precipitation
radioimmunoassay with reagents supplied by the US National Hormone and
Pituitary Program, as for rPRL.
A4.2.1 Buffers and reagents
Buffers were used as described for the rPRL assay, with the exception of
the assay buffer, which consisted of 0. 01M PBS + 1% BSA.
rGH standards were prepared from rGH-RP2 CNIADDK reference preparation
2), stored in 25pl aliquots of a stock solution of lOpg/ml in assay buffer.
Standards <0. 78-100ng/ml) were diluted in assay buffer as required.
rGH antiserum (monkey: NIADDK-anti-rGH-S-4) was diluted in assay buffer
to 1/3000 for addition to assay tubes (tube dilution 1/30000).
rGH label (NIADDK-rGH-I-5) was iodinated using the chloramine T method
as described for rPRL. Aliquots of rGH for iodination were stored at
5pg/10pl concentrations, otherwise as for rPRL. The iodination reaction
was performed exactly as described for rPRL except that volumes of rGH and




The assay was performed at room temperature, as follows:




Day 2. Y~gl°bulin in PBS lOOpl
25% polyethylene glycol in PBS 1ml
Tubes were mixed and incubated for 2h before centrifuging at
1720^ at 4*C for 45min. Supernatant was discarded and the
precipitate counted for bound radioactivity.
Assay data and rGH concentrations were calculated as described for the
rPRL assay. Assay sensitivity was approximately Ing/ml, and intra- and




A5.1 PROTEIN ASSAY: LOWRY TECHNIQUE
The transient transfection assay (Chapter 5) requires measurement of
chloramphenicol acetyl transferase activity in cell lysates, and for these
assays, the quantity of lysate used was controlled according to the protein
content. The protein assay described by Lowry et al (1951) was used for
this purpose.
A5. 1. 1 Materials
Bovine serum albumin standards were prepared at l-100pg/pl in distilled
water. Two dilutions were prepared of each sample.
Alkaline copper reagent was prepared freshly before the assay by adding
reagents as follows:
2% anhydrous Na2C03 in 0. 1M NaOH 50ml
1% sodium tartrate with 0.5% CuSO* 1ml
Reagents were mixed together immediately.
A5.1.2 Assay procedure
Reagents were added as follows:
Standard or sample 1ml -
Alkaline copper reagent 2ml
Tubes were mixed and left to stand for lOmin.
Folln's reagent lOOpl
Tubes were mixed and left to stand for at least 30min.
The optical density (750nm) of the samples was measured, and protein
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Prolactin and growth hormone
JULIAN R. E. DAVIS
ALEXANDRA BELAYEW
MICHAEL C. SHEPPARD
Abnormalities of the secretion of prolactin (PRL) or growth hormone (GH)
are important and relatively common problems in clinical endocrinology
and have prompted much clinical and basic research. In the past 10 years
knowledge of the control of the expression of these genes has grown enor¬
mously and the fruits of this new understanding are just beginning to be
applied more directly to the study of human disease. The production of
recombinant human growth hormone in bacteria has had a direct impact on
patient management but major advances have recently been made in the
understanding of basic cellular control mechanisms in normal and neoplastic
pituitary tissue and these will almost certainly influence therapeutic strat¬
egies in the future.
This chapter will present a brief description of the PRL-GH gene family,
followed by a review of our present understanding of tissue specificity and
hormonal regulation in the control of gene transcription. Finally, the prin¬
ciples of the application of such studies to human disease will be illustrated
by some recent examples.
THE PROLACTIN AND GROWTH HORMONE GENE FAMILY
Gene structure and relationships
The genes coding for PRL and GH are related and form part of a family
which also comprises chorionic somatomammotrophin (CS, or placental
lactogen, PL; reviewed in Miller and Eberhardt, 1983).* In the rat there is a
single GH gene (Barta et al, 1981), a single rPRL gene (Cooke and Baxter,
1982) and several rCS/PL genes (Duckworth et al, 1986). In man, while the
single human (h)PRL gene (Cooke et al, 1981; Truong et al, 1984) is located
on chromosome 6 (Owerbach et al, 1981), there is a cluster of related hGH
and hCS genes (Martial et al, 1979; Seeburg, 1982) grouped together on
* They all have five exons and the GH/CS genes differ mainly in the size of the four introns from
the more distantly related PRL genes. However, the trout GH gene comprises a fifth intron
interrupting the fifth exon described in all mammals (Agellon et al, 1988).
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Figure 1. (a) Arrangement of human GH/CS gene cluster, with scales shown in kilobases (kb),
Eco RI restriction sites marked by open circles. Possible alternative splicing of hGH-N and
hGH-V genes is shown, with generation of mRNAs of differing sizes. E denotes exons (shown
as black boxes) and I denotes introns; A„ denotes the polyadenylation signal, (b) Structure of
human PRL gene with scale in kb and exons indicated as black boxes.
chromosome 17 (Owerbach et al, 1980; George et al, 1981; Kidd and
Saunders, 1982; Hirt et al, 1987), as shown in Figure 1. The single hGH-N
gene is expressed primarily in the pituitary and will be considered in more
detail in this review. Alternative splicings of the hGH-N nuclear pre-mRNA
(or hGH-N gene primary transcript) (DeNoto et al, 1981) have been shown
to generate multiple mRNAs in the pituitary gland, one ofwhich leads to the
production of 20kDa variant protein (Lewis et al, 1978) which constitutes
5-10% of pituitary GH, and another would code for a novel 17.5 kDa
protein (Lecomte et al, 1987). The variant GH gene, hGH-V, was shown to
be functional when linked to a viral promoter and transfected into monkey
kidney cells in vitro (Pavlakis et al, 1981); however, the endogenous human
mRNA was only recently found in placental tissue and in very small amounts
in a pituitary adenoma (Frankenne et al, 1987). The structure of hGH-V
mRNA has recently been determined from a human placental cDNA library
and two different mRNAs appear to be generated by alternative splicing of
the pre-mRNA, giving rise to two distinct proteins (Cooke et al, 1988). The
hCS-L gene is thought to be non-functional, but hCS-A and hCS-B are
expressed in syncytiotrophoblast tissue (McWilliams and Boime, 1980),
where they lead to the production of hCS with identical amino acid
sequences (Barrera-Saldana et al, 1983).
Among the human genes there is considerable sequence homology, up to
92% between the hGH and hCS genes (Cooke et al, 1980,1981; Barsh et al,
1983), and 42% between the hPRL and hGH coding sequences (Martial et
al, 1979; Seeburg, 1982; Truong et al, 1984). Indeed, between species there
is significant homology of coding sequences, 73% between human and rat
PRL and 75% between human and rat GH (Cooke et al, 1981). It has been
calculated from data on the conservation of coding sequences and splicing
sites that the PRL and GH genes derived from a single primordial gene and
began to diverge about 400 million years ago, the period when fish and
quadrupeds started to diverge (Niall et al, 1971; Cooke et al, 1981; Cooke
and Baxter, 1982). Interestingly, the proximal regulatory 5'-flanking DNA
sequences are also highly conserved between the rat, bovine and human
PRL genes (Cooke and Baxter, 1982; Camper et al, 1984; Truong et al,
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1984), particularly in regions thought to be important for tissue-specific gene
expression.
Further members of the PRL gene family have recently been described in
other tissues. Distinct from the placental lactogen genes, 'proliferin' has
been identified from a library of DNA fragments complementary to mouse
mRNA sequences (cDNA library), and appears to be linked to cellular
proliferation (Linzer and Nathans, 1984; Linzer et al, 1985; Lee and
Nathans, 1987); a placental 'proliferin-related protein' cDNA and a third
prolactin-like protein and gene have also been described (Linzer and
Nathans, 1985; Colosi et al, 1988; Duckworth et al, 1988). These genes map
to chromosome 13 in the mouse, along with PRL itself (Jackson-Grusby et
al, 1988) and show some degree of sequence homology with PRL, but their
tissue specificity differs. PRL itself is synthesized at low levels in non-
pituitary tissue: its production is hormonally regulated in human decidual
tissue (Handwerger et al, 1987; Golander et al, 1988), and PRL mRNA has
been detected in human decidual cells by hybridization analysis (Clements
et al, 1983; Taii et al, 1984). The human decidual PRL cDNA has been
cloned and the sequence found to be almost identical to that of the pituitary
cDNA, confirming that there is only a single copy of the hPRL gene per
haploid genome (Takahashi et al, 1984). Finally, prolactin mRNA and
protein production occurs at low levels in human IM-9 lymphocytic cells,
but whether this may imply some latent biological function remains to be
seen, as normal human lymphocytes have no detectable prolactin mRNA
(DiMattia et al, 1988).
Ontogeny
Despite the close structural similarities between their genes, PRL and GH
exhibit quite distinct developmental patterns and tissue-specific expression.
PRL and GH are produced in separate cell types within the pituitary gland,
lactotrophs and somatotrophs, and immunocytochemical studies suggest
that they are expressed in the pituitary only late in fetal development (Gash
et al, 1982). However, rat PRL and GH may be co-expressed in the same
cell, and such somatomammotrophs may predominate in the late fetal
pituitary, according to an immunocytochemical study (Hoeffler et al, 1985).
In the rat, comparison of immunocytochemical studies with in situ hybrid¬
ization using the rat PRL cDNA as a probe have recently shown that PRL
mRNA accumulates well before PRL can be detected by immunostaining;
as PRL is secreted in fetal rats, this indicates that it is synthesized but not
stored in the fetal pituitary, possibly reflecting lack of fetal hypothalamic
dopamine production (Hooghe-Peters et al, 1988).
Co-production of PRL and GH has been shown in adult pituitary tissue,
both by immunocytochemical studies and also by reverse haemolytic plaque
assays (Frawley et al, 1985; Nikitovich-Winer et al, 1987). The potential for
co-expression of the PRL and GH genes in a single cell type has suggested
that tissue-specific expression of these genes may be at least partly con¬
trolled by a single common factor (Nelson et al, 1988), and experimental
support for this hypothesis will be discussed in detail below.
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Prolactin and GH receptors
In 1987 the amino acid sequences of the rabbit and human GH receptors
were deduced from their cDNAs but no homology of the GH receptor was
found with any other reported protein (Leung et al, 1987). Subsequently the
rat liver PRL receptor has also been cloned (Boutin et al, 1988); this again
does not resemble other known proteins but it does possess striking similari¬
ties to the GH receptor. Both receptors have large extracellular (hormone-
binding) regions, a single transmembrane segment and a large cytoplasmic
domain. Overall, there is 30% amino acid sequence homology but there are
localized regions of sequence identity between the two proteins. The linear
arrangement of these strongly homologous segments is conserved, suggest¬
ing functional importance (Boutin et al, 1988). The strong similarities
between the receptors for PRL and GH recall the similarities of the
hormones themselves, and suggest the possibility of a similar family of
receptor genes perhaps diverging from a single ancestral gene at a similar
time to PRL and GH themselves.
TRANSCRIPTIONAL REGULATION
The regulation of gene transcription is currently considered to be exerted by
the specific interaction of regulatory proteins (trans factors) with given DNA
sequences (cis elements). Different types of cisltrans coupling are thought to
allow both tissue-specific expression and also hormonal induction or inhi¬
bition of gene transcription. The cis regulatory sequences can be located
within promoter regions, or may be part of an 'enhancer1 that can regulate
transcription at any distance inside or outside the gene, upstream or
downstream from its promoter. Changes in the three-dimensional structure
of DNA allows the DNA-bound trans factors to interact with the transcrip¬
tion initiation complex (as shown schematically in Figure 2; for reviews see
Dynan and Tjian, 1985; Ptashne, 1986, 1988; Maniatis et al, 1987). Several
trans factors have been identified (some of which correspond to cellular
proto-oncogenes), including steroid and thyroid hormone receptors (see
Evans, 1988, for review) and activator proteins such as AP-1 and AP-2
which are thought to mediate the effects of intracellular messenger systems
(Imagawa et al, 1987; Lee et al, 1987).
The regulation of PRL and GH gene transcription involves two aspects:
tissue-specific expression and hormonal regulation. Although these will be
considered separately, the final level of transcriptional activity presumably
reflects integration of both systems, and indeed it seems likely that their
mechanisms overlap to a great extent. A general approach to understanding
these mechanisms should involve (1) the identification of cis elements in a
given gene; (2) precise definition of cis/trans interactions; that is, demon¬
stration of protein-DNA binding and identification of trans-acting factors
involved; and (3) purification and cloning of trans-acting factors, and assess¬
ment of their regulation. Such an approach has been used with great success
in the case of the PRL and GH genes, for example with the definition of






Figure 2. Possible interaction of cis and trans elements, (a) Cis elements in the gene are
indicated in black, and trans-acting factors as hatched boxes. The transcription initiation site is
shown by the right-angled arrow, (b) Hypothetical transcription initiation complex. Interaction
of bound trans factors with RNA polymerase II by looping of DNA; protein-protein inter¬
actions are suggested by links between the trans factors.
steroid and thyroid hormone receptor structure and DNA binding charac¬
teristics, and also the identification of the pituitary tissue-specific factor
Pit-l/GHF-1; these will be considered in detail below.
TISSUE-SPECIFIC EXPRESSION
The PRL and GH genes are present in all cells but are expressed only in
pituitary or placental tissue; indeed, the respective levels of mRNA for
hGH-N and hCS may differ by as much as 10 000-fold despite considerable
sequence homology, raising the intriguing question of the possible mechan¬
isms which confer this tissue specificity of gene expression. In the case of
both PRL and GH it is noteworthy that segments of the 5 '-flanking sequence
are markedly conserved between species, suggesting their importance in
gene regulation. The PRL and GH genes have normally been considered
separately, and they will be discussed separately here, before a picture of
our current understanding is summarized. However, the mechanisms
responsible for conferring tissue specificity for PRL and GH gene expression
may, in fact, be at least partly shared, and a pituitary-specific trans-acting
factor(s) has recently been identified which appears to regulate tissue-
specific expression of the PRL and GH genes and possibly also the TSH-p
subunit gene (Nelson et al, 1988); this factor, Pit—1 or GHF-1, has subse¬
quently been cloned and identified by two independent groups (Bodner et
al, 1988; Ingraham et al, 1988). Whether this factor in fact regulates both
PRL and GH has been disputed (Castrillo et al, 1989) but evidence that
some similar tissue-specific targeting mechanism operates in vivo is provided
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by the finding that upstream elements of the GH gene can direct expression
of the gene in transgenic mice to lactotrophs and thyrotrophs as well as to
somatotrophs (Lira et al, 1988).
Prolactin
Cis elements
The technique of transfection analysis has been used to study the role of the
5'-flanking DNA sequences of the rat PRL gene. This technique involves the
construction of fusion genes which contain putative regulatory elements
linked to reporter genes, such as bacterial chloramphenicol acetyl trans¬
ferase (CAT); the expression of such a reporter gene's product can be
readily measured in mammalian cell extracts to indicate the level of pro¬
moter activity. By transfecting rat pituitary GH3 cells with a series of PRL
5'-flanking DNA-CAT constructs and monitoring the transient expression
level ofCAT, Nelson et al (1986) identified two regulatory sequences whose
deletion led to a drop in CAT gene transcription. A distal element located
between —1831 and —1530 base pairs (bp) upstream of the transcription
initiation site (or 'cap site') accounted for 98-99% of basal tissue-specific
expression, and a proximal element (— 422 to — 36 bp) accounted for 1-2%
of activity. Both cis elements acted as enhancers; that is, they conferred
cell-type specific expression to a 'neutral' viral promoter sequence indepen¬
dent of their position or orientation. Similar transfection studies have
demonstrated that 250 bp of the bovine PRL 5'-flanking sequence confer
tissue-specific gene expression (Camper et al, 1985).
The functional importance of the proximal region of the PRL 5'-flanking
DNA has further been indicated by in vitro transcription experiments using
nuclear protein extracts to reconstitute transcription from a gene promoter
element in a cell-free system. In vitro transcription experiments in GH3 rat
pituitary tumour cell extracts suggested that only the proximal regulatory
elements were necessary for tissue-specific expression of the rPRL gene:
accurate initiation of transcription could be found using 420 bp of 5'-
flanking rat PRLDNA, and whereas nuclear proteins from various cell types
could direct transcription from viral gene promoters, only pituitary extracts
could do so using the PRL promoter template DNA (Cao et al, 1987;
Gutierrez-Hartmann et al, 1987; Cao et al, 1988). A pituitary-specific tran¬
scription factor binding to an upstream promoter element appears to
selectively promote transcription initiation at the + 1 site in preference to
initiation at a second site at — 27 bp upstream which may occur with non-
pituitary extracts (Barron et al, 1989).
Cis/trans interactions
The first demonstration of nuclear proteins binding to 5'-flanking segments
of the rPRL gene suggested that they could bind to two long stretches of
DNA extending as far as -4800 bp upstream of the cap site (White et al,
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more precisely the nucleotide sequences which bind trans-acting tissue-
specific proteins. They both rely on the fact that protein binding protects
DNA from non-sequence-specific nuclease digestion, either cutting from
the ends with exonuclease III, or cutting within fragments with deoxy-
ribonuclease (DNase I).
Proximal protein binding sites. Different studies and different techniques
have yielded slightly differing results but up to four protein binding sites
have been identified within the first 210 bp 5' to the cap site, as shown in
Figure 3 (Elsholtz et al, 1986; Cao et al, 1987; Gutierrez-Hartmann et al,
1987; Nelson et al, 1988; Schuster et al, 1988). At least three of these
proximal sites are pituitary specific, as the protein binding is seen only with
pituitary cell extracts and not with proteins from other tissues.
Of the four sites, the most proximal, between positions — 30 and — 78, has
also been found to behave as an enhancer element which confers the
transcriptional response to epidermal growth factor (EGF) and phorbol
ester (Elsholtz et al, 1986). Using 'gel retardation' assays it has been found
that the electrophoretic mobility of this DNA element is reduced by protein
binding, specifically with extracts from pituitary cells but not from other cell
types (Elsholtz et al, 1986; Schuster et al, 1988), again providing indepen¬
dent evidence for tissue-specific nuclear protein interactions with this
region. The second site appears in some studies not to be tissue-specific
(Gutierrez-Hartmann, et al, 1987). However, the fourth of these four
proximal sites corresponds closely to a sequence identified by Lufkin and
Bancroft (1987) which is able to direct gene transcription in hybrid pituitary-
fibroblast fusion cells but not in fibroblast cells alone; these data provide
direct evidence for the presence in pituitary cells of a diffusible protein
factor that can increase transcriptional rate, but also show that the protein
binding to this sequence is necessary for gene expression.
Distal binding sites. Using DNase I footprinting, Nelson et al (1988) found
that, in addition to the four proximal protein binding sites described above,
there are four distal sites between positions —1579 and —1718 in the rat
PRL gene. None of the total of eight sites were found with non-pituitary
protein preparations but, interestingly, the sites mutually competed for
protein binding, suggesting that all eight bound a single protein factor; in
addition, protein binding was effectively reduced by competition with the
tissue-specific enhancer sequences of the rat GH gene. Kim et al (1988)
demonstrated only one of these four sites which was distinct from the
oestrogen response element (ERE), and showed that mutations in this site
abolished nuclear protein binding and reduced the transcriptional enhancer
activity of the overall distal region several-fold.
The data of Nelson et al (1988) suggested the existence of a single
pituitary-specific factor named Pit—1, which binds to the enhancer regions of
both the PRL and GH genes. This factor may be the same as the GH-specific
factor GHF-1 described by Lefevre et al (1987); the cDNA coding for
Pit-l/GHF-1 has now been cloned independently by the two groups
(Bodner et al, 1988; Ingraham et al, 1988), though it has been disputed
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whether this protein in fact binds to the PRL promoter (Castrillo et al,
1989).
Human prolactin gene
The tissue-specific regulation of the human prolactin gene has only been
much more recently studied but the organization of at least the proximal
element of the 5'-flanking region appears similar. In vitro transcription
studies have shown that 740 bp of hPRL promoter DNA can direct tissue-
specific expression of the CAT reporter gene with pituitary cell but not
HeLa cell extracts. DNase I footprinting studies have indicated pituitary-
specific trans factor binding to three sites, corresponding to the highly
homologous sites 1, 3 and 4 in the rat gene, except that 'site 4' is slightly
further upstream (Lemaigre et al, 1989a); (Figure 3).
Growth hormone
Cis elements
Transfection studies using rat GH promoter-CAT fusion genes have shown
that as little as 235 bp of rat GH 5'-flanking sequence are able to confer
cell-type specificity (Nelson et al, 1986). The degree of expression fell
dramatically with deletion ofmore than 181 bp 5' to the cap site, suggesting
the presence of a tissue-specific enhancer element between -181 and
— 235 bp; however, neither elements extending from —235 to —146, nor
from — 181 to the cap site, were fully effective, suggesting that the putative
enhancer element was relatively extensive. Independent transfection
studies using much longer stretches of rat GH promoter and 5'-flanking
sequences (1800 bp) confirmed that CAT expression was restricted to pitui¬
tary cells, but this restriction of specificity was lost when 5' sequences were
deleted down to the —309 or —183 positions (Larsen et al, 1986a). This
suggested the presence of upstream repressor elements which normally
prevented gene activation in non-pituitary cell types. Although these data
conflict with those of Nelson et al (1986) in suggesting that tissue specificity is
not conferred solely by 235 bp of 5'-flanking sequences, further data from
Larsen et al (1986b) showed that sequences between - 183 and - 202 were
able to confer thyroid hormone responsiveness, but only in pituitary-derived
cell lines. Thus, there is evidence for overlap between these two aspects of
gene regulation: a thyroid hormone response element (discussed in more
detail below and elsewhere) may respond in a tissue-specific manner; or,
conversely, hormone responses may be mediated by interaction with tissue-
specific trans factor binding, and a larger enhancer region consisting of a
thyroid hormone response element may be functionally linked with tissue-
specific elements (Ye et al, 1988).
Cis/trans interactions
Gel retardation analysis has been used to demonstrate tissue-specific protein
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Nuclear protein extracts from pituitary GC or GH4C1 cells selectively
retarded the electrophoretic migration of — 104/+ 7 and — 236/- 146 restric¬
tion fragments, whereas nuclear proteins from rat hepatoma or fibroblastic
cells failed to do so.
More precise localization of protein-binding sites within rat GH 5'-
flanking DNA has been undertaken with DNase I footprinting studies. As
for the studies on the rPRL gene, the exact details vary slightly between
different reports, but two consensus footprints may be deduced between
positions —98 and -62 ('GC1'), and - 140 and - 106 ('GC2'), as summar¬
ized in Figure 4 (Catanzaro et al, 1987; Glass et al, 1987; de Groot et al,
1988; West et al, 1987; Ye et al, 1988). Other footprints have been shown
further upstream (Glass et al, 1987; de Groot et al, 1988); a site at —220/
— 241, termed 'GC3' has recently been shown to be pituitary specific but
binds a different protein factor from the GC1 and GC2 sites (Guerin and
Moore, 1988). The spatial relationship between the two proximal elements
is important, and Ye et al (1988) showed that proteins must bind on the same
side of the DNA helix to preserve full efficacy of this region, suggesting that
contact between two DNA bound proteins.
Human GH gene
Transfection studies of the human GH gene showed that 500 bp of 5'-
flanking DNA allowed expression of a reporter gene in rat GC or GH3 cells
but not in the non-pituitary Rat-1, HeLa or placental JEG-4 cell lines
(Lefevre et al, 1987), suggesting the presence of a cell-type specific enhancer
element within this region. Likewise Cattini et al (1986a), using deletion
analysis, found that an element between —230 and — 180 was necessary for
pituitary-specific expression.
Using DNase I footprinting, Lefevre et al (1987) found three hGH sites
binding proteins from rat GC cell extracts at - 66/ - 93 (site 1), - 106/ - 140
(site 2) and —254/—290 (site 3); of these three sites, part of site 2 and all of
the distal site 3 were also protected by HeLa cell extracts. Thus, two
pituitary-specific protein binding sites were identified (sites 1 and 2a)
(Figure 4), and they mutually competed for binding of a single protein factor
which was named GHF-1. Mutations within either site abolished GHF-1
binding. In fact both GHF-1 sites contain regions very highly homologous to
the GC1 and GC2 sites described for the rGH gene promoter (Catanzaro et
al, 1987; West et al, 1987) and have similar locations. GHF-1 is not the only
protein involved, however, and Imagawa et al (1987) have demonstrated
footprints from binding of purified activator protein-2 (AP-2) to two further
sites in the hGH gene 5'-flanking region: AP-2 is a trans acting factor which
is involved in intracellular messenger signalling; it is not a tissue-specific
factor, and, indeed, the more distal site in fact coincides with the non-tissue-
specific site 3 found by Lefevre et al (1987), as shown in Figure 4. Moreover,
Lemaigre et al (1989b) showed by footprinting in the presence of competing
oligonucleotides that the non-pituitary-specific factor SP1 binds to part of
site 2, and upstream stimulatory factor (USF) binds to the proximal part of
site 3 (the distal part binding AP-2).
PROLACTIN AND GROWTH HORMONE 809
The functional importance of these protein-binding regions in maintain¬
ing hGH gene transcription has been demonstrated by in vitro transcription
experiments. Bodner and Karin (1987) found that 289 bp of hGH 5'-
flanking DNA were able to support transcription with pituitary GC cell
nuclear protein extracts efficiently. HeLa cell extracts alone were much less
efficient in supporting transcription from the hGH promoter template but
complementation with pituitary extracts increased transcriptional activity.
Mutations in each of the two GHF-1 binding sites caused a severe reduction
in transcriptional activity of the template.
Summary
For both the PRL and GH genes, in both man and rat, there is evidence for
the existence of DNA sequences which are responsible for tissue-specific
gene expression. Binding of nuclear proteins to these regions has been
demonstrated, and appears to be responsible for establishing basal levels of
gene transcription. Two sites within the rat and human GH promoter DNA
are homologous and appear to bind the same protein factor (GHF-1, or
GC1/GC2); eight sites upstream of the rPRL gene, and at least three sites for
the hPRL gene, also appear to bind a single trans-acting factor (Pit—1) and
sequences of the GH gene compete for this protein binding.
Thus it appears that a single protein in both rat and human (Pit-l/GHF-1)
may be responsible for directing expression of both genes (Figure 5) and
may also bind to the promoter of the TSH-p gene (Nelson et al, 1988). The
cDNA encoding Pit-l/GHF-1 has recently been cloned (Bodner et al, 1988;
Ingraham et al, 1988). However the two reports disagree on the crucial point
as towhether Pit-l/GHF-1 protein can bind to the rPRL gene. Castrillo et al
(1989) have recently purified GHF-1 from GC pituitary cells and identified
it as a 33kD polypeptide. This material bound to two sites on rGH 5'-
flanking DNA, but not to rPRL sequences, whereas a separate extracted
protein bound to five sites (including the four previously recognized sites) on
the rPRL proximal upstream enhancer element. Expression of the gene for
Pit-l/GHF-1 at high levels in transiently transfected heterologous HeLa
cells selectively activates expression of fusion genes containing either the
rPRL or the rGH promoter sequences (Ingraham et al, 1988), but it still
remains to be clearly established whether expression of the rPRL gene in
vivo can be directed by Pit-l/GHF-1 or requires a separate yet uncharacter-
ized trans-acting factor.
Pit-l/GHF-1 contains a DNA-binding region closely similar to the
homeodomain first described in a class of proteins involved in embryonic
development in Drosophila. However, unlike many other transcriptional
regulators, Pit-l/GHF-1 is expressed exclusively in the pituitary gland, in
lactotrophs and somatotrophs and also a subset of thyrotrophs. The reasons
for the restriction of Pit-l/GHF-1 expression to the pituitary have yet to be
clarified; however GH gene expression is extinguished when pituitary cells
are fused with heterologous somatic L-cells, and this process is accompanied
by loss of GHF-1 mRNA accumulation and protein production
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involved in the tissue-specific expression of Pit-l/GHF-1 itself.
The most direct demonstration that ds-active elements binding Pit—1/
GHF-1 are indeed important in vivo in directing tissue-specific expression
has come recently from experiments using transgenic mice. Lira et al (1988)
showed that upstream sequences of the rat GH gene were able to direct
expression of a linked human GH structural gene predominantly in pituitary
somatotrophic cells, but also in lactotrophs and thyrotrophs, while not in
gonadotrophs or corticotrophs. Thus a working hypothesis suggests that a
single trans-acting factor directs cell-type-specific expression of these genes
to three cell types within the pituitary. The final level of gene expression
within a single cell type presumably reflects the integration of a variety of
other signals such as thyroid hormone, glucocorticoids, sex steroids and
peptide hormones. The proximity of Pit-l/GHF-1 sites to hormonally
responsive regions in both genes is noteworthy, and it may be that some
hormonal signals exert their effect by modifying the binding of tissue-
specific factors, or by covalent modification of trans factors that are already
bound to DNA sequences, increasing or decreasing their ability to interact
with the RNA polymerase II transcription initiation complex.
HORMONAL AND INTRACELLULAR REGULATION
The cell-type-specific characteristics of PRL and GH gene regulation appear
to be very similar, and the mechanisms may indeed be partly mediated by a
common factor for both genes. However, within the pituitary their hor¬
monal regulation differs markedly. Indeed if cell-type-specific expression by
Pit-l/GHF-1 targets the GH gene to lactotrophs and thyrotrophs as well as
somatotrophs, additional restrictive or permissive cell-type specification
mechanisms must exist to explain the actual targeting of endogenous gene
expression to a single cell type. A large number of hormonal signals may act
upon given cell types, and in principle these might act either independently
or by modulating tissue-specific control mechanisms. Thus, hormonally
induced trans-acting factor activation may either have a direct effect on
'dedicated' hormone-responsive DNA sequences, or an indirect effect by
modulating tissue-specific protein (for example Pit-l/GHF-1) interactions
with DNA. The latter possibility has recently been proposed to explain the
action of the glucocorticoid receptor on the PRL gene (Adler et al, 1988).
Oestrogen and thyroid hormones exert their effects by binding to specific
nuclear receptors which have been shown to be DNA-binding proteins, and
much of our present understanding of receptor-DNA interactions derives
from exciting recentwork on nuclear receptor structure (reviewed by Evans,
1988, and elsewhere in this volume). But peptide hormones and dopamine,
which bind to membrane receptors, must act through intermediate intra¬
cellular signalling systems via 'second messengers' (Berridge, 1985; B. L.
Brown et al, 1985), and the ways in which these act to regulate gene
transcription is much less clear. For these substances, the relevant pathways
linking second messenger formation to trans-activating proteins have yet to
be characterized: do the various intracellular signals linked to given mem-
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brane receptors initiate a cascade which converges on to a final common
pathway in the nucleus, or is the variety of second messenger signals an
important channelling mechanism allowing integrated effects on a gene of a
wide variety of different trans-activation proteins?
Prolactin
Nuclear hormone receptors
PRL gene transcription is stimulated or inhibited by a variety of hormones
(Table 1); for some of these, hormone-responsive elements have been
identified in the 5'-flanking region of the rPRL gene, but no studies have yet
characterized the regulation of the hPRL gene.
Table 1. Summary of known effects of hormones and intracellular





Thyroid hormone — +
Glucocorticoid — +
Vitamin D +
Thyrotrophin-releasing hormone + -
Growth hormone releasing factor +
Dopamine -
Somatostatin ?—
Vasoactive intestinal peptide +
y-Aminobutyric acid -
Insulin + +/—
Insulin-like growth factor I -
Epidermal growth factor +
Intracellular signals
Cyclic AMP + +
Calcium + +
Phorbol ester +
rPRL, rat prolactin; rGH, rat growth hormone; hGH, human growth
hormone; +, stimulation; -. inhibition.
Oestrogen. Physiological effects of oestrogen on PRL mRNA accumulation
in vivo have been clearly shown by in situ hybridization (Steel et al, 1988). In
vitro, 17-fLoestradiol causes increased accumulation of PRL mRNA in rat
pituitary cells (Stone et al, 1977) and this effect is due to a rapid stimulation
of the rate of gene transcription (Maurer, 1982a; Shull and Gorski, 1984;
Waterman et al, 1988). The stimulatory effect of oestrogen is exerted by
direct binding of oestrogen receptor (ER) to DNA (Green and Chambon,
1986; Evans, 1988) and an oestrogen response element (ERE) in rat PRL
5'-flanking DNA has been located more than 1500 bp distant from the
transcription initiation site (Maurer, 1985; Maurer and Notides, 1987;
Waterman et al, 1988; Somasekhar and Gorski, 1988). It is interesting to
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note, however, that this ERE is close to a region of DNase I hypersensi¬
tivity, which may be important in the mechanism of transcriptional activa¬
tion (Durrin and Gorski, 1984; Durrin et al, 1984); but the ERE is also
immediately adjacent to one of the four distal Pit—1 binding sites described
by Nelson et al (1988), suggesting possible interactions between oestrogen
receptor and a separate tissue specific protein (see also Kim et al, 1988).
Glucocorticoids. Dexamethasone inhibits bovine PRL gene transcription
by an action exerted within the first 250 bp of 5'-flanking DNA (Camper et
al, 1985). More recently it has been shown that dexamethasone has a similar
effect on proximal promoter elements of the rPRL gene (Adler et al, 1988;
Somasekharand Gorski, 1988). However, interestingly, it was found that an
inhibitory effect of oestrogen on the proximal region of the rPRL promoter
could be expressed in specially manipulated circumstances (by inducing
over-expression of the ER); it was then shown that the inhibitory effect of
the glucocorticoid receptor (GR) and the over-expressed ER was not
exerted by their DNA-binding domain (Adler et al, 1988). Thus, the stimu¬
latory and inhibitory effects of these receptors were exerted by different
parts of the molecule, and the negative effects did not involve direct protein-
DNA interaction but most probably indirect effects on other DNA-binding
proteins. Various protein-protein interactions have recently been proposed
for glucocorticoid receptor action on other genes. Glucocorticoid response
elements are frequently clustered with other trans factor binding sites
(Schiile et al, 1988) and their spatial arrangement is critical for hormonal
regulation. Indeed in the pituitary glycoprotein a subunit gene, Akerblom
et al (1988) found overlap between the cAMP responsive region of the gene
promoter and the GR binding element, and suggested that negative regu¬
lation could result from interference of a hormone receptor-DNA complex
with other positive frans-activating proteins.
Thyroid hormone and vitamin D. Two other nuclear receptors, binding T3
and vitamin D respectively, are closely related (Evans, 1988) and seem
likely to exert effects on the PRL gene but, in contrast to the rapid advances
in knowledge of GH gene regulation by T3, much less is known about their
mechanism of action on the PRL gene. It has been shown that T3 causes
inhibition of mRNA accumulation in rat pituitary cells (Maurer, 1982b;
Stanley and Samuels, 1984), and that the weak thyroid hormone agonist
drug phenytoin has similar effects (Davis et al, 1986). Vitamin D has been
shown to stimulate cytoplasmic accumulation of PRL mRNA (Wark and
Tashjian, 1983) and this stimulation is antagonized by glucocorticoids
(Wark and Gurtler, 1986). Transient transfection of GH4 cells with plasmid
expression vectors containing the c-erb-A a and (3 genes (encoding T3
receptors) have shown T3-inducible inhibition of expression of a co-
transfected PRL promoter-reporter gene construct, providing the first evi¬
dence that c-erb-A proto-oncogenes can directly affect the PRL (and also
GH) gene expression (Forman et al, 1988). It seems reasonable to speculate
that nuclear receptors for T3 and vitamin D may interact with DNA or other
trans factors in a manner similar to the ER and GR, and indeed it has been
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found that T3 receptor may bind to oestrogen response elements in a
transcriptionally inactive form, to decrease the overall level of gene tran¬
scription (Glass et al, 1988).
Peptide and dopamine regulation
Thyrotrophin-releasing hormone (TRH) stimulates rPRL gene tran¬
scription within minutes, and increases cytoplasmic mRNA accumulation
(Laverriere et al, 1983; Murdoch et al, 1983; White and Bancroft, 1983). In
addition, TRH increases the half-life of cytoplasmic mRNA from 17 to 27 h
(Laverriere et al, 1983). Similar stimulation is seen with EGF (White and
Bancroft, 1983; Murdoch et al, 1985b). Supowit et al (1984) showed by
transfection studies that 3000 bp of 5'-flanking DNA conferred EGF
responsiveness on to a reporter gene and an EGF-responsive element was
located within the first 78 bp by Elsholtz et al (1986). For the bovine PRL
gene also, Camper et al (1985) have shown that 250 bp were sufficient to
allow stimulation by TRH and EGF, implying that this region of DNA
contains the necessary sequences for recognition of the intracellular signals
generated by these two peptide hormones. Vasoactive intestinal peptide
(VIP) also elevates PRL mRNA levels in pituitary cells (Carrillo et al, 1985).
Dopamine inhibits PRL gene transcription, as does the dopaminergic drug
bromocriptine (Maurer, 1980, 1981, 1982c). Finally, y-aminobutyric acid
(GABA) has an inhibitory effect on PRL mRNA accumulation (Loeffler et
al, 1985), while insulin is stimulatory (Prager et al, 1988).
These various hormones are thought to act through different intracellular
mechanisms: TRH stimulates the hydrolysis of membrane phospholipids
resulting in protein kinase C activation and calcium mobilization, and
leading to phosphorylation of cytoplasmic and nuclear proteins (Drust and
Martin, 1982; Murdoch et al, 1982; Gershengorn, 1986); EGF activates a
transmembrane protein kinase (Stoschek and King, 1986); VIP activates
adenylate cyclase (Gourdji et al, 1979), which results in phosphorylation of a
different group of proteins than with TRH action (Drust et al, 1982;
Murdoch et al, 1983). Thus the rPRL gene is likely to be controlled by a
number of interacting intracellular messenger systems (Bancroft et al, 1985;
Murdoch et al, 1985a).
Intracellular messenger pathways
Cyclic AMP. Cyclic AMP has been shown to increase rPRL gene transcrip¬
tion (Maurer, 1981), and forskolin (which activates adenylate cyclase)
increases cytoplasmic mRNA accumulation (Murdoch et al, 1982b; Dave et
al, 1987). Two cyclic AMP responsive elements (CREs) (reviewed by
Roesler et al, 1988) have been defined: one of these CREs has been found in
various genes including the pituitary glycoprotein a-subunit (Delegeane et
al, 1987), VIP (Tsukada et al, 1987) and somatostatin (Montminy and
Bilezikjian, 1987). The corresponding trans factor is the protein CREB,
whose DNA binding and transcriptional efficacy are regulated by phos¬
phorylation (Yamamoto et al, 1988). A second system of cyclic AMP
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regulation involves AP-2, which has two binding sites in the hGH promoter
(Imagawa et al, 1987) and a potential binding site in the rPRL promoter.
Calcium. Two intracellular signals are known to mediate TRH action,
namely intracellular calcium and protein kinase C. Intracellular calcium
appears to be crucial for PRL gene expression: GH3 cells grown in low-
calcium medium respond to addition of calcium by a dramatic rise in both
PRL synthesis and mRNA accumulation (White et al, 1981), which occurs
within 10 h. On the other hand, removal of extracellular calcium by EGTA
rapidly reduces PRL mRNA to undetectable levels, whereas GH mRNA
levels show a smaller, slower fall (Gick and Bancroft, 1985). Calcium
ionophores and calcium channel agonists can stimulate PRL gene transcrip¬
tion rate (Hinkle et al, 1988; Laverriere et al, 1988), again suggesting an
effect of intracellular calcium concentration per se. A requirement for
calcium has further been demonstrated by studies using calcium channel
blocking agents such as verapamil or nifedipine, and calcium antagonists
such as cobalt (Murdoch et al, 1985b; Davis et al, 1988a; Hinkle et al, 1988).
Studies with calmodulin antagonist drugs have suggested that PRL mRNA
accumulation is calmodulin dependent (Bancroft et al, 1985; Murdoch et al,
1985b; White, 1985). The possible mechanisms for calcium/calmodulin
action in the induction of PRL gene transcription may involve the calcium/
calmodulin-dependent nuclear protein, DNA topoisomerase, which has
DNA-unknotting and relaxing activity in vitro (White and Preston, 1988).
DNA topoisomerase interacted with three sites within 3000 bases of PRL
5'-flanking DNA, and one of these sites was within the first 100 bp (White
and Preston, 1988). Further recent evidence from transfection studies has
suggested that a 'calcium regulatory element' may lie within the first 174
bases of the 5'-flanking DNA (Jackson and Bancroft, 1988).
Protein kinase C. PRL gene transcription is stimulated by activation of
protein kinase C with phorbol esters (Murdoch et al, 1985b). Studies of
rPRL gene 5'-flanking DNA have demonstrated an upstream phorbol ester
responsive element (Supowit et al, 1984). This in fact coincides exactly with
the EGF-responsive element, and lies between —78 and —35 bases
upstream from the transcription start site (Elsholtz et al, 1986). This region
of DNA is clearly of major interest as it forms part of a putative calcium-
regulatory element and a site of DNA topoisomerase action (Jackson and
Bancroft, 1988; White and Preston, 1988), but also represents the first
proximal binding site of the tissue-specific factor Pit-l/GHF-1 (Nelson et al,
1988). The mechanisms of protein kinase C action on gene transcription may
involve allosteric modifications of proteins already bound to DNA, as
nuclear proteins from phorbol ester-stimulated cells behaved no differently
in their DNA binding from those obtained from unstimulated cells (Elsholtz
et al, 1986).
In summary, responses to various intracellular messengers seem to
involve proximal 5'-flanking sequences in the rPRL gene, and the relevant
response elements may coincide with binding sites for a tissue-specific
protein factor. However the distal enhancer region may also be involved,
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and Day and Maurer (1989) have recently shown that a distal element
(— 1713/- 1495) conferred regulation by TRH, EGF and cyclic AMP onto a
reporter gene. This regulation was equally effective as that seen with the
proximal enhancer element, and a synergistic interaction was found
between these agents and oestradiol, suggesting co-operative interactions
between protein-binding czs-acting elements in transcriptional control.
Growth hormone
The number of probable hormonal regulators of the GH gene is rather
smaller than for PRL (Table 1). The best studied of these regulators is
thyroid hormone (reviewed by Samuels et al, 1988), which is well known to
be a major regulator of GH secretion in vivo, at least in the rat; the peptide
hormones, growth hormone releasing factor (GRF), somatostatin and
IGF-I have so far received much less attention.
Thyroid hormone
Rat GH gene transcription is induced by T3 by up to tenfold in vitro in the
pituitary GC cell line (Spindler et al, 1982; Nyborg et al, 1984; Yaffe and
Samuels, 1984). This induction coincides with T3 receptor occupancy and
alterations in chromatin structure (Nyborg and Spindler, 1986) and requires
the presence of yet uncharacterized short-lived proteins (Santos et al, 1987).
The c-erb-A proto-oncogene, which encodes the T3 nuclear receptor has
now been shown in co-transfection experiments to induce GH gene expres¬
sion (Forman et al, 1988).
The cis elements involved in this T3 regulation have been more precisely
located by transfection studies using various lengths of rat GH gene pro¬
moter linked to reporter genes. In a series of experiments with cells that had
stably integrated the exogenous constructs into their genome, T3 induction
could be observed with progressively smaller promoter fragments, from
1800 bp (Casanova et al, 1985) down to 235 bp of 5'-flanking DNA (Crew
and Spindler, 1986). Further analysis showed the simultaneous presence of a
positive and a negative thyroid response element (Wight et al, 1987); the
first of these behaved as an enhancer (at position -254/-241) but the
second did not, and overlapped with the TATA box (position -46/-21).
Later studies with staged deletions of 5' and 3' regions in rGH fragments
(from which the negative element had been deleted) mapped the borders of
the positive element to position — 194/- 169 (Wight et al, 1988) correspond¬
ing closely to a T3 receptor footprint described by Koenig et al (1987), and
which contains part of a DNA sequence that binds the c-erb-A proto-
oncogene translation product (Glass et al, 1987) (Figure 6.)
In another series of studies (Larsen et al, 1986a; Flug et al, 1987) the
transcription of the CAT reporter gene was measured in transient expres¬
sion 2 to 3 days after cell transfection. The data obtained are slightly
different from the results described above (Figure 6), perhaps because the
constructs are not integrated in the host cell genome while T3 has an
important effect on GH cell proliferation, or possibly because the higher
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copy number of constructs per cell might compete for binding of some
regulatory factors. The apparent T3 response element is close to the cis
elements shown to bind nuclear proteins (including T3 receptor) and to be
necessary for tissue-specific expression. Larsen et al (1986a) found that
sequences between positions — 183 and — 202 were able to confer thyroid
hormone responsiveness, but only in pituitary cell types, indicating that a
thyroid hormone response element itself may have tissue-specific char¬
acteristics. Ye et al (1988) proposed that two interacting tissue-specific cis
elements (at — 137/- 107 and - 95/— 65) are functionally linked with the T3
response element to act as an enhancer-like unit which confers both cell-
type-specific and T3-regulated gene expression. Both interacted to confer
regulated expression to heterologous promoters, and it was suggested that
the T3-receptor-DNA complex is able to enhance the function of the cell-
specific elements to increase the level of rat GH gene expression. Finally, gel
retardation and DNase I footprinting studies have shown that partially
purified T3-receptor preparations show binding to upstream regions of the
GH gene, and that there may in fact be multiple sites which can interact with
receptor within the region —530/+7 (Ye and Samuels, 1987; Apriletti et al,
1988; de Groot et al, 1988; Lavin et al, 1988).
Glucocorticoids
Transcription of the endogenous rat GH gene is induced by five to twenty-
fold in the GH cell line (Martial et al, 1977; Evans et al, 1982; Wegnez et al,
1982). Initial attempts at studying the mechanism of glucocorticoid action
were undertaken using heterologous (non-pituitary) recipient cells which
had stably integrated the transfected rGH gene into their genome. This
experimental approach led to the production of mRNAs that had aberrant
transcription initiation sites, but whose amounts were nevertheless variably
glucocorticoid inducible (Doehmer et al, 1982; Kushner et al, 1982; Karin et
al, 1984; Miller et al, 1984). An rGH promoter region as short as 248 bp was
able to confer glucocorticoid induction to a reporter gene in heterologous
ceils (Heiser and Eckhardt, 1985), but in transient transfection analyses in
pituitary cells using rGH 5'-flanking DNA linked to a reporter gene, Crew
and Spindler (1986) and Flug et al (1987) found only minimal glucocorticoid
effects. Birnbaum and Baxter (1986) found that a promoterless rGH gene
was glucocorticoid inducible, with mRNA of a nearly correct size, suggest¬
ing that glucocorticoid regulatory elements were contained downstream,
not upstream, from the transcription initiation site. A glucocorticoid
response element has been described in the first intron of the human GH
gene (Slater et al, 1985), and although such a site has not yet been shown in
the rat GH gene, its first intron does contain a TGTCCT sequence typical of
GR binding sites.
Peptide hormone regulation and intracellular messenger systems
Hypothalamic GRF stimulates rat GH gene transcription in primary cell
cultures (Barinaga et al, 1983,1985; Gick et al, 1984) and also in transgenic
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mice over-expressing the human GRF precursor gene (Hammer et al,
1985a). Somatostatin reduces rat GH mRNA accumulation (Wood et al,
1987), although a separate study failed to show short-term effects on tran¬
scriptional rate (Barinaga et al, 1985). Insulin blocks T3 stimulation of rGH
secretion (Melmed and Slanina, 1985) and may inhibit GHmRNA accumu¬
lation (Melmed et al, 1985a; Yamashita and Melmed, 1986), but, depending
on culture conditions, other workers have found that insulin may also exert
stimulatory effects (Isaacs et al, 1987a). Ectopic hypersecretion of GH by
transplanted tumours in the rat has been shown to inhibit GH mRNA
accumulation in vivo (Yamashita et al, 1986a), and this autoregulation
probably involves negative feedback from insulin-like growth factor I
(IGF-I) (Yamashita and Melmed, 1987).
Transcription of the rat GH gene may be modulated independently ofGH
release: GRF stimulation of GH release is highly dependent upon extra¬
cellular calcium whereas both basal and GRF-stimulated GH gene tran¬
scription are much less so (Barinaga et al, 1985). Rat GH mRNA
accumulation is somewhat inhibited by removal of extracellular calcium but
this effect is much less marked than for PRL mRNA (Bancroft et al, 1985;
Gick and Bancroft, 1985). GRF is thought to exert its effect on somato¬
trophs through stimulation of adenylate cyclase, and its effects on rat GH
gene transcription may be mimicked by exogenous cAMP (Clayton et al,
1986) and adenylate cyclase activation, but not by activation of protein
kinase C or cell depolarization, which stimulate only secretion of GH
(Barinaga et al, 1985; Morita et al, 1987).
Human GH gene
Analysis of stable transformants obtained by transfection of the human GH
gene with 500 bp of promoter sequences into GH3 cells (Cattini et al, 1986b)
has shown that T3 inhibits hGH gene transcription while stimulating that of
the rat GH gene. However this T3 inhibition is not clearly linked to the hGH
promoter as it could not be shown in transient expression studies using the
CAT reporter gene (Cattini and Eberhardt, 1987; Brent et al, 1988). The
endogenous gene may not always behave in a similar fashion to a transfected
construct. Transcriptional control of the endogenous human GH gene has
been the subject of limited study, using tissues obtained from surgically
removed pituitary somatotroph adenomas. Isaacs et al (1987b) found stimu¬
lation of hGH gene mRNA accumulation by dexamethasone, but no effect
of T3, in contrast to the inhibitory effects of T3 seen in 7 of 11 rat GC cell lines
stably transfected with a human GH gene construct. These differences
between transfected and endogenous genes, and the variability of the
transfection data, suggest that the cellular environment is critically impor¬
tant in determining the ultimate response to a hormonal stimulus.
Although a T3 response element has not yet been precisely identified in
the human gene, T3 receptor from lymphoblastic IM-9 cell nuclear extracts
is able to bind specifically between positions -129 and —290 in the 5'-
flanking region of the gene (Barlow et al, 1986), a position similar to that of
the positive T3 response element in the rat gene. Glucocorticoids stimulate
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expression of the transfected human GH gene (Robins et al, 1982; Cattini et
al, 1986b; Brent et al, 1988) similar to their effect on the rat gene, and
glucocorticoid response element has been demonstrated within the first
intron of the gene, that is, downstream of the transcription initiation site
(Eliard et al, 1985; Moore et al, 1985; Slater et al, 1985). A weaker gluco¬
corticoid receptor binding site found within the promoter region (Eliard et
al, 1985; Slater et al, 1985) could be responsible for the hGH-CAT response
to the hormone (Cattini and Eberhardt, 1987).
Little work has been reported on the effects of peptide hormones on the
human GH gene, but Yamashita et al (1986b) showed suppression of hGH
mRNA levels by IGF-I using cultured cells from five human pituitary
adenomas; IGF-I also prevented GRF-induced stimulation of GH mRNA
levels. The intracellular messenger systems which may regulate GH gene
transcription in the human pituitary are not yet known, but Brent et al
(1988) showed that the hGH promoter was cAMP-responsive, and prelimi¬
nary data have shown stimulation of endogenous hGH mRNA levels and
GH release by GRF and by cAMP, whereas stimulation of protein kinase C
caused only GH release without affecting mRNA levels (Davis et al, 1988b).
These findings are similar to results obtained using normal rat pituitary
tissue (Barinaga et al, 1985; Morita et al, 1987), and suggest that in some
tumours at least, the intracellular mediators affecting hGH gene regulation
are similar to those studied in the normal rat pituitary.
Summary
For both the PRL and GH genes, a wide variety of hormones and intra¬
cellular signalling systems appear to have significant transcriptional effects.
While basal expression of the PRL or GH genes requires the interaction of
the Pit-l/GHF-1 protein with defined sites in their promoters, modulation
of a given level of expression may involve additive effects of adjacent or
distant hormone response elements, or modification of Pit-l/GHF-1 or
other factors already bound to their cis elements.
For the DNA-binding nuclear hormone receptors, the molecular basis of
their effects is increasingly well understood, with evidence for both direct
protein-DNA effects, and also for indirect protein-protein-DNA inter¬
action. The picture is much less clear for the effects of intracellular second
messenger systems; however, a number of interesting models have recently
been proposed for cAMP action on other genes, which may be relevant
(discussed above and reviewed by Roesler et al, 1988). The cyclic AMP-
responsive VIP gene (Tsukada et al, 1987) can be activated in single cells by
microinjection of purified catalytic subunit of cAMP-dependent protein
kinase (Riabowol et al, 1988) and in a cell-free system the transcription of
the urokinase plasminogen activator gene is enhanced by addition either of
cAMP itself or of the purified kinase catalytic subunit (Nakagawa et al,
1988). Thus amodel may be proposed whereby cAMP (formed as a result of
hormone-membrane receptor activation) activates a kinase, resulting in
dissociation of its catalytic subunit: this is then translocated to the nucleus
and phosphorylates a positive nuclear trans-acting factor to enhance gene
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transcription by RNA polymerase II. As this group also found that addition
of calcium to the cell-free system enhanced in vitro transcription, it is
tempting to speculate that such a direct mechanism may mediate the effects
of calcium on gene transcription, especially as calmodulin itself may also be
translocated into the nuclear matrix (Simmen et al, 1984).
It is now recognized that many proto-oncogene products are directly
involved in intracellular signalling pathways and the regulation of gene
transcription (Berridge, 1986), and some such proteins are now implicated
in the expression of the prolactin and GH genes, apart from the well known
example of the T3 receptor, encoded by the proto-oncogene c-erb-A (Sap et
al, 1986; Weinberger et al, 1986). It has been shown that GRF, acting via
cAMP, can stimulate somatotroph cell division and also rapidly increases
levels of c-fos mRNA (Billestrup et al, 1986, 1987). The function of the fos
protein in the pituitary is not yet known, but it may act by modulating the
DNA-binding of another proto-oncogene produce, c-jun, which is now
known to encode 'activator protein 1' (API), a recognized transcription
factor which is responsive to activation of protein kinase C (Lee et al, 1987;
Chiu et al,1988; Curran and Franza, 1988). AP-2, on the other hand,
appears to be linked both to protein kinase C and to cAMP (Imagawa et al,
1987), and it will be interesting to learn whether the potential AP-2 binding
sites in the prolactin and GH gene promoters are involved in intracellular
control, and indeed whether they may interact with Pit-l/GHF-1 binding
sites.
In conclusion, evidence is rapidly accumulating for mechanisms of
steroid, thyroid hormone and peptide hormone action on gene transcription
in a variety of systems. It seems likely that the precise molecular mechanisms
for regulated expression of the prolactin and GH genes will be greatly
clarified in the near future. The next challenge will be to assess the potential
importance of such mechanisms in the pathogenesis of pituitary disease, and
this topic will be approached in the next section.
CLINICAL ASPECTS
Over the past 10 years there has been a rapid advance in knowledge of the
structure of the coding and regulatory regions of the PRL and GH genes,
and of the normal cellular mechanisms which regulate their expression.
While much of the work has been based on rat pituitary tissue, the human
genes are increasingly coming under study and it appears that some regula¬
tory mechanisms, just as the gene structures themselves, are strikingly well
conserved between species. The clinical situations for which this new
knowledge is relevant can be divided into diseases of hormone deficiency (in
effect, just GH deficiency) or of hormone excess, namely pituitary tumours
secreting PRL or GH.
Growth hormone deficiency
Several single gene disorders have been found to result in isolated GH
deficiency (IGHD) with different modes of inheritance (Phillips et al,
822 J. R. E. DAVIS ET AL
1981a). Type IIGHD is inherited by autosomal recessive transmission, and
low but detectable levels of immunoreactive GH are found, but in type IA
GH secretion is entirely absent. This latter condition has been found to be
due to a large deletion within chromosome 17, which includes the hGH-N
gene but not hGH-V (Phillips et al, 1981a, 1981b). As these patients have
never been exposed to the authentic pituitary hGH-N protein product,
treatment with GH results in a strong initial anabolic response followed by
development of hGH antibodies and arrest of growth.
Deletion of the hCS-A gene, which forms part of the GH/CS gene cluster
on chromosome 17 has been incidentally found, although this appears to
have no adverse effects on the fetus, and is not apparently related to the
hGH-N deletion syndrome (Wurzel et al, 1982).
In contrast to IGHD, acquired GH deficiency is relatively common and an
important clinical problem but is amenable to GH therapy. Cadaveric GH
was formerly used for replacement therapy but recently has been suspected
of transmitting viral infection, including Jacob-Creutzfeld disease (P.
Brown et al, 1985). Its withdrawal coincided with the development of
commercially available recombinant GH following the successful expression
of the hGH-N cDNA in bacteria (Goeddel et al, 1979). Commercially
available recombinant hGH is identical to authentic hGH, except for a
single N-terminal methionine addition (although methionine-free hGH can
now be produced in bacteria). Antibody formation in response to met-hGH
was due partly to the extra methionine but also partly to contaminating
bacterial proteins, and better purification procedures have allowed hGH
therapy to become much more readily available than in the past, raising new
ethical and economic issues (Grumbach, 1988).
Transgenic animals and gene therapy
The fact that the GH gene could be integrated into the genome of stably
transfected heterologous cells, and was expressed and regulated normally,
suggested the possibility of introducing the gene into germ cells. Thus
Palmiter et al (1982) fused the promoter region of the mouse metallo-
thionein gene to the structural gene encoding rat GH (and later human GH)
(Palmiter et al, 1983) and microinjected the fusion gene into fertilized
mouse oocytes, which were then placed into the reproductive tracts of foster
mothers. Most mice that had stably incorporated the MT-hGH fusion genes
into their genome had high serum concentrations of hGH and grew larger
than control mice. Synthesis of hGH was enhanced by dietary supplemen¬
tation with cadmium or zinc, which enhance gene expression from the
metallothionein promoter. The use of transgenic manipulations with the
GH gene has obvious agricultural implications and the technique has been
experimentally extended to produce transgenic rabbits, sheep and pigs
(Hammer et al, 1985b).
The expression of trans-genes with metallothionein promoters is not
tissue specific, but recently trans-genes containing GH gene promoters show
a remarkable degree of tissue specificity, and Lira et al (1988) have shown
that as little as 180 bp of rat GH 5'-flanking DNA are sufficient to direct
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hGH gene expression to the pituitary, although it was shown to be produced
in lactotrophs and thyrotrophs as well as somatotrophs. These experiments
have been considered as models for gene therapy of somatic cells. However,
two main technical issues still have to be addressed, namely the precise roles
of regulatory DNA elements in controlling and timing tissue-specific expres¬
sion (Swanson et al, 1985), and the mechanisms for exact targeting of the
'curative' gene to replace its inactive counterpart in recipient cells. One
alternative approach may be to consider the implantation of cells which have
been stably transfected with the required gene and display regulated
hormone expression (Morgan et al, 1987).
Pituitary tumours
Pathological hypersecretion of GH causes the clinical syndromes of
gigantism or acromegaly, and generally results from a pituitary somatotroph
adenoma. Acromegaly may result from non-pituitary tumours with ectopic
GRF production, but ectopic secretion of GH itselfmay rarely occur, and in
one case hGH synthesis by a pancreatic tumour was confirmed by demon¬
stration of mRNA in cytoplasmic extracts (Melmed et al, 1985b). The basic
cellular mechanisms which may result in the formation of hormone-
secreting pituitary adenomas are not yet understood (Melmed et al, 1986),
but a number of recent studies of PRL and GH gene expression have
suggested some potential pathological processes which may be relevant. In
particular it is interesting to note that for both PRL and GH, hormone
secretion and tumour growth appear to be functionally linked, suggesting
that the mechanisms for gene regulation elaborated above may have direct
relevance for understanding tumour growth.
Abnormalities in membrane transduction proteins linked to intracellular
signalling systems have recently been found in pituitary tumours, with
evidence for relatively autonomous adenylate cyclase activity in a group of
human GH-secreting adenomas (Vallar et al, 1987) and a selective
deficiency of G0 proteins (which may mediate dopamine action) in two
dopamine-resistant PRL-secreting rat pituitary tumours (Collu et al, 1988).
These abnormalities may well result in abnormal gene expression: investi¬
gation of PRL and GH gene regulation in human pituitary tumour tissue is
clearly of interest, but until recently such studies have been hampered by
lack of large amounts of tissue. Yamashita et al (1986b) showed that hGH
mRNA levels were appropriately inhibited by IGF-I and stimulated by GRF
in human somatotroph adenomas, as has been found in normal rat pituitary
tissue (Barinaga et al, 1983; Yamashita and Melmed, 1987). Another study
confirmed this appropriate effect of GRF, but found that somatostatin was
ineffective in suppressing GH mRNA levels (Davis et al, 1988b), in contrast
to similar studies of normal rat tissue (Wood et al, 1987). Comparable
resistance of PRL mRNA accumulation to dopaminergic suppression was
also seen in a prolactinoma (Davis et al, 1988b), again suggesting that gene
expression was relatively autonomous.
Isaacs et al (1987b) compared the expression of the endogenous hGH
gene in cultured human pituitary tumour cells with the hGH gene trans-
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fected into rat cell lines and found differences in T3 regulation, while insulin
and glucocorticoid regulation was similar: does this imply a tumour-specific
abnormality in GH gene control? Comparison of normal pituitary tissue
with adenoma tissue may answer this question, and quantitative in situ
hybridization analysis should prove useful in further studies of small tissue
samples (Pixley et al, 1987; Levy and Lightman, 1988).
Abnormalities at the level of the hGH gene itself have been proposed by
U et al (1988) who found evidence for hypomethylation of the hGH gene
and its 5'-flanking region in adenomas compared to normal pituitary tissue:
gene hypomethylation is generally associated with enhanced expression in
tissues where the genes are normally expressed (Razin and Riggs, 1980;
Compere and Palmiter, 1981; Hjelle et al, 1982; Durrin et al, 1984;
Laverriere et al, 1986).
U et al (1988) also found that the c-fos proto-oncogene was amplified in a
single prolactinoma, which is of interest in that c-fos has been implicated in a
mitogenic action of GRF and cyclic AMP in somatotrophs (Billestrup et al,
1987), and may modulate the DNA binding of the transcription factor AP-1
(Chiu et al, 1988). The role of such transcription factors in pituitary tumour
development has yet to be addressed, but abnormalities in their DNA
binding or in their phosphorylation by kinases may clearly have major
effects on the level of gene transcription, and may be further sites of gene
dysregulation involved in adenoma formation. The recent cloning and
sequencing of cDNAs coding for the pituitary-specific transcription factor
Pit-l/GHF-1 (Bodner et al, 1988; Ingraham et al, 1988) will undoubtedly
stimulate investigation into the potential interactions between trans-acting
factors in pituitary tumours.
Finally, pituitary tumours may be generated in transgenic mice. Massive
lactotroph tumours have been induced in transgenic mice expressing a
fusion gene consisting of 3000 bp of the PRL 5'-flanking region linked to the
SV40 T antigen coding region (Rosenfeld et al, 1987), indicating that the
malignant transformation induced by the SV40 gene was targeted
exclusively to lactotrophs by the PRL 5'-flanking DNA. Mayo et al (1988)
linked the GRF structural gene to a metallothionein promoter sequence,
and found that the chronic high levels of GRF caused massive somatotroph
hyperplasia. Interestingly, the pituitary was a major site of transgene
expression in these mice, in contrast to other metallothionein-promoter
transgenes, and GRF was co-produced with GH in many cells, suggesting
that the transgenic pituitaries might have developed autocrine regulation by
GRF. The development of a GH-secreting tumour in a patient who had
long-standing ectopic GRF secretion (Asa et al, 1984) indicates a possible
pathogenetic role for abnormal (possibly autocrine) expression of GRF.
CONCLUSIONS
The prolactin and GH genes are related and their structure and regulation
have been extensively studied in rat pituitary cell systems. Mechanisms for
their tissue-specific expression and hormonal regulation are rapidly being
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elucidated, and a complex picture of inter-related nuclear protein/proto-
oncogene effects on the genes is developing. The recent identification and
cloning of such frans-acting factors as Pit-l/GHF-1 and AP-1 are major
advances in the field, and will undoubtedly clarify our understanding. The
pathogenesis of pituitary tumours remains a challenge, and has recently
stimulated the application of molecular biological techniques and
knowledge to human pituitary tissue. Whether tumour development can be
attributed to specific defects at the level of hormone gene regulation will be
the next exciting question that must now be addressed.
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SUMMARY
Very large prolactinomas are rare and may be difficult to treat. We present the report of a
patient with an exceptionally aggressive tumour which extended outside the skull and emerged
within the internal jugular vein. Bromocriptine induced only transient suppression of serum
prolactin. In vitro studies of tissue from this prolactinoma showed that although prolactin
secretion was reduced by both bromocriptine and dopamine, neither agent affected cytoplasmic
levels of prolactin mRNA, suggesting relative autonomy of prolactin synthesis.
We reviewed the progress of nine other patients with very large prolactinomas and serum
prolactin levels > 100,000 mU/1. In three cases, treatment with bromocriptine rapidly reduced
tumour size and serum prolactin levels became normal, but in the other cases responses were
slower and less marked. Substantial amounts of residual pituitary tumour were seen in all cases
where serum prolactin remained above 1000 mU/1, but also in one case where serum prolactin
returned to normal, showing that serum prolactin levels are not reliable indicators of tumour
size. Two patients died: one developed a CSF leak, and one pneumococcal meningitis in the
absence of recognized CSF leakage. This emphasizes the significant morbidity associated with
very large prolactinomas. The ideal long-term treatment of these tumours remains uncertain,
but bromocriptine therapy alone is often inadequate. Cases of apparent bromocriptine
resistance may reflect abnormal regulation of prolactin gene expression.
INTRODUCTION
Prolactin-secreting pituitary tumours in women commonly present as small intrasellar
microadenomas, but in men, the tumours may be much larger, and present as macroadeno-
mas ofmore than 1 cm diameter [1,2]. 'Giant' prolactinomas, several centimetres in diameter
show massive extrasellar extension, and appear to be rare: they may provide special
problems of management. One such case from this department [3] showed dramatic
shrinkage over six days of bromocriptine therapy, although this was complicated by CSF
rhinorrhoea requiring lumbo-peritoneal shunting. A further report described two tumours
> 4 cm diameter treated with bromocriptine [4]: one tumour was only partially responsive to
Address correspondence to Dr J. R. E. Davis, Department of Medicine, Manchester Royal Infirmary, Oxford
Road, Manchester M13 9WL.
© Oxford University Press 1990
228 J. R. E. Davis and others
this therapy, as measured by both serum prolactin levels and tumour size, although the other
tumour had responded satisfactorily about eight years after radiotherapy.
We present the case of a man with a large prolactinoma whose tumour was locally
aggressive, extending through the inferior petrosal sinus to emerge within the internal
jugular vein. Serum prolactin levels rose above 100,000 mU/1 and were only partially
responsive to treatment with bromocriptine. Tissue from this tumour was examined in vitro
to assess regulation of prolactin secretion and mRNA levels by bromocriptine. We also
review our experience with the nine other cases of giant prolactinomas with serum prolactin
levels > 100,000 mU/1 seen in this department within the past five years.
CASE REPORT
Patient 1. MH, male, 45 years old
This man presented in 1982 at the age of40 years with a six-week history of frontal headache,
diplopia and right-sided ptosis. He had been previously fit and healthy, and took no
medication. He was single and had no children. On examination, he had partial right 3rd, 4th
and 6th cranial nerve palsies, and there was partial loss of the nasal field of vision in the left
eye. Skull radiography showed an expanded pituitary fossa, and CT scan revealed a tumour
extending laterally and into the right sphenoid sinus, but with little suprasellar extension.
Endocrine testing pre-operatively revealed a serum prolactin of 91,600 mU/1 (normal < 500
mU/1), and total thyroxine of 73 nmol/1 (normal 60-140 nmol/1); 9 a.m. plasma Cortisol was
260 nmol/1, testosterone was <0.6 nmol/1 (normal 10-30 nmol/1) with luteinizing hormone
and follicle stimulating hormone levels of 3 and 4U/l, respectively. A frontal craniotomy was
carried out and the lack of suprasellar extension was confirmed. All of the intrasellar tumour
was removed, but some of the laterally extending tissue was not accessible. Histological
examination of the pituitary tissue revealed excessive nuclear variation with a large number
of mitoses.
Post-operatively, the patient's visual fields became normal, but the 3rd, 4th and 6th cranial
nerve palsies remained. Serum prolactin levels fell only slightly, but he became panhypo-
pituitary. He was treated with bromocriptine 7.5 mg daily and hydrocortisone, thyroxine
and testosterone replacement therapy. He then received 4500 cGy external irradiation to the
pituitary region (three fields) in 30 fractions over a six-week period. Serum prolactin levels
fell to 11,000 mU/1 after two months on bromocriptine 7.5 mg daily, but over the next nine
months gradually rose to >39,000 mU/1, despite increasing the drug dose to 15 mg daily
(Figure 1A).
Bromocriptine was discontinued during 1984 in view of its lack of sustained effect on
serum prolactin levels, but he remained well over the next two years.
In April 1986, he developed nausea and vomiting, and was found to be dysarthric, and to
have right-sided 9th, 10th and 12th cranial nerve palsies, in addition to his pre-existing 3rd,
4th and 6th nerve palsies. CT scans (Figure 2) showed little change compared to 1982, but the
tumour was assumed to have extended inferiorly, causing lower cranial nerve damage.
Serum prolactin was 120,000 mU/1. A further trial of bromocriptine, up to 30 mg daily was
commenced. Although this reduced prolactin levels to 20,000 mU/1 after eight weeks (Figure
IB), the patient experienced severe nausea on the highest doses, and in June 1986 he
underwent a transethmoidal hypophysectomy in an attempt to reduce the tumour bulk.
Most of the large tumour mass, which extended laterally to the right, superiorly and
inferiorly, was removed. Histological examination showed a cellular chromophobe
neoplasm composed of solid sheets of pleomorphic cells with hyperchromatic nuclei and a
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FIG. 1. A. Case I, MH: initial response of serum prolactin to surgery, radiotherapy and bromocriptine,
days 0-600. B. Later responses of serum prolactin to bromocriptine, pergolide and CV 205-502, over
days 1200-2000. Note serum prolactin shown on a logarithmic scale.
FIG. 2. Case 1, MH: CT scan at the level of the floor of the pituitary fossa in 1986, showing extensive
bony destruction and right inferior and parasellar extension.
variable amount of cytoplasm. Numerous binucleate cells and mitotic figures were found.
Tumour tissue obtained at this operation was used for in vitro studies ofprolactin release and
mRNA accumulation.
Post-operatively, the patient continued to suffer from severe nausea, and as a result the
bromocriptine was stopped. Serum prolactin levels began to rise again (Figure 1B), but he
remained otherwise well until December 1986 when he developed worsening headache,
nausea and deterioration of his diplopia. Other neurological signs were unaltered.
In view of a report that some patients with bromocriptine-resistant prolactinomas may
Bromocriptine
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respond to pergolide [5], this treatment was started, but doses up to 75 daily had no effect
on prolactin levels over a three-week period (Figure 1B) and it was therefore stopped. One
week later he developed a right parapharyngeal abscess, which was treated successfully with
antibiotics. A residual hard lymph node was found at the angle of the right mandible, and
excision biopsy revealed a lymph node adjacent to a mass of tumour tissue within the internal
jugular vein. Histological examination revealed only reactive changes in the lymph node, but
confirmed infiltration of the vein wall with pleomorphic cells which showed positive
immunostaining for prolactin. A fragment of this tissue secreted prolactin when cultured in
vitro (data not shown).
The patient was given further radiotherapy to the neck and skull base, receiving 3000 cGy
in 10 fractions over 14 days, in an effort to halt extracranial extension of the pituitary
tumour, and serum prolactin levels fell markedly over the next three months from 140,000 to
18,000 mU/1, in the absence of any further bromocriptine therapy. Four months later a CT
scan suggested a substantial mass of tumour remaining in the inferior petrosal sinus, and he
was therefore offered a trial of the new non-ergot dopamine agonist drug CV 205-502
(Sandoz Pharmaceuticals). Although acute administration of this agent caused transient
suppression of serum prolactin within 24 hours (from 18,000 to 11,000 mU/1) this
suppression was not sustained with chronic treatment over the subsequent three months, and
serum prolactin levels remained between 12,600 and 22,100 mU/1 (Figure 1B). The patient
reverted to bromocriptine treatment (7.5 mg daily), but his prolactin levels continued to rise
gradually to >46,000 mU/1 in 1988. He complained of facial pain at this time, and clinical
examination suggested tumour involvement of the right fifth cranial nerve. A third
hypophysectomy was performed in a further attempt to reduce the tumour bulk, and this
resulted in complete relief of the facial pain.
CELL CULTURE STUDIES
Methods
Prolactinoma tissue obtained at the second hypophysectomy was grown in monolayer
culture for in vitro studies of the regulation of prolactin release and prolactin mRNA
accumulation. These experimental data have previously been presented as part of a separate
report [6], Pituitary tumour tissue was enzymatically dispersed using collagenase and
hyaluronidase, as previously described for rat pituitary tissue [7], Dispersed prolactinoma
cells were plated onto plastic cell culture dishes at a density of approximately 2 x 105 cells/2
ml/well in final culture medium (Dulbecco's modified Eagle's medium supplemented with
10% horse serum, 2.5% fetal calf serum and 2 mM glutamine). Cells were allowed to attach
to the plastic dishes and were grown in monolayer culture for five days. They were then
washed by repeated medium exchanges, and treated with bromocriptine or dopamine in
serum-free medium for 24 hours. Medium was then removed for radioimmunoassay of
released hormone, using MRC 83/562 as prolactin standard, and MRC 66/217 as standard
for growth hormone. Meanwhile cytoplasmic extracts were prepared for dot hybridization
analysis, which was carried out as described previously [7] using a 32P-labelled cDNA probe
specific for human prolactin [8], generously provided by Dr J. A. Martial, University of
Liege, Belgium.
RESULTS
Over the first four days in culture the cells produced large quantities of prolactin, and very
small amounts of growth hormone (data not shown); however growth hormone secretion
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was not detectable in subsequent 24-hour incubations, implying that any contamination
with normal pituitary tissue was negligible. Treatment for 24 hours with either 10 nM or 100
nM bromocriptine reduced prolactin release from the cultured cells to approximately 50% of
control values; 10 /tM dopamine had a similar effect. On the other hand, prolactin mRNA
levels were only minimally reduced by bromocriptine, and a single high dose of dopamine
had no effect (Figure 3). These data contrast with those found with normal rat pituitary
tissue, where clear inhibition of prolactin mRNA accumulation by similar doses of
bromocriptine can be demonstrated [9]. A single high dose (100 nmol/1) of thyrotrophin-
releasing hormone stimulated prolactin release, but had only marginal and non-significant
effects on prolactin mRNA levels, again in contrast to results obtained with normal rat
pituitary tissue (data not shown).
REVIEW OF NINE FURTHER CASES OF GIANT PROLACTINOMA
The unusual problems encountered with this patient prompted us to review the experience in
this department with other cases of 'giant' prolactinomas. Nine other patients were identified
from the endocrine clinic in whom serum prolactin had exceeded 100,000 mU/1, as an
arbitrary criterion for massive lactotroph hyperplasia. Their cases are briefly summarized
below and in Table 1, and initial responses to bromocriptine are shown in Figure 4 in
approximate order of their responsiveness to bromocriptine. Four of the patients received
bromocriptine alone, but five were treated surgically before receiving the drug. Only one
patient (case 4) also had radiotherapy.
CASE REPORTS
Patient 2. EO, female, 60 years old
This patient has been reported in detail previously [3], She presented in 1983 at the age of 55
years with visual deterioration, headache, loss ofmemory and long-standing amenorrhoea.
Her initial serum prolactin level was 696,000 mU/1. She had bitemporal hemianopia and
cranial CT scanning revealed a massive pituitary tumour extending upwards into the middle
and anterior cranial fossae, inferiorly into sphenoid and ethmoid sinuses, and posteriorly
along the skull base. Bromocriptine at doses reaching 30 mg/day, induced a dramatic fall in
100,0001
Control 10 nM 100 nM 10 pM
Bromocriptine Dopamine
FIG. 3. In vitro responses of cultured prolactinoma cells from patient MH: prolactin release (open
bars) and cytoplasmic prolactin mRNA concentrations (stippled bars), in response to 10 and 100 nM
bromocriptine, and 10 /iM dopamine. Data shown are means + SEM, n = 4 per group and mRNA data
are shown in arbitrary units of optical density; *2P< 0.002 compared to respective controls.
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TABLE 1. Summary of initial and final serum prolactin levels, CT scan outcome, and
complications in giant prolactinoma cases
Patient Serum prolactin (mU/1) Final CT Bromocriptine Complications
appearance maintenance
dose (mg)
Initial Final (time) (maximum)
1. MH 91,600 46,000 (6 years) Extensive skull base
erosion
7.5 (30) Local extension
2. EO 696,000 450 (5 years) Empty sella 5 (30) CSF leakage
3. JW 270,000 350 (4 years) Persistent sphenoid
sinus extension
10 (10) -
4. AH 290,000 560 (2 years) Partial regression but
persistent suprasellar
tumour
5 (10) Sudden death (2
years); uncertain
cause
5. FK 119,750 730 (4 years) Small intrasellar
tumour residue
5 (15) -

















10. AC 160,000 55,000 (15 days) No change in tumour
volume at 15 days
10 (10) Death (15 days);
presumed pituitary
infarction
serum prolactin levels, to 3010 mU/1 after three weeks, by which time her visual fields were
normal, and CT scanning showed rapid shrinkage of the tumour. Prolactin levels were
normal (< 450 mU/1) by four months after bromocriptine treatment. The only complication
of treatment was CSF rhinorrhoea which developed as the tumour shrank. Nearly five years
later she remains well with normal serum prolactin levels on bromocriptine 5 mg daily. A CT
scan in 1987 showed a largely empty pituitary fossa.
Patient 3. JW, male, 67 years old
This man presented in 1984 with visual failure and hypogonadism. His initial serum
prolactin was 270,000 mU/1, and a CT scan showed a large pituitary tumour extending
through the pentagonal cistern to indent the inferior aspect of the third ventricle; the tumour
extended 5 cm superiorly, and 4 cm transversely. The patient was treated with bromocriptine
in doses of up to 10 mg daily, and serum prolactin levels fell below 1000 mU/1 within two
months; after 4 years serum prolactin remains at 330-470 mU/1. However repeat CT
scanning showed that despite significant reduction in the suprasellarmass, persistent tumour
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FIG. 4. Summary of nine cases of giant prolactinoma: initial responses of serum prolactin to
bromocriptine over days 0-400. Longer term outcome for each patient is summarized in Table 1. Doses
of bromocriptine are shown by hatched bars, and serum prolactin is shown on a logarithmic scale.
still extends into both sphenoid sinuses, partly destroying the dorsum sellae and posterior
clinoid processes, implying a large tumour mass despite normal prolactin levels in the
peripheral blood.
Patient 4. AH, male, 34 years old
This man presented in 1984 with a history of right-sided headaches, and symptoms of
hypogonadism. He had first presented to a neurosurgical unit in 1970 with headaches and
visual field loss. A large pituitary chromophobe adenoma was removed at transfrontal
hypophysectomy, and he subsequently received pituitary radiotherapy. He remained well on
steroid and thyroxine replacement therapy until 1984 when he developed further headaches.
Serum prolactin was 290,000 mU/1, and testosterone was undetectable. CT scanning showed
a large enhancing mass with parasellar extension, suprasellar extension with a total vertical
extent of 4.5 cm, and erosion of the petrous temporal apex. Bromocriptine, increased to 10
mg daily, induced a rapid reduction in serum prolactin (Figure 4). When the dose of
bromocriptine was reduced to 2.5 mg daily, prolactin levels rose to 42,200 mU/1, but on
raising the dose to 5 mg daily, serum prolactin fell to 560 mU/1, and the patient was well and
symptom-free. The most recent CT scan, in 1986, showed some reduction in tumour size, but
persistence of moderate suprasellar extension. The patient died suddenly in early 1987, and
no obvious cause was found at post-mortem, apart from the presence of the pituitary
tumour.
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Patient 5. FK, male, 54 years old
This man presented in 1984 at the age of 50 years, with a three-week history of headache,
decreasing conscious level and left-sided weakness. A CT scan showed a large cystic lesion in
the right frontal and central areas, arising from the pituitary fossa region, with enhancing
tissue at its base. A cystic tumour was aspirated at craniotomy with clinical improvement.
Serum prolactin was 154,000 mU/1 initially and 119,000 mU/1 post-operatively; this fell
progressively with bromocriptine therapy, reaching 1300 mU/1 at eight weeks and eventually
becoming normal nearly two years after treatment started (Figure 4). He remains well after
four years of 10 mg bromocriptine treatment. CT scans two years after treatment
demonstrated that the tumour had largely regressed to a small area within the pituitary fossa,
with only minimal parasellar extension still present.
Patient 6. GJ, male, 22 years old
This patient presented in 1985 at the age of 19 years with a 15-month history of progressive
visual loss. He was obese and clinically hypopituitary, and CT scanning showed a large
lobulated suprasellar mass extending approximately 4 cm into the middle cranial fossa, and
also extending inferiorly into the sphenoidal and ethmoidal sinuses and nasopharynx,
destroying much of the base of the skull. A large tumour mass was partly excised at
craniotomy. Post-operatively, serum prolactin levels were between 450,000 and 1,652,000
mU/1, and the patient was referred for medical treatment ofhis prolactinoma. Bromocriptine
(2.5 mg) reduced serum prolactin to 190,500 mU/1 over an initial six-hour period; continuing
bromocriptine treatment (up to 25 mg daily) over the subsequent eight weeks progressively
reduced serum prolactin levels to 13,500 mU/1 (Figure 4).
At this stage, the patient developed pneumococcal meningitis which was successfully
treated with penicillin. Although he had never developed CSF rhinorrhoea, a defect in the
skull base was the presumed portal of bacterial entry. With subsequent bromocriptine
therapy (20 mg daily), prolactin levels fell to 3900 mU/1, but have not normalized during a
total treatment period of 18 months. CT scanning 15 months after presentation showed
some reduction in size of the tumour in the middle cranial fossa, but persistence of large
inferior, posterior and parasellar extensions of the tumour.
Patient 7. JB, male, 35 years old
This man presented in 1981 with obesity, and was found to be hypopituitary. Serum
prolactin was initially 141,600 mU/1, and CT scanning revealed a large pituitary tumourwith
downward extension to the left and 2 cm suprasellar extension. Visual fields were normal.
With bromocriptine (up to 25 mg daily), prolactin levels fell from 84,800 mU/1 to
approximately 1000 mU/1 (Figure 4). Seven years after diagnosis serum prolactin levels have
become stable at 1200-1900 mU/1; however repeat CT scans show that, despite regression of
the suprasellar component, large amounts ofpituitary tumour persist with extension into the
upper part of the left sphenoid sinus, and erosion of the dorsum sellae.
Patient 8. GA, male, 40 years old
This man presented in 1986 at the age of 39 years with grand mal convulsions. A CT scan
showed a pituitary tumour with an irregular enhancing suprasellar mass. This was sub-
totally removed at a craniotomy; histological examination showed a cellular tumour,
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staining strongly positive for prolactin. The post-operative serum prolactin level was 113,100
mU/1 and after starting bromocriptine (5 mg daily) there was a progressive fall to 3,900 mU/1
over the next 12 months (Figure 4). CT scanning approximately 15 months after treatment
revealed a small amount of suprasellar enhancing tissue, implying partial regression of the
tumour. There have been no complications over the 18 months to date.
Patient 9. RP, male, 41 years old
This patient presented in 1983 with a two-year history of headache. CT scanning showed a
pituitary tumour with modest suprasellar extension to 0.5 cm above the fossa, but marked
left parasellar involvement. Serum prolactin level was 170,000 mU/1; this was reduced to
46,000 mU/1 after three months' bromocriptine therapy, at which time a transethmoidal
hypophysectomy revealed a largely empty sella. Subsequent CT scans confirmed low density
within the pituitary fossa, but demonstrated persistent posterior and parasellar extension of
the tumour.
In December 1984 the patient recommenced long-term bromocriptine treatment (10 mg
daily), and prolactin levels fell very slowly from 107,000 to 70,800 mU/1 at the end of the first
year (Figure 4). There was a further fall, to 23,500 mU/1 after nearly three years of
maintenance treatment with 20 mg bromocriptine daily, but recent CT scans have shown
only minimal reduction in size of the tumour.
Patient 10. AC, male, 65 years old
This patient presented with collapse, possibly a convulsion, after which he was found to have
inappropriate secretion of anti-diuretic hormone. He had complained of impotence for over
40 years, and on examination he was clinically hypopituitary. A CT scan showed a large
pituitary tumour, and a serum prolactin level was 160,000 mU/1. During this admission the
patient suddenly collapsed again, becoming unrousable and mute; he had neck stiffness and
deviated gaze, and then had one grand mal convulsion. A clinical diagnosis ofacute pituitary
infarction was made. Treatment with dexamethasone and bromocriptine resulted in an
initial improvement, with regained consciousness and a fall in serum prolactin levels;
however a repeat CT scan 10 days after starting bromocriptine showed no change in the size
of the tumour. His condition deteriorated during the second week and he died 15 days after
bromocriptine therapy commenced. A post-mortem examination was not performed.
DISCUSSION
We have presented the cases of ten patients with extremely high serum prolactin levels who
could be classed as having giant prolactinomas. The index case (MH) had an unusually
aggressive and locally invasive tumour which appeared to be only partly responsive to
treatment with bromocriptine. The tumour was particularly unusual in its spread along the
skull base, with local extension through the inferior petrosal sinus; to our knowledge, this is
the first case where prolactinoma extension outside of the skull has been reported. The
aggressive nature of the tumour was suggested by the numerousmitotic figures in the original
tissue. Intracranial metastases from prolactinomas have been described [10-13] but appear
to be exceptional, and in the absence of distant metastasis this patient's tumour cannot truly
be classed as a carcinoma.
This tumour appeared to be partly responsive to dopamine agonist therapy, since acute
challenges with bromocriptine, pergolide and CV 205-502 resulted in transient suppression
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of serum prolactin levels; however such suppression was not sustained, and prolactin levels
rose despite continuing bromocriptine treatment on two separate occasions. Failure of
bromocriptine to suppress prolactin secretion completely in a proportion of cases is well
recognized [14-16], although the reasons why tumours differ in this way are not clear. The
basis for dopamine resistance is not understood, but rat tumour models suggest a loss of
dopamine receptors or loss of receptor-associated G-proteins, which may be involved in
both dopamine and thyrotropin releasing hormone action [17]. The in vitro study showed
50% inhibition of prolactin release by high doses of bromocriptine and dopamine, implying
intact receptor and post-receptor function, but there was no significant effect on cytoplasmic
accumulation of prolactin mRNA. These data therefore suggest relative autonomy of pre-
translational stages ofprolactin synthesis in this tumour, and it may be that this underlies the
lack of sustained prolactin suppression in this patient. Similar in vitro studies of tumour
somatotrophs removed at hypophysectomy from patients with acromegaly have also
suggested variable and abnormal mRNA regulation [18], and further studies of gene
expression in these tumours are likely to clarify potential pathological mechanisms.
Review of the other nine cases of'giant prolactinomas' suggests that this patient's tumour
was unusually aggressive, even considering its extent. All but one of the other patients
responded to bromocriptine with at least some suppression of serum prolactin levels, but the
speed and degree of response was variable. Three patients (EO, JW and AH) showed rapid
and nearly complete responses to bromocriptine, reduction of serum prolactin to normal
within four months; only one of the other patients' prolactin levels became normal after two
years of treatment (FK), while in three cases (GJ, JB and GA), prolactin levels remained
static between 1200 and 3900 mU/1 at one to seven years after initial treatment. Patient AC
died before any assessment could be made of his likely long-term response to treatment. The
only patient who showed marked resistance to bromocriptine was RP, although even this
man has shown sustained partial suppression of serum prolactin on high doses, in contrast to
the index case. There was no apparent correlation between the dose of bromocriptine used
and the ultimate response in these patients, although a rapid initial fall in prolactin levels
appeared to favour better long-term control.
Serum prolactin is often regarded as an approximate marker of prolactinoma volume, and
it appears that incomplete suppression of serum prolactin by bromocriptine may imply the
persistence of substantial amounts of residual tumour. However, in one patient (JW) a large
tumour mass persisted despite normalization of serum prolactin. A previous report of two
large invasive prolactinomas describes one case where a 95% reduction in serum prolactin
levels was associated with only 20% reduction in tumour size [4], and, together with our data,
this suggests that serum prolactin level may not be a reliable marker of tumour size [19].
The ideal management for patients with large prolactinomas remains uncertain [1, 4],
Estimation of serum prolactin is essential before proceeding to surgical treatment, and a trial
of dopamine agonist therapy should be considered, as these patients will not be cured by
surgery alone. Bromocriptine will induce at least 50% reduction in the initial volume of
prolactin-secreting macroadenomas in about two-thirds of cases [2, 20], but the very large
tumours may differ. The present series indicates that patients with very large prolactinomas
may suffer serious morbidity (MH and GJ), and indeed two patients in this series (AH and
AC) died suddenly; one death (AH) remains unexplained, and the other patient (AC) is
thought to have suffered pituitary infarction before bromocriptine treatment was started.
Bromocriptine was clearly able to correct serum prolactin levels in some patients, although
the speed and extent of response was highly variable, and normal prolactin levels were not
achieved for nearly two years in one case.
The policy in this unit has been to use low doses of bromocriptine as long as there is a
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continuing reduction in the level of serum prolactin, and then increase doses to themaximum
that the patient can tolerate. However the ideal drug regimen remains to be established in
such cases; the persistence of large tumour masses despite normal levels of serum prolactin
may possibly be related to slow response, and this could argue for more aggressive initial
treatment. Special problems with bromocriptine treatment in these patients appeared to
relate mainly to the risk of skull base defects appearing once tumour tissue had regressed,
either causing CSF rhinorrhoea, as is well recognized [21], or allowing CSF infection. Long-
term treatment with bromocriptine may be well tolerated and maintain clinical remission
even in cases of very large prolactinomas, but a rebound rise in serum prolactin and re-
expansion of tumour usually occurs on stopping the drug [22], The documented persistence
of tumour tissue may make pituitary megavoltage radiotherapy advisable for long-term
control of the disease [2], In conclusion, large prolactinomas may be very aggressive and
cause serious morbidity or even death, and they may not always respond adequately to
bromocriptine. Their treatment requires close supervision, with an awareness of the
potential serious complications.
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Suppression of prolactin release
and mRNA accumulation
by two novel dopamine agonist agents
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.bstract. Two novel dopamine agonist drugs, CV
05—502 and CQP 201—403, have been investigated to
impare their effects on prolactin secretion and prolac-
n mRNA accumulation in cultured rat pituitary cells,
oth drugs gave dose-dependent suppression of prolac-
n release over a 24 h incubation period: when each drug
■as used at 100 nmol/1 CV 205-502 and CQP 201-403
lduced suppression to 8.9 ± 1.7 and 10.2 + 1.8% of con-
ol release, respectively, compared to 26.7 ± 4.8% of con-
ol with 100 nmol/1 bromocriptine. There was no con-
stent effect on growth hormone release. Cytoplasmic
ccumulation of prolactin mRNA was also inhibited by
oth drugs at this concentration, to 50.2 + 5.5% of con-
ol values by CV 205—502 and to 67.4 ± 8% of control by
QP 201—403, and to a similar extent by 100 nmol/1 bro-
locriptine (50.6 ±9.1% of control). None of the drugs
ad any significant effect on GH mRNA levels. These
ata suggest that the agents exert their effect at a pre-
anslational stage of prolactin synthesis, as well as at the
;vel of hormone release.
'rolactin synthesis and release are under the con-
rol of a number of different hormones, but the
ominant inhibitory influence in vivo is thought to
>e exerted by dopamine (Franks & Jacobs 1983).
lopamine acts in vitro to inhibit prolactin gene
ranscription and hence reduce accumulation of
irolactin messenger RNA (mRNA) in cultured pi-
uitary cells (Maurer 1980), and the dopamine
gonist drug bromocriptine has a similar effect
Vlaurer 1981). The prolactin-inhibitory effect of
romocriptine has been of dramatic benefit clini¬
cally in the treatment of prolactin-secreting pitui¬
tary tumours; in addition to reducing serum pro¬
lactin levels, both bromocriptine and the newer
ergot derivative pergolide have been shown to re¬
duce the size of large prolactinomas (Kendall-Tay¬
lor et al. 1982; Franks & Jacobs 1983)
The use of these ergot-derived agents has
become well-established, but the frequency of ad¬
verse effects has led to the recent development of
two new agents, CV 205—502 and CQP 201—403
(Sandoz Pharmaceuticals). CQP 201—403 is a pro-
pylergoline and CV 205—502 a benzo(g)quinoline
(Nordman & Petcher 1985). Both drugs have been
shown to be active at lower doses than bromocrip¬
tine in vivo in both normal subjects and in hyper-
prolactinemic women (Grevel et al. 1986; Ras-
mussen et al. 1987; Hanssen et al. 1988), and so far
they appear to have few adverse effects.
Both agents exert inhibitory effects on prolactin
release by normal rat pituitary tissue and also
human prolactinoma tissue (Venetikou et al. 1987).
These studies showed that in comparison to the
transient inhibitory effect of dopamine, both CV
205—502 CQP 201—403 caused profound and pro¬
longed inhibition of prolactin secretion, while
there was little or no effect on growth hormone re¬
lease.
Although it is therefore clear that these agents
reduce prolactin release, there is so far no informa¬
tion as to possible effects on hormone synthesis,
72
which is of some importance if the drugs are to be
of value in the long-term treatment of hyperpro-
lactinemia or in attempts to reduce the size of
large prolactinomas. We have therefore assessed
the effects of these two drugs on the pre-transla-
tional stages of prolactin synthesis by measuring
cytoplasmic accumulation of prolactin and growth




Anterior pituitary glands were removed from male Wis-
tar rats and were enzymatically dispersed as described
previously (Davis & Sheppard 1986a). Cells were plated
onto 24-well culture plates at a density of approximately
0.5 X 10° cells/well in final culture medium which con¬
sisted of Dulbecco's modified Eagle's medium with 0.3%
bovine serum albumin, supplemented with 10% horse
serum, 2.5% fetal calf serum and 2 mmol/1 glutamine.
Cells were allowed to attach to the dishes and were grown
in monolayer culture for 3—4 days before experiments.
They were then transferred to serum-free medium,
washed by repeated medium exchange, and treated for
24-h periods with either CV 205-502, CQP 201-403 or
bromocriptine (Sigma Chemical Company, Poole, Dorset,
UK). All three drugs were initially dissolved in ethanol,
before dilution in medium to the final concentrations in¬
dicated. At the end of treatment periods, medium was
removed for radioimmunoassay of released hormone,
and cells were scraped from culture wells for preparation
of cytoplasmic samples as described previously (Davis &
Sheppard 1986b).
MessengerRNA measuremen ts
Cytoplasmic accumulation of prolactin or GH mRNA
was measured by a cytoplasmic dot hybridization tech¬
nique (White 8c Bancroft 1982), as described previously
(Franklyn et al. 1986). Briefly, samples of cytoplasmic ex¬
tract from the cultured pituitary cells were diluted and
applied in duplicate to a hybridization transfer mem¬
brane (Gene Screen, New England Nuclear, Du Pont UK,
Southampton, UK), and hybridized with 32P-labelled
plasmid probes containing complementary DNA inserts
specific for rat prolactin (pPRL-1; Gubbins et al. 1979) or
rat GH (pBR322 rGH-1; Harpold et al. 1978) (kindly pro¬
vided by Dr R A Maurer, University of Iowa, USA, and Dr
F C Bancroft, Mt Sinai School of Medicine, New York,
USA respectively). Probes were labelled by nick transla¬
tion using commercial reagents (Amersham Interna¬
tional, Amersham, Bucks, UK) to a specific activity of
1—4 X 10s dpm/pgDNA. After hybridization, mRNA con¬
centrations were measured by autoradiography and
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scanning densitometry; mRNA concentrations are ex¬
pressed in arbitrary units of optical density relative to
control data which are given a value of 1.0 units.
Radioimmunoassays
Prolactin and growth hormone release were measured by
radioimmunoassay using reagents supplied by the Na¬
tional Hormone and Pituitary Program, NIADDK, Be-
thesda, MD. Prolactin results are expressed in terms of
the standard rPRI,-RP3, and GH in terms of standard
rGH-RP2.
Statistics
Statistical significance was calculated using one-way ana¬
lysis of variance, and results were considered signifi¬
cantly different from control when P had a value less
than 0.05.
Results
Both CV 205—502 and CQP 201—403 caused simi¬
lar dose-dependent inhibition of prolactin re¬
lease in initial experiments to 8.9 and 13.6% of con¬
trol release, respectively, at 100 nmol/1 concentra¬
tions (P< 0.01; Fig. 1). GH release in these experi¬
ments was somewhat variable but no consistent





Effect of increasing doses of CV 205—502 (□) and CQP
201—403 (E3) on prolactin release from cultured rat pitui¬
tary cells. Data are means ± sem, N = 7 replicate culture
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Fig. 2.
Effects of 100 nmol/1 of CV 205—502, CQP 201—403 and bromocriptine on prolactin release, prolactin mRNA concen¬
trations, GH release and GH mRNA concentrations. Messenger RNA data are expressed in arbitrary units of optical
density (O.D.), relative to control values of 1.0. Data shown are combined results of 3 (prolactin data) or 2 (GH data) sep¬
arate experiments, N = 8—18 replicate culture wells for each group; *: l'< 0.005 compared to control.
Both agents also inhibited prolactin mRNA ac¬
cumulation. Dose-dependent inhibitory effects of
each drug were variable and not readily reproduc¬
ible between experiments, but statistically signifi¬
cant inhibition of prolactin mRNA levels (to 69%
and 52% of control in single experiments) could be
seen with 1 nmol/1 doses of CV 205—502 and CQP
201—403 (P< 0.05; data not shown). However, the
maximal inhibition was in all experiments less
than that seen for prolactin release, and the grea¬
test degree of suppression seen in individual ex¬
periments was to 42% of control with 100 nmol/1
CQP 201-403.
Because of individual variability between dose-
response experiments, a comparison was made of
maximally effective prolactin-inhibitory doses of
CV 205—502, CQP 201—403 and bromocriptine
using data pooled from three separate experi¬
ments; this confirmed the striking inhibition
achieved by all three agents on prolactin release
(P< 0.005), slightly greater with CV and CQP than
with bromocriptine; on the other hand, prolactin
mRNA accumulation was definitely reduced, but
only to 50.2 + 5.5, 67.4 + 8.0 and 50.6 + 9.1% of
control values by CV 205—502, CQP 201 —403 and
bromocriptine, respectively (P< 0.005; Fig. 2). In
contrast, no inhibitory effects were seen on either
GH release or GH mRNA accumulation (P> 0.05;
Fig. 2).
Discussion
These data show that both of these dopamine
agonist drugs caused dose-dependent inhibition of
secretion of prolactin but not growth hormone,
and both agents also induced significant suppress¬
ion of prolactin mRNA concentrations without ef¬
fect on GH mRNA levels.
In contrast to the profound inhibitory effects of
both agents on prolactin release, the inhibition of
prolactin mRNA accumulation was less marked,
but comparable to that achieved by a similar high
(100 nmol/1) dose of bromocriptine. The reason for
this lesser effect on mRNA levels may be the rela¬
tively long half-life of prolactin mRNA (Laverriere
et al. 1983; Rosenfeld et al. 1987), whichmeans that
rapid changes in the rate of gene transcription
have slow effects on the cytoplasmic accumulation
ofmRNA species. In previous studies of the effect
of bromocriptine, 50% inhibition of prolactin
mRNA accumulation was seen between 24 and 48
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h, (similar to the present findings with CV
205—502 and CQP 201—403), though maximal
suppression of mRNA levels took up to 96 h
(Maurer 1980). The newer dopamine agonists are
more potent than bromocriptine in vivo (Ras-
mussen et al. 1987; Hanssen et al. 1988); the prolac¬
tin mRNA data shown here do not provide clear
evidence for greater potency at the level of gene
regulation, and further studies of longer term ef¬
fects of lower doses of these drugs may be necess¬
ary to detect differences between the potency.
Neither CV 205-502 nor CQP 201-403 had any
significant effect on either GH release or GH
mRNA levels in this study. One previous study of
these drugs in vitro showed a small inhibition of
GH release with CQP 201—403 and no effect with
CV 205—502 (Venetikou et al. 1987), although both
drugs at least partly blocked the stimulation ofGH
release by GHRF. The present data confirm pre¬
vious findings from this laboratory that GH mRNA
levels were unaffected by bromocriptine (Wood et
al. 1987), as was found with both the new do¬
pamine agonist drugs.
In conclusion, the present study demonstrates
suppressive effects on lactotrope cells of two new
dopamine agonist agents, both at the level ofacute
hormone release but also a pre-translational site of
action, to reduce prolactin mRNA accumulation
and hence prolactin synthesis. These results are
comparable to previous data for bromocriptine,
and encourage the hope that the drugs may prove
to be of value not only in the treatment of hyper-
prolactinemia, but also possibly in inducing
shrinkage of large prolactin-producing pituitary
adenomas.
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Tissue-specific regulation of prolactin gene expression
J. R. E. Davis
Production of prolactin is very tissue-specific - the
gene is present in all cells, but in the rat it is expressed
only in the anterior pituitary gland, while in man it is
also expressed at low levels in the decidualized endo¬
metrium. Much of the work on rat prolactin gene
expression has been greatly facilitated by the avail¬
ability of the rat pituitary tumour-derived GH cell line
(including the GH,, GH3 and GH4 cell subclones)
which produces both prolactin and growth hormone.
In contrast, much less is so far known about the regu¬
lation of the human prolactin gene, due in part to the
lack of readily available human pituitary tissue for
in-vitro studies.
An increasing amount is known about hormonal
and intracellular regulation of prolactin mRNA pro¬
duction, which has been reviewed elsewhere (Davis,
Belayew & Sheppard, 1989). However, some of the
most impressive and important recent advances have
been concerned with the molecular mechanisms of
tissue-specific expression of prolactin, and these will
form the subject of this brief survey. The majority of
the work relates to the rat prolactin gene, but some
information is now emerging for the human gene,
which will be discussed separately.
Rat prolactin gene: upstream regulatory DNA
sequences
A variety of studies have recently provided a general
model for eukaryotic gene regulation in which diffusible
nuclear protein transcription factors (trans-acting fac¬
tors) interact with defined sequences in 5'-flanking
DNA (cw-acting elements) to effect both tissue-
specific and hormonal regulation of gene transcription
(Mitchell & Tjian, 1989). An analysis of these DNA-
protein interactions is essential to a detailed under¬
standing of the mechanisms of gene regulation. In the
case of prolactin, the cloning of the gene itself has
revealed that upstream of the structural gene there is a
long stretch of regulatory DNA which is essential for
tissue-specific and hormonally regulated expression of
the protein.
The function of 5'-flanking DNA from the rat pro¬
lactin gene has been assessed by transfection studies in
which up to 3 kb of upstream DNA sequences were
linked to a reporter gene whose activity was then
measured in the transfected cells as a function of the
promoter sequence activity. There are two distinct
upstream enhancer regions (Fig. 1), the proximal region
located between —422 and —36 base pairs (bp)
upstream of the transcription initiation site and the
distal one between —1831 and — 1530 bp upstream
(Nelson, Crenshaw, Franco et al. 1986). Although these
studies showed that the distal enhancer region alone
was responsible for the majority of the transcriptional
activity of the intact 3 kb upstream region, subsequent
reports have shown that the proximal enhancer region
is able to confer tissue-specific expression in its own
right (Gutierrez-Hartmann, Siddiqui & Loukin, 1987;
Lufkin & Bancroft, 1987). For example, using the tech¬
nique of in-vitro transcription, the prolactin gene
proximal enhancer region (— 425 bp) had trans¬
criptional activity in vitro only when incubated with
nuclear or whole cell extracts from pituitary cells, and
not with extracts from non-pituitary tissue (Gutierrez-
Hartmann et al. 1987). This suggested that 5'-flanking
DNA sequences from the proximal enhancer region
contained sufficient information to direct tissue-
specific expression, and that they interacted with a
nuclear transcription factor that was present only in
pituitary tissue. In summary, therefore, both the
proximal and distal enhancer regions are important
for transcriptional activation of the gene, although
both regions have enhancer activity in their own right.
Protein-DNA interactions: Pit-I/GHF-1
Detailed assessment of protein-DNA interactions
with the prolactin gene regulatory DNA was carried
out using the DNase I footprinting technique in which
DNA regions protected from DNase I digestion by
protein binding can be visualized by gel electrophore¬
sis of digestion products. Gutierrez-Hartmann et al.
(1987) found that incubation with pituitary nuclear
proteins gave rise to four protected regions within the
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figure 1. Diagrammatic representation of protein binding sites in the 5'-flanking DNA of the rat prolactin
gene, with distances in base pairs upstream from the transcription initiation site, shown by the arrow.
Proposed sites for the binding of the single protein factor Pit-1 are indicated by open regions; the four sites in
the proximal enhancer region are indicated 1P-4P, and the four sites in the distal enhancer region 1 DMD.
The oestrogen response element (ERE) is shown by the cross-hatched area in the distal enhancer region.
proximal 210 bp of the prolactin 5'-flanking DNA.
One of these four sites was also seen with non-pitu¬
itary extracts, but the other three sites were pituitary
cell-type specific. Similar footprinting studies were
performed by Nelson, Albert, Elsholtz et al. (1988),
who found that the distal enhancer region also con¬
tained four further sites which bound a pituitary-
specific factor. These studies demonstrated mutual
competition for protein binding between the different
sites, implying that a single protein factor, named
Pit-1, was involved. The rat growth hormone gene
likewise contains two cA-acting elements which bind a
pituitary-specific transcription factor, named GHF-1
(Bodner & Karin, 1987; Lefevre, Imagawa, Dana
et al. 1987): interestingly, the studies of Nelson et al.
(1988) showed that these sequences, like the prolactin
sequences, also competed for factor binding to the
prolactin promoter. Hence it was proposed that both
the prolactin and growth hormone genes interacted
with a common or functionally related pituitary-
specific transcription factor(s). A number of different
groups have now identified this factor for the rat
prolactin gene using similar techniques (Cao, Barron
& Sharp, 1988; Kim, Day & Maurer, 1988; Schuster,
Treacy & Martin, 1988; Lufkin, Jackson, Pan &
Bancroft, 1989).
DNA affinity purification using Pit-1 binding sites
has shown that the protein is expressed as a 31 kD-
33 kD doublet. The cDNAs for Pit-1 and GHF-1 were
cloned independently by two groups in 1988 (Bodner,
Castrillo, Theill et al. 1988; Ingraham, Chen,
Mangalam et al. 1988), and it appears that the factors
are indeed the same 33 kD protein. This protein con¬
tains an amino-terminal 60 amino acid region which is
related to the 'homeodomain' which characterizes a
class of genes important in embryonic development in
Drosophila. At the carboxy-terminal a further 76 amino
acid region is homologous to two other mammalian
transcription factors, Oct-1, Oct-2, and the inverte¬
brate protein factor unc-86 (see Mitchell & Tjian, 1989
for review).
There is disagreement as to whether Pit-1/GHF-1
recognizes both the prolactin and growth hormone
promoters, or only the growth hormone promoter
JournalofEndocrinology (1990) 125, 171-173
(Castrillo, Bodner & Karin, 1989; Mangalam, Albert,
Ingraham et al. 1989). The mRNA for Pit-1 /GHF-1 is
expressed in lactotrophs and somatotrophs, but also in
thyrotrophic cells (Crenshaw, Kalla, Simmons et al.
1989). The affinity purified Pit-1 protein is capable of
directing transcription from both rat prolactin and
growth hormone promoters in vitro, and permanent
transfection studies have recently shown that expres¬
sion of Pit-1 in non-pituitary HeLa cells, even at low
levels, will direct transcription from both the prolactin
and growth hormone promoters in vivo (Mangalam et
al. 1989). Hence it appears that a single protein, found
in three cell types in the anterior pituitary, can selec¬
tively activate transcription of either of two genes in
their respective pituitary cell types, implying that
further (possibly restrictive) mechanisms must exist to
account for the final somatotrophic or lactotrophic
phenotype.
The nature of such restrictive mechanisms remains
unknown, but some further information has recently
been gained by the use of transgenic mice. Either the
proximal or the distal enhancer elements alone were
able to direct a low level ofpituitary-specific expression
of reporter genes; the two elements together interacted
synergistically to give high levels of expression which
was almost exclusively restricted to lactotrophs
(Crenshaw et al. 1989). However, these studies also
showed that when the distal enhancer element was iso¬
lated from its flanking DNA it directed reporter gene
expression to thyrotrophs as well as lactotrophs. Thus
a model was proposed in which prolactin gene expres¬
sion was activated in lactotrophs and restricted in
somatotrophs by the proximal and distal enhancer
regions, and restricted in thyrotrophs by elements
which flank the distal enhancer region (Crenshaw
et al. 1989). The precise mechanisms involved have yet
to be elucidated, but are likely to be a useful model for
the study of differentiation in other endocrine and
non-endocrine tissues.
Human prolactin gene
The human prolactin gene contains a long upstream
regulatory element which is related to the rat gene, but
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much less is known about its regulation. DNase I foot-
printing studies reveal the presence of three pituitary-
specific protein binding sites in the proximal 217 bp of
the human prolactin promoter, and two such sites
within the human growth hormone and human chori¬
onic somatomammotrophin (CS) genes (Lemaigre,
Peers, Lafontaine et al. 1989). Competition studies
suggested that a single factor bound to all three genes,
and that it was related to Pit-l/GHF-1, although the
relevant factor has yet to be purified or cloned from
human tissue.
One important difference between rat and man is
the fact that the human gene is expressed in the
decidualized endometrial tissue of the placenta as well
as the pituitary (Clements, Whitfeld, Cooke et al.
1983). The mRNA has a slightly different size
(Gellersen, DiMattia, Friesen & Bohnet, 1989), which
may suggest a different transcription initiation site
and possibly that different transcription factors may
be involved. It remains to be seen whether a factor
related to Pit-l/GHF-1 is expressed in the human
placenta, but the cellular localization of the prolactin
and CS genes within the placenta differs, and presum¬
ably other factors interact to dictate the ultimate
pattern of expression.
Summary
The past 2 years have seen dramatic progress in our
understanding of the molecular basis of prolactin gene
expression in the pituitary gland. The identification of
the pituitary-specific factor Pit-l/GHF-1 has been a
major advance, and it leads to new questions, such as
the basis for the tissue-specificity of Pit-l/GHF-1
expression itself. It clearly cannot be the only factor
involved, as it is found in three pituitary cell types, yet
prolactin is expressed in only one of these. It is prob¬
able that a network of trans-acting factors, some tissue-
specific and some ubiquitous but hormonally activated,
interact to determine the overall pattern of expression
of the prolactin gene, and the dissection of this system
should provide some valuable insights into endocrine
gene regulation in general.
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Regulation of Growth Hormone Secretion and Messenger
Ribonucleic Acid Accumulation in Human
Somatotropinoma Cells in Vitro*
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ABSTRACT. GH secretion and mRNA levels were measured
in cultured cells obtained from six human pituitary somatotroph
tumors to investigate their hormonal and intracellular regula¬
tion. The responses were variable between tumors, but, in gen¬
eral, mRNA levels were less responsive than GH release to in
vitro manipulation. GH-releasing factor [GRF-(l-29) amide; 10
nMj increased GH release and mRNA levels in three of four
tumors tested to 30-97% above control values, but the fourth
tumor was unresponsive. Somatostatin (1 nM) inhibited GH
release significantly in four of the six cases, to 35-79% of control
levels, but had no inhibitory effect on GH mRNA accumulation,
in contrast to earlier studies on rat pituitary tissue. Bromocrip¬
tine (100 nM) likewise inhibited GH release (50-75% of control),
but not GH mRNA levels, in the four tumors tested. Forskolin
(10 mm; used to activate adenylate cyclase) stimulated GH release
and mRNA levels in the two cases that responded most clearly
to GRF, but had no significant effect in the other tumors;
however, the phorbol ester 12-O-tetradecanoyl phorbol-13-ace-
tate (100 nM) had no consistent effect on mRNA levels despite
stimulating secretion in four of six cases. Thus, there was
considerable variation in responses among the tumors tested;
however, the responsiveness to GRF was approximately paral¬
leled by that to forskolin, consistent with the suggestion that
adenylate cyclase activity and responsiveness are variable among
these tumors. Furthermore, the divergent effects of somatostatin
on GH release and mRNA suggest uncoupling between its recep¬
tor and transcriptional regulatory mechanisms. (J Clin Endocri¬
nol Metab 69: 704, 1989)
GH SECRETION is regulated in vivo primarily byGH-releasing factor (GRF) and somatost tin, al¬
though a number of other hormones are involved, includ¬
ing thyroid hormones, glucocorticoids, and insulin.
Knowledge of the hormonal control of GH gene expres¬
sion has so far been largely based on studies of rat
pituitary cells (1-3), and the availability of clonal rat
pituitary cell lines has allowed detailed examination of
the mechanisms involved (4, 5). Detailed study of the
endogenous human GH (hGH) gene has been limited by
the difficulty in obtaining sufficient tissue, but may be
important in relation to the possible pathogenesis ofGH-
secreting pituitary tumors. Cytoplasmic levels of hGH
mRNA in pituitary tumor cells may be suppressed in
vitro by insulin-like growth factor-I (6) and increased by
dexamethasone, but not by thyroid hormone, in contrast
to rat GH (rGH) mRNA (7). However, there is so far no
information on the possible effects of the other important
regulators of somatotroph function on endogenous hGH
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gene expression in human pituitary tissue.
In a preliminary report (8) we have presented results
of studies on the regulation of PRL and hGH mRNA
accumulation in two human pituitary tumors, one pro¬
lactinoma, and one somatotropinoma. We now present
data on the hormonal and intracellular control of hGH
release and mRNA accumulation in cultured cells from
six human somatotropic tumors. We have examined
the effects of a GRF fragment [GRF-(l-29) amide], so¬
matostatin, bromocriptine, forskolin, and phorbol ester
in order to determine the possible involvement of aden¬
ylate cyclase and protein kinase-C in hGH synthesis and
secretion.
Materials and Methods
Pituitary adenoma tissue was obtained for cell culture from
routine transsphenoidal or transfrontal hypophysectomy op¬
erations on six patients with acromegaly; patient details are
given in Table 1. At operation, pituitary tumor tissue was
immediately placed in ice-cold culture fluid, which consisted of
Dulbecco's Modified Eagle's Medium (Gibco BRL, Paisley,
Scotland) supplemented with 10% horse serum and 2.5% fetal
calf serum (Gibco BRL) with antibiotics. The tissue was
chopped into small fragments and enzymatically dispersed us¬
ing collagenase and hyaluronidase, as previously described for
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rat pituitary tissue (9). Each pituitary tumor yielded between
2.0-7.8 x 106 cells, with a viability determined by trypan blue
exclusion of 84-95%. Dispersed adenoma cells were plated onto
plastic culture dishes at a density of 1-2 x 106 cells/well in 2
mL culture fluid, incubated at 37 C in a humidified atmosphere
of 5% C02-95% air, and allowed to grow in monolayer culture
for at least 5 days before experiments were carried out. The
cells were then washed by repeated (serum-free) medium ex¬
changes and treated for 24 h with test substances in serum-free
culture fluid. After treatment periods culture fluid was removed
for RIA of released hGH, and cell cytoplasmic extracts were
prepared for mRNA determinations.
mRNA measurements
mRNA accumulation was measured by cytoplasmic dot hy¬
bridization using the technique of White and Bancroft (10).
Cells were scraped from culture dishes, and cytoplasmic ex¬
tracts were prepared as described previously (11). Cytoplasmic
samples were applied in duplicate to a hybridization transfer
membrane, and mRNAs were immobilized by baking before
prehybridization, hybridization, and autoradiography (11). A
cDNA probe specific for hGH (12) was radiolabeled with [32P]
dCTP using the oligo labeling technique (13) (Amersham In¬
ternational PLC, Radiochemical Centre, Amersham, United
Kingdom) to a specific activity of approximately 0.5 X 109 dpm/
/ig DNA.
The degree of hybridization was assessed by scanning den¬
sitometry of developed autoradiographs (11); for each experi¬
mentmRNA results were expressed in arbitrary units of optical
density relative to control samples, which were assigned the
value of 1.0 U (100%). For Northern blot analysis mRNA
species were extracted from cytoplasm of cultured cells from
one of the tumors, and then separated by agarose gel electro¬
phoresis before hybridization.
were dissolved in dimethylsulfoxide before dilution in culture
fluid immediately before experiments.
Hormone assays and statistics
hGH released into culture fluid was measured by RIA, using
MRC 66/217 hGH standard. Blank samples consisting of cul¬
ture fluid alone did not cross-react in this assay. Midrange
intra- and interassay coefficients of variation were less than
10%. Results are presented as the mean ± sem, and statistical
significance was assessed by one-way analysis of variance.
Results
Similar densities of viable cells were plated onto cul¬
ture wells in each experiment, and the amounts of hGH
released by unstimulated tumor cells in culture were
similar, except for tumors 3 and 4 where basal hGH
release was over 4-fold higher (Table 1).
Cultured cells obtained from tumor 1 were used to
prepare RNA for Northern blot analysis (Fig. 1). This
confirmed that a single species of hGH mRNA was
present, and that its size was approximately 1000 bases,





A GRF fragment [GRF-(l-29) amide; equipotent to authen¬
tic human GRF; Bachem, Saffron Walden, Essex, United King¬
dom] and somatostatin-(l-14) (Sigma Chemical Co., Poole,
Dorset, United Kingdom) were dissolved directly into culture
fluid. Forskolin (Calbiochem, Cambridge, United Kingdom)
and bromocriptine (Sigma) were dissolved initially in ethanol,
and the phorbol esters 12-O-tetradecanoyl phorbol-13-acetate
(TPA; Sigma) and phorbol 12,13-didecanoate (PDD: Sigma)
rABLE 1. Summary of patient details, showing random preoperative













1 M, 34 4100 75 ± 10"
2 M, 42 32 67+ 10
3 M, 42 160 249 ± 39
4 M, 39 130 398 ± 30
5 F, 42 130 64 ± 4.7
6 F, 36 14 55 ± 2.5
0.56
CON FSK
' Mean ± sem.
TPA
Fig. 1. Northern blot hybridization analysis of RNA (10 /ig/lane)
extracted from cultured cells from tumor 1. The cells were treated for
24 h with control medium (CON), 10 /iM forskolin (FSK), or 100 nM
TPA before extraction of RNA. The RNA was electrophoresed on a
1% agarose gel and blotted onto a hybridization membrane for hybrid¬
ization with the 32P-labeled hGH cDNA probe, followed by autoradi¬
ography. Standard DNA size markers (in kilobases) migrated as indi¬
cated at the right of the autoradiograph. (See also Table 2 for quanti¬
tative data for forskolin and TPA from dot hybridization studies.)
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with one previous report of such studies on human pi¬
tuitary tissue (6).
The effects of 10 nM GRF-(l-29) amide were studied
in four tumors (no. 1-4; Fig. 2); hGH release was stimu¬
lated in three of the four tumors, although the degree of
stimulation varied from 129-199% of control values.
Moderate stimulation of hGH mRNA levels was likewise
seen only in these three tumors, with values of 130-167%
of the control levels in each case.
Somatostatin (1 ^m) was studied in all six tumor
cultures (Fig. 3). GH release was suppressed in four cases,
although the degree of inhibition in the responsive tu¬
mors varied from 35-79% of the control values. In con¬
trast, hGH mRNA accumulation was not consistently
affected; slight and nonsignificant reductions were seen
in three of the six cases, the maximum suppression was
only to 70% of control values, and other values ranged
between 80-176% of control (P — NS).
Bromocriptine (100 nM) was studied in four tumor
cultures (no. 1-4; Fig. 4). GH release was reduced in all
four cases to between 50-75% of control values (although








Control 12 3 6
TUMOR NUMBER
Fig. 2. Effects of GRF on tumors 1, 2, 3, and 6. Cultured pituitary
tumor cells were incubated with control medium or 10 nM GRF-(l-29)
amide for 24 h. Hormone release data (H) are expressed in terms of
percentage of unstimulated hGH secretion (see Table 1); mRNA data
(■) are expressed in arbitrary units of optical density, also as percentage
of control values in unstimulated groups of cells. Data are the mean ±
SEM (n = 5-8 replicate culture wells/group). *, P < 0.02 compared to





Control 1 2 3 4 5 6
TUMOR NUMBER
Fig. 3. Effects of somatostatin on tumors 1-6. Cultured pituitary
tumor cells were incubated with control medium or 1 fiM somatostatin
for 24 h. Hormone release data (M) and mRNA data (■) are expressed
as in Fig. 2 and are the mean ± SEM (n = 4-8 replicate culture wells/








Control 12 3 4
TUMOR NUMBER
Fig. 4. Effects of bromocriptine on tumors 1-4. Cultured pituitary
tumor cells were incubated with control medium or 100 nM bromocrip¬
tine for 24 h. Hormone release data (H) and mRNA data (■) are
expressed as in Fig. 2 and are the mean ± SEM (n = 4-7 replicate
culture wells/group). *, P < 0.05; **, P < 0.005 (compared to control
samples for each tumor).
significantly suppressed in only one of the four tumors
(to 70% of control) and was unaffected in the others.
All six tumor cultures were treated with 10 nM forsko-
lin (to activate adenylate cyclase and, thus, raise intra¬
cellular concentrations of cAMP) and the phorbol ester
TPA (100 nM; activating protein kinase-C); the results
are shown in Table 2 (and see also Fig. 1). Forskolin
doubled hGH release and moderately increased mRNA
levels in tumors 1 and 2, but had no effect in the others.
However, it is noteworthy that tumors 1 and 2 were also
those that responded most clearly to GRF, whereas tu¬
mor 3 showed a smaller response, and tumor 6 failed to
respond to either agent. The tumor-promoting phorbol
ester TPA stimulated hGH release in four of the six
cases. [In a single experiment tumor 3 was treated with
the nontumor-promoting phorbol ester PDD (100 nM),
which had no significant effect: hGH release was 121 ±
6% of control (n = 4 replicates; P = NS compared to
control) compared to 193 ± 25% of control with 100 nM
TPA (n = 4; P < 0.02).] In contrast to hGH release,
hGH mRNA levels showed no consistent changes, with
nonsignificant stimulation by TPA only in tumors 2 and
6 (Table 2).
Discussion
A major limitation of studies of human pituitary tissue
is the lack of large amounts of tissue or clonal cell lines
for in vitro manipulation. Cytoplasmic dot hybridization
assays have proved valuable in studying mRNA regula¬
tion in small tissue samples (10) and were, therefore,
used here to investigate hGH mRNA regulation in hu¬
man pituitary tumor tissue. The present results show 1)
that responses of both hGH release and mRNA accu¬
mulation are variable between different tumors, but dif¬
fer from those in normal rat pituitary tissue in vitro; 2)
that mRNA levels do not necessarily parallel changes in
hormone secretion; and 3) that adenylate cyclase and
protein kinase-C differentially regulate hGH secretion
and mRNA accumulation.
Ik
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Table 2. GH release and mRNA levels in tumors 1-6 in respones to treatment for 24 h with forskolin or phorbol ester (TPA)
Tumor no.
Forskolin (10 jtM)
hGH release (% of control) 197 ± 37" 193 ± 24" 148 ± 18 77 + 37 82 ± 5 108 ± 11
hGH mRNA (% of control) 178 ± 9° 132 ± 30 80 ± 10 93 ± 44 120 + 20 86 + 11
TPA (100 nM)
hGH release (% of control) 426 + 70' 263 ± 39' 193 ± 25° 55 ± 8° 120 ± 6 130 ± 2°
hGH mRNA (% of control) 109 ± 20 155 ± 25 90+ 10 80 ± 30 160 ± 30 112 + 16
Hormone release data are expressed in terms of percentage of unstimulated hGH secretion (see Table 1); mRNA data are expressed in arbitrary
units of optical density and in terms of percentage of control values in unstimulated groups of cells (100%). Data are the mean ± sem (n = 3-6
replicate culture wells/group). Significance is indicated compared to control samples for each tumor; all other data are not significantly different
=from control values.
°P < 0.02.
' P < 0.001.
GH release and mRNA levels were stimulated in three
if four tumors by GRF-(l-29) amide. Previous reports
-have indicated stimulation of hGH release by equipotent
■loses ofGRF-(l-40) and GRF-(l-44) in five of six tumor
cultures, although the increases varied between 30-500%
-ibove the control value (15). GRF is known to stimulate
GH mRNA levels (2, 3, 16), and one previous report
describes stimulation of hGH mRNA accumulation by
jRF, although only to approximately 35% above control
/alues (6). Relatively small effects of GRF-(1-29) amide
-vere also seen in the present studies, although this could
ie partly explained by the absence in the culture fluid of
supplementary glucocorticoid, which is known to aug-
nent somatotroph responsiveness to GRF (17, 18), or to
he relatively short (24-h) incubation period. One tumor
vas completely unresponsive in terms of both hGH
nRNA levels and secretion.
Somatostatin and bromocriptine in high doses had
dear inhibitory effects on hGH release, confirming the
data of Lamberts et al. (19); although mRNA levels were
suppressed by bromocriptine in one tumor, no consistent
)attern was found for hGH mRNA accumulation in the
>thers, and somatostatin had no effect. The results ob-
ained with bromocriptine accord with previous data
'rom normal rat pituitary tissue (20). There is little
nformation regarding the effects of somatostatin on GH
<ene expression; using identical experimental techniques
ind design, Wood et al. (20) found that somatostatin
reatment (in the presence of dexamethasone) for 24 h
educed rGH mRNA levels to 35% of control values,
:omparable to the suppression of rGH release (20). How¬
ever, Gick and Bancroft (21) found no effect of so-
natostatin on rGH mRNA accumulation in GH3 cells,
vhile Barinaga et al. (16) found no effect on rGH gene
=ranscriptional rate. One previous report, using a quan-
itative in situ hybridization technique to study three
luman somatotroph tumors, has described the failure of
omatostatin to suppress hGH mRNA levels (22). The
ack of effect of somatostatin in the present six tumors
cannot be explained by lack of membrane receptors in
view of the inhibition of hGH release and might suggest
abnormal postreceptor signal transduction.
cAMP is known to be involved in GRF action, and
high intracellular levels of cAMP stimulate rGH release
and endogenous rGH gene transcription in normal rat
pituitary tissue (16) and also the transcription of a re¬
porter gene from the hGH promoter region in transfected
rat pituitary cells (23). Forskolin caused significant stim¬
ulation of hGH release and mRNA accumulation in only
two tumors. These two tumors also showed the most
marked responses to GRF-(1-29) amide, implying that
the coupling between cAMP generation and hGH gene
transcription and hormone release was intact in these
cases; on the other hand, the lack of response to either
GRF or forskolin in the other tumors might suggest
uncoupling at some level between receptor and cellular
response. Vallar et al. (24) found a subgroup of about
30% of somatotroph tumors characterized by higher hGH
secretion rates and high intracellular cAMP levels; in
these tumors adenylate cyclase activity was not stimu¬
lated by GRF, and this was related to the presence of an
altered Gs protein. In the absence of data for cAMP
accumulation it is not possible to say whether the present
results indicate two differing types of tumors with dis¬
tinctive levels of basal adenylate cyclase activity, al¬
though there was no correlation between GRF-respon-
siveness and the absolute level of basal hGH secretion.
In previous studies of rat pituitary tissue, activation
of protein kinase-C by phorbol esters was found to stim¬
ulate rGH release without increasing rGH gene tran¬
scription, in contrast to activation of adenylate cyclase,
which increased both (16, 25). In the present study TPA
was able to stimulate hGH release up to 4-fold basal
levels, demonstrating that protein kinase-C can mediate
hGH release. However TPA had no consistent effects on
hGH mRNA levels, suggesting that, as in the rat, protein
kinase-C has no effect on hGH gene regulation.
In conclusion, the present data show that the previ-
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ously recognized heterogeneity in the patterns of hGH
release by pituitary tumor cells in vitro also applies to
hGH mRNA accumulation. However, more importantly,
the data imply that there may be divergences between
the regulation of hGH secretion and mRNA production,
as in the case of somatostatin, which could result in the
rate of gene transcription being relatively autonomous
and independent of receptor-mediated inhibitory control.
Uncoupling between cAMP production and hGH pro¬
duction may be a further factor in a group of somatotroph
tumors. Several different mechanisms may underlie the
development of adenomatous change in the pituitary
gland, including hypomethylation of the hGH gene itself
(26), amplified proto-oncogene expression (26), and ab¬
normal signal transduction (24). The apparent relative
autonomy of hGH gene transcription seen in the present
study may be related to these findings and could be
involved in tumor pathogenesis.
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2alcium and Calmodulin Regulation of
Prolactin Gene Expression
ulian R. E. Davis
Prolactin gene transcription is critically dependent upon
'ntracellular calcium and the calcium-binding protein calmodulin.
rhe effects of calcium and calmodulin on the prolactin gene appear
o involve defined regions of the 5'-flanking sequence, and
nteractions between nuclear proteins and this DNA may be related
o mechanisms of transcriptional control by pituitary cell-type-
ipecific trans-acting factors.
ntracellular calcium is an important
•egulator of a variety of cellular func-
ions, and it is involved in the secretion
tnd synthesis of many different hor-
nones. The cytoplasmic concentrations
if calcium are affected by hormonally
nduced influx of extracellular calcium
ons, and calcium mobilization from in-
.racellular stores, probably the endo¬
plasmic reticulum. In many cell types
the resultant intracellular concentra¬
tions of free calcium are not stable but
Dscillate, and some calcium-mediated
responses may in fact be frequency-
modulated rather than amplitude-mod¬
ulated (Schlegel et al. 1987). The precise
mechanisms for calcium action within
the cell are not yet known; it may exert
direct effects, or it may act through one
or more calcium-binding proteins or ki¬
nases, for example calmodulin and pro¬
tein kinase C.
Prolactin secretion by pituitary lacto-
trophic cells is stimulated by thyrotro-
pin-releasing hormone (TRH)-induced
hydrolysis of phosphatidylinositol bis-
phosphate, which is thought to lead to a
rapid mobilization of intracellular
calcium stores, with a subsequent
slower inllux of extracellular calcium
(Gershengorn 1986). Whereas the acute
release of prolactin by TRH is now well
recognized to be calcium dependent,
there is increasing evidence for a crucial
role of calcium in the regulation of pro-
Julian R. E. Davis is at the Department of
Medicine, University of Manchester, Man¬
chester M13 9PT, UK.
lactin gene transcription, and some
clues as to the possible mechanisms in¬
volved are emerging from recent work.
• Regulation of the Prolactin Gene
Prolactin gene transcription (and
mRNA accumulation) is influenced by a
variety ofhormones, including estrogen,
thyroid hormone, and glucocorticoids,
acting through nuclear receptors; and
dopamine, TRH, vasoactive intestinal
peptide, and epidermal growth factor
(EGF), acting through membrane recep¬
tors coupled to a variety of intracellular
second messenger systems (Davis et al.
1989). Recently, the general actions of a
number of intracellular regulators have
been studied, and important advances
have been made in our understanding of
the mechanism of action of cAMP and
protein kinase C. Much less is yet
known about calcium and the calcium-
binding protein calmodulin, although
the calcium-calmodulin system ap¬
pears to be important in regulating pro¬
lactin gene expression. A particular puz¬
zle in the case of the prolactin gene is
the very wide range of known regulators
and intracellular signals that affect its
expression; are the mechanisms differ¬
ent in each case, or do they converge
onto a small number of common targets
at the level of the gene itself?
• Effects of Calcium
Evidence for a role for calcium in prolac¬
tin gene regulation has come from a va¬
riety of experimental approaches. How¬
ever, it remains controversial whether
calcium is a major regulator in its own
right, or is simply an essential cofactor.
Calcium entry into cells may in certain
circumstances stimulate prolactin gene
transcription with a resultant increase
in mRNA levels. White et al. (1981) de¬
prived clonal GH3 cells of extracellular
calcium and then added calcium chlo¬
ride to the culture fluid, which resulted
in over fivefold stimulation of prolactin
mRNA levels. Similar experiments in
normal rat anterior pituitary cells
showed that these effects of calcium
were much greater for prolactin than for
growth hormone (Gick and Bancroft
1985) and were reversible on with¬
drawal of calcium. Removal of calcium
from extracellular culture fluid by
EGTA rapidly reduced accumulation of
prolactin mRNA to undetectable levels,
whereas growth hormone mRNA was
much less affected (Gick and Bancroft,
1985). Under these conditions TRH ac¬
tion was abolished, although EGF still
induced some increase in mRNA levels
(White and Bancroft 1983). Hence, ex¬
pression of the prolactin gene is reduced
in low-calcium conditions, and in¬
creases on restoration of normal intra¬
cellular calcium. But while these effects
are greater for prolactin than for growth
hormone, they do not necessarily imply
that calcium per se is a major regulator
of prolactin gene expression in calcium-
replete cells.
Pharmacological manipulations of
calcium flux have involved ionophores
or calcium channel agonists or antago¬
nists, but have given conflicting results.
Murdoch et al. (1985) found that neither
of the calcium ionophores ionomycin
and A23187 had any effect on the rate of
gene transcription in GH4 cells, imply¬
ing that elevation of intracellular free
calcium was not a sufficient stimulus.
However, the ionophores did augment
the stimulation achieved with phorbol
ester to levels comparable with those
induced by TRH, suggesting that eleva¬
tion of intracellular calcium was acting
as a cofactor in concert with protein ki¬
nase C, but was inactive alone. In con¬
trast to these results, Laverriere et al.
(1988) found that both ionomycin and
A23187 appreciably enhanced tran¬
scription in GH3B6 cells, implying that
mobilization of intracellular calcium by
itselfwas in fact a sufficient stimulus. In
addition, influx of extracellular calcium
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through voltage-sensitive channels in¬
duced by the dihydropyridine calcium
channel agonist Bay K 8644 increases
transcriptional rate and mRNA levels
(in cells never deprived of calcium), sim¬
ilar in magnitude to the effect of TRH
but not additive to the TRH effect (La-
verriere et al. 1988; Hinkle et al. 1988).
The differences between ionophores and
channel agonists may be explained by
the disruptive effects of ionophores on
intracellular calcium gradient and pools
(White et al. 1989).
The importance of extracellular cal¬
cium has been studied with the use of
various calcium channel blocking
agents, including verapamil and nifedi¬
pine; these agents slightly reduce intra¬
cellular free calcium concentrations,
but markedly reduce prolactin gene
transcription and cytoplasmic mRNA
accumulation. They do not, however,
prevent the severalfold stimulation in¬
duced by TRH (Murdoch et al. 1985;
Davis et al. 1988; Hinkle et al. 1988),
implying that a stimulatory effect of
TRH may be at least partly independent
of calcium influx.
Regarding the role of intracellular cal¬
cium, pure intracellular antagonists of
calcium action have not been identified,
but several divalent cations, including
manganese and cobalt, are thought to
have intracellular as well as channel-
blocking effects. Both these cations dra¬
matically reduce prolactin secretion,
and cobalt chloride has been shown to
inhibit prolactin gene transcription and
reduce mRNA levels, also abolishing the
stimulation normally seen with TRH
(Murdoch et al. 1985; Davis et al. 1988).
These effects were much greater than
those seen with high doses of calcium
channel blockers, suggesting that cal¬
cium influx into these cells was less criti¬
cal than intracellular calcium. These
agents are, however, quite markedly cy¬
totoxic at high concentrations, and thus
these data have to be interpreted with
some caution.
Transcription of a number of other
genes is now known to be calcium-re¬
sponsive, indicating that the marked
calcium responsiveness of the prolactin
gene is not unique. These include the
glucose-regulated genes p3C5 and p4A3,
related to the heat shock protein family
(Resendezet al. 1986), and also the cellu¬
lar proto-oncogene c-fos (Bravo et al.
1985; Morgan and Curran 1986), which
in pituitary cells is induced relatively
slowly by calcium, in parallel with the
prolactin gene (Bandyopadhyay and
Bancroft 1989). Indeed, a calcium-re¬
sponsive element has been demon¬
strated for this gene (Sheng et al. 1988),
which also confers responsiveness to
cAMP (Sassone-Corsi et al. 1988).
In summary, there is controversy over
the precise function of calcium in the
regulation of prolactin gene expression.
Calcium is clearly a cofactor for protein
kinase C action; however, calcium may
in some circumstances be a sufficient
stimulus in its own right to increase pro¬
lactin gene transcription and mRNA lev¬
els, and this effect depends on both in¬
tracellular and extracellular calcium.
• Mechanisms for Calcium Action
The precise function of calcium in pro¬
lactin gene regulation is controversial,
but evidence exists for a potential role
for calcium as a regulator in its own
right. The mechanism of calcium action
on the prolactin gene may involve the
calcium-dependent kinase protein ki¬
nase C and calmodulin. Activation of
protein kinase C by the phorbol ester
TPA stimulates prolactin gene tran¬
scription (Murdoch et al. 1985), and this
kinase requires calcium as a cofactor
(Nishizuka, 1984). Down-regulation of
protein kinase C by chronic exposure to
phorbol esters, however, does not affect
the calcium induction of the prolacti
gene (Bandyopadhyay and Bancro
1989), suggesting that this kinase is nc
an essential intermediate in this actio
of calcium.
Studies of the role of calmodulin hav
depended heavily on the use of calmodi
lin antagonists such as the phenoth
azinc drugs trifluoperazine and calm
dazolium. These reduce both gen
transcription rate and prolactin mRN,
accumulation (Bancroft et al. 1985
White 1985; Murdoch et al. 1985). Thei
specificity is, however, relatively pool
as they also inhibit a number of othc
intracellular enzymes, including pre
tein kinase C. The more recently intrc
duced naphthalene sulfonamide derive
tives such as W7 are much more specifi
antagonists, and, in fact, these drug-
have similar dramatic effects in redut
ing both basal and TRH-stimulated pre
lactin RNA accumulation, with rela
tively small effects on growth hormon
mRNA levels (Davis and Wilson 1989)
• DNA Elements
A major advance in our understandin
of prolactin gene regulation has been th
identification of pituitary-specific nu
clear protein interactions with the up
stream regulatory 5'-flanking DNA. Th
prolactin gene is now known to contaii
a long upstream regulatory region (Fig
ure 1), which consists of a proximal en
hancer region (up to 400 bp upstream
and a distal region (up to 1700 bp up
stream) (Nelson et al. 1986). Both o
these regions are important inmaintain
ing transcriptional activity, althougl
their relative importance is disputed
The proximal region contains four site:
(IP—4P) that bind a pituitary-specific
protein variously termed Pit-1," "PUF
1," or "LSF-1" (Gutierrez-Hartmann e
al. 1987; Cao et al. 1988; Nelson et al
1988; Lufkin et al. 1989); the distal re
gion is reported to contain up to foui
"Pit-l"sites(lD—4D; Nelsonetal. 1988)
one of which is close to an estrogen re
ceptor binding region (Kim et al. 1988)
Response elements have recently beer
defined for some intracellular regula
tors. For example, the transcriptiona
response to both EGF and protein kinast
C activation by phorbol ester is con
ferred by DNA sequences between posi
tions -35 and -78 bp upstream fron
the cap site (Elsholtz et al. 1986), anc
this coincides with the first proxima
It remains controversial whether calcium is a major
regulator in its own right, or is simply an essential
cofactor.
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Figure 1. Schematic representation of the 5'-flanking region of the rat prolactin gene. Approxi¬
mate boundaries of reported pituitary cell-specific protein binding sites are indicated, with
putative response regions indicated below (for references, see the text). ERE, estrogen response
element; and TPA, phorbol ester.
site (IP) for pituitary-specific nuclear
protein binding (Nelson et al. 1988). A
precise response element for calcium
has not yet been identified, but the infor¬
mation required for a full response to
calcium (induced in both calcium-de¬
prived cells by calcium and in calcium-
replete cells by Bay K 8644) is contained
within the first 174 bp of DNA upstream
from the cap site (Jackson and Bancroft
1988), and the proximal 395 bp of up¬
stream DNA also confer very marked
calmodulin sensitivity onto a reporter
gene (Davis and Wilson 1989). Potential
response elements may, however, be
multiple, as TRH, EGF, and cAMP ef¬
fects may be conferred on a reporter
gene by distal as well as by proximal
enhancer regions of the prolactin gene
(Day and Maurer 1989), implying inter¬
actions between DNA-bound proteins in
both proximal and distal enhancer re¬
gions. The 174 bp calcium-responsive
stretch of the prolactin 5'-flanking DNA
contains three of the four proximal "Pit-
1" binding sites, inviting the speculation
that the binding or efficacy of such a
protein may in some way be regulated
by calcium itself, or by a separate cal-
cium/calmodulin-dependent protein.
• DNA-Binding Protein Factors
One calcium- and calmodulin-depen-
dent protein that has received recent at¬
tention is DNA topoisomerase. Phos¬
phorylation of this enzyme by protein
kinase C increases its DNA unknotting
and relaxing activity, and it has been
implicated in the regulation of some
prokaryotic genes (Wang 1985). Specific
inhibitors of this enzyme markedly re¬
duce the induction of prolactin mRNA
production by calcium, and three major
DNA cleavage sites for this enzyme are
found in vitro within the 5'-flanking re¬
gion of the gene (White and Preston
1988). One of these sites was found in a
region (-42 to —63 bp) that contained
consensus recognition sequences for this
enzyme, but which also coincides with
the first "Pit-1" site and EGF/phorbol
ester response element.
The coincidence of response regions
for calcium and EGF/phorbol ester and
a potential cleavage site for DNA topo¬
isomerase with pituitary-specific pro¬
tein binding sites suggests that these in¬
tracellular signals may exert their effect
by modifying the binding of tissue-spe¬
cific proteins to DNA or to other DNA-
binding factors, or alternatively, by
modifying already bound trans factors
to affect their interaction with the tran¬
scription initiation complex. So far
there are few data available that address
this question. Gel retardation assays
have indicated that the pattern of bind¬
ing of pituitary nuclear proteins to the
EGF/phorbol ester response element
(site IP) is unaffected by a 1-h exposure
of cells to phorbol esters (Elsholtz et al.
1986). A short exposure ofpituitary cells
to specific calmodulin antagonists, how¬
ever, dramatically alters the pattern of
protein binding to site 3P (— 138/— 162)
in a similar assay (Davis, unpublished
data), suggesting some calmodulin-sen-
sitive protein-DNA interaction, though
the proteins involved are as yet unchar-
acterized.
• Conclusions
Regulation of prolactin gene expression
involves calcium and calmodulin, but
although a lot has been learned about
some aspects of this regulation, the pre¬
cise mechanisms for calcium effects on
target DNA sequences have yet to be dis¬
covered. Of the possible intermediates
in calcium action, calmodulin now ap¬
pears to be a more likely candidate than
protein kinase C, and DNA topoiomerase
is one potential substrate for calmodulin
that appears to act at appropriate sites
in the proximal 5'-flanking region of the
gene. The data so far available also hint
at likely interactionswith the tissue-spe¬
cific nuclear protein that binds to multi¬
ple sites in both proximal and distal
enhancer sites upstream of the
transcription initiation site, though
such mechanisms remain speculative
(Figure 2). There may be at least a func¬
tional relationship between the prolac¬
tin gene and that for c-fos. Although c-fos
has a very general role in cell function,
it shares marked calcium-dependence
with the prolactin gene (Bandyopad-
hyay and Bancroft, 1989), and c-fos
mRNA levels are regulated similarly to
prolactin secretion (Gourdji et al. 1989).
The kinetics of c-fos induction in GH3
pituitary tumor cells are unusually
slow, without the rapid decline in
mRNA levels seen in other cell types.
Moreover, one report suggests that the
c-fos gene was amplified in cells from a
human prolactin-secreting pituitary tu¬
mor (U et al. 1988). A functional link
between the two genes remains specula¬
tive, but is ofparticular interest in terms
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Figure 2. Tentative and simplified model for calcium action in lactotrophic cells: DAG,
diacylglycerol; and IP3 inositol triphosphate. Pituitary cell-specific nuclear proteins are repre¬
sented as bound to sites 1P-3P in 5'-flanking DNA of the prolactin gene, interacting with
putative calmodulin- or kinase C-sensitive nuclear protein(s).
of the pathogeneis of human pituitary
adenomas, as it may provide some in¬
sight into the close relationship between
prolactin production and lactotroph
proliferation seen in these tumors.
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Pioneering in Pancreatic Transplantation
International Handbook of Pan¬
creas Transplantation
Edited by J. M. Dubernard and D. E. R.
Sutherland, Developments in Surgery
Series .Dordrecht, Kluwer, 1989, $185.00.
(xi + 552 pages). ISBN 0-89838-399-4.
The contents of the book are aptly re¬
flected in its title. Published in 1989, the
authors' bibliographies extend through
1987. Approximately 100 contributors
from 14 countries ofwestern Europe and
the United States have produced this
volume, which is divided into 18 chap¬
ters. Commentaries supplement each
chapter.
The book is about the treatment of
severe diabetes mellitus by pancreatic
allotransplantation. It covers the patho¬
genesis of diabetes, the history of pan¬
creatic transplantation, and the indica¬
tions for transplantation of the pancreas
alone or in association with renal trans¬
plantation.
Techniques, pre- and postoperative
care, complications, and results are
comprehensively covered. Conclusions
are based in part on the results in 1077
recipients of primary pancreatic trans¬
plants reported to a central registry by
April, 1987. Two-thirds of the patients
had received simultaneous renal grafts.
Among the highlights of the volume is
a chapter on "Surgical Techniques and
Complications" by Dubernard and col¬
leagues and another by Dubernard and
Sutherland, "Perspectives in Pancreatic
Transplantation." Two chapters on indi¬
cations for transplantation are clearly
presented.
With so many contributors, some du¬
plication is unavoidable. The book is
beautifully produced by the publisher
and carefully edited by two leaders in
this highly specialized held. This book,
authoritative at present, is essential to
any surgeon or scientist performing,
supporting, or considering pancreatic
transplantation. The authors have suc¬
ceeded in what they set out to do. tem
John M. Howari
Medical College of O)
Toledo, OH 43699, U?
From Seat of the Soul to Timekeeper
The Pineal: Endocrine and Non-
endocrine Function
Sue Binkley, Englewood Cliffs, New Jer¬
sey, Prentice Hall, 1988 (304 pages). ISBN
676-189.
As an early pineal worker, I received
great satisfaction from reading Sue
Binkley's book on the present status of
the pineal as a physiologically import¬
ant organ and as the focus of research
as a model neuroendocrine system.
Binkley has summarized and organized
research since the 1960s that has clearly
established the sensitivity and respon¬
siveness of the pineal gland to environ¬
mental light and its role as a biological
timekeeper. Binkley also introduces us
to other, less defined areas of pineal in¬
vestigation.
This is one of the first volumes in a
series focusing on endocrinology and in¬
tended to supplement standard texts.
The author, as mentioned in her preface,
has written this volume on the pineal
gland for senior undergraduate and
graduate students; therefore, this vol¬
ume serves as an entry level text for
those unfamiliar with the pineal or en¬
docrinology in general.
The teaching focus is particularly ob¬
vious in the second chapter, inwhich the
methods for both in vivo and in vitro
study are outlined and explained. The
material is clearly at the level of the tar¬
get group and would serve as a good
source book for individuals needing
more information on 24-h measurement
protocols, pinealectomy, ganglionec-
tomy, preparation of silastic capsules,
and pineal enzyme assays, along with
the means of measuring melatonin,
chemically and by bioassay.
One particular strength of the book is
its focus on comparative anatomy and
physiology. The author has carefully
pointed out the responses common to
many species as well as those areas
where there are species-specific differ¬
ences. For example, there are quite dif¬
ferent responses between those animals
that synthesize melatonin only in the
pineal gland (rats) and those that also
make comparable amounts in the retina
of the eye (chickens). The book is partic¬
ularly good for descriptions of these dif¬
ferences and their subtle influence on
physiological responses. Chapters 5-8
are the strongest in the book. They serve
as an excellent introduction to circadian
rhythms, photoperiodism, and
responses to varying light/dark ~
There is a cohesiveness to these .
ters, with good explanations of pii,
function well supported by experimen¬
tal evidence and clearly presented in
graphs and tables.
Other areas of pineal physiology are
still unclear and ambiguous—hiberna¬
tion, coloration, thermoregulation, and
interactions with other endocrine sys¬
tems. Differences may relate to species
as indicated by Binkley, but other possi¬
ble differences, such as the experimental
procedures, are not assessed. Some
parts of the book, such as chapters 9—12,
become litanies of experiments per¬
formed. There is some attempt to corre¬
late disparate results but no clear analy¬
sis of data. One begins to wonder
whether the author is listing every ex¬
periment ever performed or if some min¬
imal criteria of validity have been ap¬
plied. While there is some value to a
listing of work in the field as a central
source for other investigators, the reader
does not have any sense of value or con¬
nection. For example, in Chapter 12,
which focuses on pineal function in hu¬
man subjects, the section on reproduc-
I
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